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This thesis is concerned with the detection of viruses in blood and blood products,
with the general aim of improving the safety of blood donations and factor
concentrates for clinical use. The prevention of virus transmission by blood and
blood products is currently based on the screening of blood donations for virus
specific antibody or antigen and by incorporation of virus inactivation procedures in
the manufacturing process. In this study virus detection was by reverse transcription
(RT) of virus RNA (where appropriate) followed by amplification of cDNA of virus
DNA by the polymerase chain reaction (PCR). The viruses studied were hepatitis C
virus (HCV), parvovirus B19 and hepatitis A virus (HAV).
For HCV, the relationship between detection of anti-HCV by recombinant
immunoblot assay (RIBA-2) and viraemia was examined and a good correlation
(84.4%) between a positive result in the RIBA-2 and detection of HCV by PCR was
observed. However 5.4% of donations that were RIBA-2 indeterminate were PCR
positive, demonstrating that PCR can be useful in the confirmation of ambiguous
serological results. An assay system was developed that identifies different HCV
genotypes by restriction fragment length polymorphisms (RFLP) in the 5' non-coding
region of the genome. In a worldwide study of the distribution of HCV genotypes in
blood donors, two new genotypes were discovered. Distinct geographical distributions
of HCV genotypes were observed; HCV types 1, 2, and 3 were widely distributed
while genotypes 4, 5, and 6 were detected exclusively in donors from one country
only. Donors infected with HCV type 1 showed broad serological reactivity with all
ix
four antigens of the RIBA (5-1-1, cl00-3, c33c, c22-3) while infection with other
genotypes elicited antibody responses restricted to two antigens only (c33c and c22-
3), irrespective of the geographical origin of the donor. This lack of cross-reactivity
provides an explanation for the continued transmission of HCV by blood screened
by assays relying on reactivity to c 100-3 alone. Genotype determined by the RFLP
typing assay correlated well with a type specific serological assay.
Transmission of HCV by intravenous immunoglobulin (IVIG) has been reported. In
a retrospective study of a group of immunodeficient patients, HCV RNA was
detected in patient plasma samples and some of the associated IVIG batches.
Similarly, in a large group of rhesus negative women, HCV RNA was detected
following administration of a specific batch of anti-D immunoglobulin after
pregnancy. In this case, it was possible to show that the HCV variant in the IVIG
preparation closely matched those in the samples obtained from recipients, indicating
the value of direct nucleotide sequence comparison in molecular epidemiological
studies.
For parvovirus B19 and HAV a method for screening a large number of blood
donations was developed, and could be applied to prevent transfusion of these and
other transfusion-transmission related viruses by exclusion of blood at source. B19
could be detected in batches of non-heat treated factor VIII and IX concentrate
manufactured from plasma unscreened for B19 DNA. Dry-heat treatment reduced but
did not eliminate detectable B19 from the product. Comparison of virus titre
x
established by PCR and by cell culture infectivity assays for both human
immunodeficiency virus and canine parvovirus (an in vitro model for B19)
demonstrated that virus DNA could still be detected in concentrates in which
infective virus had been eliminated by heat treatment.
Overall, this work has shown the value of PCR in the screening of individual or
pooled blood donations for the presence of viruses, in the identification of novel




THE SAFETY OF BLOOD AND BLOOD PRODUCTS
The disease first known to be transmitted by blood and blood products was syphilis,
which was also the first to be prevented by storage at low temperature. Parasitic
diseases are also of concern. However they tend to be restricted to specific
geographical areas while viral diseases are of universal concern. New infectious
diseases are constantly arising which may be transmitted by blood and its products.
A single unit of contaminated blood has the potential to infect many recipients. A
unit of donated blood is routinely separated into red-cell concentrates, platelet
concentrates and plasma. Human plasma in pools of 10,000 donations or more is
used to manufacture a large range of therapeutic proteins (table 1.1.). The most
frequently required are concentrates of Factor VIII and IX used in the treatment of
haemophilia A and B respectively, and immunoglobulin preparations for intravenous
infusion in treatment of patients with natural or induced immunodeficiency.
Fractionation of contaminated plasma, combined with thousands of other donations
ultimately yield products for a thousand different patients. Some infectious agents are
more likely to be transmitted by the cellular components of blood while others may
be transmitted by plasma and plasma products (table 1.2.). Protozoa and bacteria are
the major contaminants of cellular blood components while viruses are the problem
with plasma derivatives. Specific geographic areas constitute reservoirs with a high
prevalence of certain infectious agents eg: donors from a malarial area are likely to
transmit plasmodia, although it is quite probable that a recipient in such an area is
likely to be infected anyway.
1
Table 1.1.
PLASMA PRODUCTS : INDICATIONS FOR USE
Plasma product concentrate Indications for Use
Albumin Volume expander
Human factor VIII complex Congenital deficiency (haemophilia A:
von-Willebrand's disease)
Factor IX prothrombin complex Congenital deficiency (haemophilia B)
Reversal of oral anticoagulant overdose






Types of immune thrombocytopenic purpura
Other acquired immune disorders
Antithrombin III Congenital deficiency
Disseminated intravascular coagulation,
liver transplantation,
other acquired deficiency states
Factor IX Congenital deficiency
Factor XIII Congenital deficiency, fibrin sealant
Activated prothrombin complex Factor VIII inhibitors
Protein C Congenital deficiency
CI esterase inhibitor Hereditary angioedema
Alpha-1 Antitrypsin Hereditary deficiency (emphysema, cirrhosis)
Fibronectin Acquired deficiency states, wound healing
Fibrinogen Wound healing, tissue sealing
2
Table 1.2.








































1.1. VIRUSES TRANSMITTED BY BLOOD AND PLASMA PRODUCTS
As blood and plasma therapy developed during the Second World War it became
clear that post-transfusion hepatitis was a "common" event in the USA (Beeson et
al.,1943) resulting in programmes being introduced to reduce or remove the risk.
Based on epidemiological characteristics and the incubation period after infusion of
blood products, two clinical forms of hepatitis were defined (1) 'serum' hepatitis :
associated with the use of blood and its products (now known to be hepatitis B); (2)
'infectious' hepatitis : associated with faecal-oral transmission and with a shorter
incubation period (now termed hepatitis A). Introduction of screening for hepatitis
B virus between 1970 and 1972 by detection of hepatitis B surface antigen (HBsAg)
in association with the exclusive use of volunteer donations has reduced the incidence
of carriers in the blood donating population to under 1 in 1000. With the introduction
of HBsAg screening the frequency of post-transfusional hepatitis (PTH) has been
reduced to less than 1% of hospitalised transfused recipients becoming infected in the
UK. Although a few cases do occur they can be attributed to blood donors in whom
the concentration of circulating HBsAg is below the levels of detection. Prior to the
introduction of anti-HCV screening the majority of cases of PTH that occurred were
attributed to non-A non-B hepatitis (NANBH), the causative agent is now known to
be hepatitis C virus (HCV) (or group of viruses).
The number of viruses thought to be transmitted by blood products is quite limited.
The reason whether a virus is likely to cause contamination of a plasma pool depends
on the virus physicochemical properties and epidemiology. Viruses such as
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cytomegalovirus (CMV), Epstein-Barr virus (EBV) and human T-cell lymphotropic
virus-I (HTLV-I) are not known to be transmitted by plasma products (Prince et al.,
1987). Although blood-borne viruses, they are almost totally eel'-associated and
significant levels of cell-free virus are rarely found. Viruses such as hepatitis A
(HAV) have a short-lived viraemia of 0 to 14 days, therefore the risk of a plasma
donation being obtained during this period is quite low. However, recent reports
(Mannucci 1992; Gerritzen et al., 1992; Normann et al., 1992) indicate that
transmission of HAV by blood products does occur. Viruses transmitted by plasma
products are usually those that cause persistent infection, also the frequency with
which the virus is likely to cause active infection in the donating population needs
to be taken into account with routes and frequency of transmission being important.
Viruses that generate high plasma titres can remain at infective levels even following
dilution in a plasma pool, while low viral titres present in a small number of
donations are liable to be diluted to insignificant levels. To date, based on
epidemiological data, only five human viruses have been shown to be transmitted:
(1) human immunodeficiency virus type I (HIV I)
(2) hepatitis B virus (HBV)
(3) hepatitis D virus (HDV)
(4) Non-A Non-B Hepatitis (NANBH or HCV)
(5) human parvovirus B19
although, as stated above, it is possible that other viruses have been transmitted by
plasma products occasionally. The physicochemical properties of these viruses are
5
shown in table 1.3. and are relevant in consideration of inactivation procedures used
in manufacturing processes.
Table1.3.
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1.2. METHODS FOR REDUCING VIRUS LOAD IN PLASMA POOLS
At present there are two main approaches to improving the safety of blood and
plasma pools prior to use or manufacture :
(1) careful selection of donors
(2) screening of donated units of blood
1.2.1. DONOR SELECTION
This approach relies on the selection of "healthy" donors using physical and
laboratory techniques. Where possible donors are interviewed and questioned about
history of hepatitis, intravenous drug abuse, homosexual activity or any other
behaviour that would indicate a "high-risk" category. This approach has limited
success as studies have shown that many blood donors who later developed AIDS
were found to be homosexual and often drug addicts. In countries where donors are
paid, such as the United States there is the added complication of the economic needs
of the individual prompting him or her to give false answers when questioned. In
addition the majority of carriers of hepatitis B have no history of hepatitis and
therefore only a few carriers would be excluded by such a question.
1.2.2. SCREENING OF DONATIONS
Automated antibody screening tests are commercially available for selected infectious
diseases. The use of microtitre plate formats enable reagents to be added to the test
wells with ease either manually or mechanically. Results on several hundred samples
can be obtained within a few hours of donation. Currently at the Scottish National
8
Blood Transfusion Service (SNBTS), donations are routinely screened for HBsAg and
antibody to hepatitis C virus (HCV), human immunodeficiency virus (HIV) and
syphilis.
1.3. INACTIVATION OF INFECTIOUS AGENTS IN COAGULATION
FACTOR CONCENTRATES
The manufacturing method is of great importance since adverse reaction to the
product may arise and the possibility of viral transmission by the preparation may
occur. It is difficult to develop a manufacturing viral inactivation or removal
procedure as any physical or chemical stage must not denature the plasma proteins.
The European Community Note for Guidance states that" The virus reduction factor
of an individual purification or inactivation step is defined as the log10 of the ratio
of the virus load in the starting material and the virus load in the final material which
is ready for use in the next step of the process" (Ad Hoc Working Party on
Biotechnology/Pharmacy, 1991). Several methods are available for viral inactivation
and different manufacturers favour different methods. A general overview of
currently available techniques is shown in table 1.4 and those under development in
table 1.5, immunoglobulin preparations are considered separately in chapter 5.
Up until 1991 heat treatment was the main method of virus inactivation used at the
Protein Fractionation Centre (PFC) in Edinburgh. Experiments in which the
temperature was raised from 68°C to 80°C in different product formulation showed
9
Table 1.4.
METHODS CURRENTLY USED FOR VIRAL DEACTIVATION BY
MANUFACTURERS OF PLASMA PRODUCTS
Method Mechanism
Physical-Heat Treatment Heating in solution
Dry heat treatment
Steam treatment of freeze-dried powder
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a significant increase of virus kill (Cuthbertson et al., unpublished data SNBTS). It
is important to validate the heat/time combination used with infectivity studies fora
particular product as varying reports have been published on the inactivation of HIV
with different time/temperature regimes (McDougall et al., 1985; Tersmette et al.,
1986; Prince, 1986a; Piszkiewicz et al., 1987; Levy et al., 1985; Reid et al.,
unpublished data SNBTS). Products developed in 1987 can be heated at 80°C for 72
hours (a severe dry-heat treatment) and clinical results indicate no transmission of
NANBH, HBV or HIV (Colvin et al., 1988; Mcintosh et al., 1987). The major
advantage of dry-heat treatment is that it is carried out in sealed containers as the
final step in production, thus preventing the possibility of inadvertent contamination.
The presence of a lipid envelope on a virus particle renders it susceptible to
inactivation by lipid solvents. The use of a nonvolatile solvent tri-(n-butyl) phosphate
(TNBP), in combination with one or another of a range of detergents usually sodium
deoxycholate (a natural constituent of the human gut) was first developed at the New
York Blood Donor Centre (Prince et al., 1987) and is now used by many
manufacturers worldwide. The TNBP/detergent treatment is carried out at 20 - 30°C
as the rate of viral inactivation is temperature dependent and is much slower at 4°C.
At the end of the inactivation step the solvent/detergent mixture is removed either by
precipitation of the product or by chromatography. Virus inactivation studied by in
vitro models have shown that the method is very effective for inactivation of lipid
enveloped viruses, as expected. No cases of transmission of NANBH or HIV have
been reported with this product, however the non-lipid enveloped
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encephalomyocarditis virus (EMC) has been shown to be completely resistant to all
TNBP/detergent treatment combinations. Although there have been no reports on
parvovirus transmission it is unlikely that this virus would be inactivated by such a
procedure due to a lack of a lipid envelope.
1.3.1. ASSESSMENT OF VIRUS INACTIVATION
In order to assess the manufacturing process it is necessary to have appropriate
validation tests for the inactivation methods. Tissue culture (in vitro) studies are
commonly used to demonstrate the adequate kill of HIV. The advisory committee in
the U.K. (UK BTS/NIBSC Liaison Group) recommends that each manufacturer
provides data demonstrating that one single step in the manufacturing process is
capable of inactivating 5 logs of HIV-1 (Thomas, 1988). The laboratory-scale
validation of HTV inactivation must simulate the full-scale process as closely as
possible, so that the data is representative of the potential of large-scale manufacture.
However at present there is no reliable culture system for the agents HBV, NANBH
(HCV), HDV and parvovirus B19. Most manufactures make use of "model viruses"
which include DNA and RNA viruses, with representatives of both enveloped and
non-enveloped viruses, commonly used "models" are vaccinia - a lipid-enveloped,
double-stranded DNA virus, and Semliki Forest Virus (SLFV) - a lipid-enveloped,
single-stranded RNA virus. Problems arise with agents such as HCV as this has yet
to be assign to a family, and shows similarity to both flaviviruses and togaviruses.
Recent infectivity studies using the two flaviviruses, yellow fever virus (YFV) and
tick-borne encephalitis virus (TBEV), and one pestivirus bovine diarrhoea virus
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(BVDV) showed that all three viruses were inactivated after 6 hours heat treatment
in aqueous solution at 60°C. The physicochemical properties of HCV suggests that
this virus is more closely related to the pestivirus group than the flavivirus group
which would indicate that BVDV would be the appropriate virus for use in routine
in vitro virus safety studies (Nowak et al., 1992). The most reliable model system for
parvovirus B19 is the canine parvovirus (CPV) which can be cultured readily.
Animal (chimpanzee) studies are used by some manufactures as they are the only
means of demonstrating the inactivation of HBV and HCV. However correlation of
non-infectivity in chimpanzees with that in clinical evaluation have proven to be poor
(Colombo et al., 1985; Kernoff et al., 1987). In addition the moral dilemma of using
an endangered species such as the chimpanzee for a test that supplies limited
information must also be considered.
Clinical (human) studies rely on the regular assessment of the serostatus of treated
patients with any seroconversions traced to a particular product and/or batch. HBsAg
status can be monitored indicating any HBV infection, while the seroconversion to
HIV and parvovirus B19 can also be detected. Detection of abnormal liver enzyme
levels (usually alanine aminotransferase - ALT) in combination with anti-HBc has
until recently been the only available predictive monitor of NANBH infection.
However most haemophiliacs have already been infected with NANBH, the only
recognised method for assessing the risk of NANBH transmission is to study ALT
levels in previously untreated patients (PUPs) following their initial infusions of
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coagulation factor concentrates. This presents problems as the elevation in ALT
levels may be transient so sampling frequency and times may be critical. However
the advent of second and third generation enzyme-linked immunoassays (EIAs) and
recombinant immunoblot assays (RIBA) which reliably detect HCV seroconversion
have certainly overcome the need for ALT testing as the EIA is available for mass
screening of donated blood with repeatedly reactive samples being tested by the
supplemental test, the RIBA.
1.4. AIMS
The aim of the work described in this thesis was to provide a contribution to
improving the safety of blood and blood products with respect to the transmission of
viruses. One approach was at the level of donor screening, for HCV the results of
antibody screening with the detection of viraemia were compared to assess the
efficacy of currently available blood donor screening tests. This study was extended
to investigate the effect of HCV sequence variation on the sensitivity and specificity
of reaction in antibody tests. To overcome problems associated with antibody
detection an alternative method would be to screen for viraemic donations on a
routine basis. Parvovirus B19 and HAV were used as model viruses in the application
and assessment of a pooling system for detection of viruses in blood donor screening.
The role of PCR and sequence analysis to confirm cases and provide evidence for
iatrogenic transmission of viruses by blood products was examined. Finally, the




2.1. PLASMA SAMPLES, FACTOR CONCENTRATES AND INTRAVENOUS
IMMUNOGLOBULIN PREPARATIONS
Plasma samples, factor concentrates and intravenous immunoglobulin preparations
were made available from a wide range of sources and details are given in the
appropriate sections. Blood donor plasma samples were frozen at either -20°C or -
40°C as soon as practically possible in all studies. Freeze-dried preparations of Factor
VIII and IX and intravenous immunoglobulin were stored at 4°C prior to
reconstitution. Once reconstituted aliquotes were removed and subjected to nucleic
acid extraction immediately. The remaining product was stored at -20°C. Lyophilised
vials were reconstituted as specified by the manufacturer, 11 and 36 U/ml for factor
VIII and IX respectively, and 50g/litre for intravenous immunoglobulin.
2.2. DNA EXTRACTION
The work carried out in this project required the extraction of nucleic acid from a
large number of samples. The initial procedures used involved different protocols for
the purification of DNA and RNA, in the second half of the work a new highly
efficient extraction method was used which purified nucleic acid with equal
efficiency for RNA and DNA (see section 2.4.). The DNA extraction procedure
described in this section represents a reasonable compromise between quality of DNA
and ease of use, yielding DNA in a reasonable time scale.
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DNA was extracted from 0.5ml of plasma, by ultracentrifugation. The plasma
sample was mixed with 6mls of RPMI medium (pH 7.3) in a polycarbonate
centrifuge tube and sealed with a noryl cap assembly. Virus was pelleted at 100000
X g for 2 hours at 4°C in a fixed angle rotor (rotor: Beckman Ti70; centrifuge:
Beckman Model L8M). For Factor VIII and IX concentrates, intravenous
immunoglobulin and plasma pools, 2.5mls of reconstituted product or plasma pool,
was mixed with 4.0mls of RPMI medium and ultracentrifuged as described.
Supernatant was removed using a pastette to ensure that the pellet was not disturbed,
the pellet was resuspended in 400pl of lysis buffer: 50mM Tris-HCl pH8.0; 50mM
EDTA pH8.0; lOOmM NaCl; 0.01% w/v Proteinase K; 1% N-laurylsarcosine) and
incubated at 65°C for 2 hours. The pellet was then transferred to a 1.5ml eppendorf
tube and extracted twice with 600pl of phenol and once with chloroform. The DNA
was precipitated overnight in two volumes of ethanol at -20°C. DNA was pelleted by
centrifugation at 18000 X g for 15 minutes at 4°C, the supernatant removed carefully
and the pellet dried at 42°C for 10 minutes, DNA was solubilised in 20 to 200pl of
distilled water.
2.3. RNA EXTRACTION
In preparation of RNA considerable care must be taken to avoid degradation of the
preparation by exogenous RNAses which may be present in vitro and in vivo. Virus
was pelleted by ultracentrifugation as described in section 2.2.1. The pellet was
resuspended in 1.0ml of a denaturing solution (2M guanidine thiocyanate; 12.5 mM
sodium citrate pH7.0; 0.25% sarkosyl; 0.05M 2-mercaptoethanol; 50% water-
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saturated distilled phenol). The solution was then transferred to a 1.5ml eppendorf
microfuge tube and 200pl of chloroform added and mixed thoroughly using a
vortimixer (Chomczynski et al., 1987). The solution was incubated at 4°C for 15
minutes then spun at 18000 X g for 10 minutes, the aqueous phase was removed into
an equal volume of chloroform and mixed thoroughly as before, followed by further
centrifugation to resolve the aqueous phase from the organic phase. The resulting
aqueous phase was mixed with an equal volume of isopropanol and left at -20°C
overnight to precipitate viral nucleic acid.
When the sample volume was 200pl or less a direct extraction was carried out. The
plasma was added directly to the denaturing solution and mixed vigorously
immediately. The extraction procedure was then carried out as described above.
Precipitated RNA was pelleted by centrifugation for 15 minutes at 18000 X g at 4°C.
The pellet was washed once with 1ml of 75% ethanol and dried at 42°C for 10
minutes. The pellet was then dissolved in 20pl of pyrogen-free water treated with
diethylpyrocarbonate (DEPC dH20).
2.4. IMPROVED EXTRACTION METHOD FOR NUCLEIC ACID
Either lOOpl of plasma was extracted directly or 500pl was spun as described in
section 2.2. and the pellet resuspended in the lysis buffer. (It was found that direct
extraction of a volume larger than lOOpl of serum or plasma had an inhibitory effect,
probably due to there being insufficient proteinase K to inactivate proteins present).
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A solution of TNE buffer+0.5% (0.11 M NaCl; 55mM Tris pH 8.0; l.lmM EDTA
pH8.0; 0.55% SDS) plus lmg/ml proteinase K and 40pg/ml poly-adenylic acid (Poly-
A) was prepared prior to use and incubated at 37°C for 10 minutes to inactivate any
endogenous RNAses. Serum was either added directly to 400pl of this solution or
used to resuspend the pellet, the tubes were mixed thoroughly using the vortimixer.
Samples were incubated at 37°C for 2 hours. Extraction was carried out by addition
of 450pl of phenol the tubes were mixed thoroughly and centrifuge for 10 minutes
at 18000 X g. The aqueous phase was removed and extracted into 450pl of
phenol:chloroform:isoamylalcohol (1:1:0.01) containing 75pl of TNE buffer+0.1%
(0.1M NaCl; 50mM Tris pH8.0; ImMEDTA pH8.0; 0.1% SDS), mixing and
centrifugation was carried out as described and the aqueous phase removed into
450pl of chloroform:isoamylalcohol (50:1). The aqueous phases was then removed
into an equal volume of 100% ethanol and 40pl of 3M Sodium Acetate pH5.2 added.
The solution was mixed and nucleic acids precipitated overnight at -20°C. Nucleic
acid was pelleted by centrifugation at 18000 X g for 15minutes, the pellet washed
once with 80% ethanol and dried prior to resuspending in 25pl of DEPC treated
distilled water.
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2.5. REVERSE TRANSCRIPTION OF VIRAL RNA
For detection by PCR the RNA must first be reverse transcribed into DNA as the
PCR method is ultimately dependent on primer-initiated DNA synthesis, fig 2.1. That
is, the DNA replicating enzyme requires a short section of double-stranded DNA on
a single stranded template to initiate DNA copying. The efficiency of detection of
RNA is critically dependent on the spacing of the primers used in the subsequent
PCR (Zhang et al., 1991). The reverse transcripts have a size distribution in which
only a minority exceed 1000 bases in length, thus the wider the spacing of primers,
the fewer transcripts will be long enough to be amplifiable in the PCR. An efficiency
of 5% in the RT reaction with primer spacings of 480bp has been reported, while
amplification of cDNA using primer pairs separated by 858bp occurs with an
efficiency of 1.8% (pers.comm. Dr.L.Q.Zhang, now at Aaron Diamond AIDS
Research Centre, New York). In the work carried out a virus-specific primer for
initiation of cDNA synthesis from the viral template was used. Other groups have
used random priming with hexameric oligonucleotides (Garson et al., 1990a) however
there has been no published data comparing the two methods.
Routinely, 5pl volumes of solubilised RNA were incubated in a reverse transcriptase
reaction buffer containing: 50mM Tris-HCl pH8.0; 5mM MgCl2; 5mM DTT; 50mM
KC1; 0.05pg/pl BSA; 600pM of each dGTP, dATP, dCTP, dTTP; 20% DMSO;
1.5pM outer anti-sense primer; 10 units RNAsin [Promega] and 10 units reverse -





















The reaction tubes were incubated at 42°C for 30 min, the primary PCR was set up
immediately after the reverse transcription reaction as cDNA produced in this
reaction is slightly unstable and long term storage leads to significant reductions in
the amount of target DNA amplifiable by the PCR.
2.6. AMPLIFICATION OF DNA BY PCR
The polymerase chain reaction (PCR) is an in vitro method for the enzymatic
synthesis of specific DNA sequences, using two oligonucleotide primers that
hybridise to opposite strands and flank the region of interest in the target DNA.
Repetitive cycles of template denaturation, primer annealing, and the extension of the
annealed primers by DNA polymerase results in the near exponential accumulation
of a specific fragment whose termini are defined by the 5' ends of the primers (fig
2.1). Because the products of one cycle can serve as a template in the next, the
number of target DNA copies approximately doubles every cycle. The sensitivity and
specificity of the PCR can be enhanced by using a "nested PCR". Following
completion of the first PCR reaction a lpl aliquot of the product is transferred to a
second reaction tube containing the PCR reaction mixture with sense and anti-sense
primers that lie within the region defined by the outer primers. This highly sensitive
technique results in a 10000-fold increase in amplification over that achieved by a
single step PCR and has been used to amplify a single copy of the target sequence
(Simmonds et al., 1990a). Quantification of viral DNA and RNA can therefore be
carried out directly from plasma samples.
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The first PCR was set up using 5pl of DNA or cDNA in a final reaction volume of
50pl of 1 X PCR buffer: lOmM Tris-HCl, 1.5mM MgCl2, 50mM KC1, lmg/ml
gelatine, pH8.3; containing 33pM each of dGTP, dATP, dCTP and dTTP; 0.5pM of
each of the outer nested primers and 20 units/ml of Taq polymerase [Boehringer
Mannheim], Twenty-five heat cycles were used, each consisting of 0.6 min at 94°C,
0.7 min at 50°C and 3.0 min at 68°C. One microlitre of the product was then
transferred to a second tube, reaction conditions were the same as for the first PCR
but with the inner nested primers and a further 25 heat cycles carried out. The
reaction volume for the secondary PCR was generally 20pl but when the amplified
DNA was to be sequenced a reaction volume of 50pl was made. The products of the
second reaction are sufficient to be visualised under UV light on an 2% agarose
[low-melting point agarose, TBI] gel stained with ethidium bromide (final
concentration 0.5pg/ml). Figure 2.1. outlines the cDNA reaction and PCR reactions,
fig 2.2. is an example of HCV extracted, reverse transcribed, amplified by PCR and
run on an agarose gel.
Primers used for the amplification HCV, Parvovirus B19, Canine Parvovirus (CPV),
HAV and HIV are shown in Tables 2.1.: 2.2.; 2.3.; 2.4.; 2.5. respectively.
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Figure 2.2. AGAROSE GEL OF AMPLIFIED HCV RNA
44 blood donor samples prepared as described in sections 2.4, 2.5, 2.6., PCR product
run a 2% agarose gel shown below. From left to right: 1st row: 3 positive blood
donor samples; 2nd row: 4 positive control, 2 negative control and 3 positive blood
donor samples (controls are placed randomly amongst test samples); 3rd row: 3















































































































































2.7. QUALITY CONTROL OF THE PCR
The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service
(CLB) are actively involved in standardisation of HCV-RNA detection. In 1992 a
series of samples were supplied to laboratories throughout Europe, called the Eurohep
panel. HCV RNA detection was assessed comparing the sensitivity and specificity
of the different laboratories. A further HCV Eurohep study is currently being carried
out (1993-1994). The author has performed the RT-PCR tests required for both of
these studies. The results of the 1992 Eurohep study are presented and discussed in
chapter 7, section 7.3..
On a routine basis positive and negative controls were extracted and handled in the
same way as test samples. Plasma from a HCV positive haemophiliac was used a
positive control. Five serial ten-fold dilutions of the plasma were made with each
sample extracted separately. The sample titrated out to the third dilution being
positive. This provided an indication of the sensitivity of the extraction procedure on
a routine basis. It is important to incorporate such a dilution series as any variation
in the positivity cut-off for the control indicates that there may be a problem with the
procedure. In particular the enzyme reverse transcriptase is a relatively labile enzyme
and batch variation may also occur which could give rise to false negative results
being reported for test samples. For every extraction two negative controls were
incorporated. At no time did these samples give a positive result.
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2.8. DIRECT SEQUENCING OF PCR PRODUCTS
A final PCR volume of 50|il is required to produce sufficient DNA for use in a
sequencing reaction. Excess, un-incorporated nucleoside triphosphates and primers
must be removed prior to sequencing as these will interfere with subsequent
reactions. Initially, samples were purified using a MAGIPREP kit [Promega], DNA
was eluted into a final volume of 20pl of 1 X TE buffer (lOmM Tris HC1 pH7.4;
ImM EDTA pH8.0). In the latter part of the work, single strand sequencing was
carried out using DYNABEADS [Dynal Ltd.]. The sample to be sequenced was
amplified in a lOOpl volume using a biotinylated primer in the secondary PCR. For
each sample, 20pl of streptavidin coated beads were washed once with 40pl of 0.1%
bovine serum albumin (BSA) pH7.2, followed by washing with 40pl of BW (lOmM
Tris HC1 pH7.5; ImM EDTA; 2.0M NaCl). Forty microlitres of the biotinylated
product was incubated with 40pl of beads resuspended in BW for 15-20 min at room
temperature with gentle agitation to enable immobilization. The beads were then
washed once with 40pl of BW followed by incubation for 10 min at room
temperature with 8pl of 0.15M sodium hydroxide (NaOH) which renders the DNA
single stranded. A further wash with 50pl of 0.15M NaOH followed by a wash with
40pl of BW then TE buffer were carried out. The final product was resuspended in
20pl TE buffer pH7.0 and a 5pi aliquote used in the sequencing reaction. The
opposite sense primer is used in the sequencing reaction to that which is biotinylated.
The sequencing reaction was carried out following a modification of the Sanger
protocol by Winship (Winship, 1989) in which 10% DMSO (tissue culture grade) is
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used in the reaction which serves to enhance the intensity of the signal and reduce
background. Purified PCR product (5pl) containing approximately 100-200ng of DNA
was added to an equal volume of annealing mixture: 10% DMSO; 200mM Tris HC1
pH7.5; lOOmM MgCl2; 250mM NaCl; lOng primer). The mixture was boiled for 3
minutes to denature the template. When the DNA was prepared by MAGIPREP, it
was immediately placed on ice for ten minutes to minimise template renaturation.
DNA prepared by the DYNABEAD method was heated to 65°C for 5min then
allowed to cool slowly to room temperature. The template-primer mix was then
added to the extension reaction solution: 0.025M DTT; labelling mix (diluted 1 in
20) 7.5pl dGTP, 7.5pl dCTP, 7.5pl dTTP; a-35S-dATP; 2 units of Sequenase enzyme
(T7 DNA polymerase). The tubes were manipulated on ice prior to aliquoting into
the termination mixture: 80pM dNTP (dGTP, dATP, dCTP, dTTP); 8pM ddNTP
(ddGTP, ddATP, ddCTP, ddTTP respectively); 50mM NaCl; 10% DMSO, which was
pre-warmed to 37°C. The termination reaction was stopped after 5 min incubation at
37°C by the addition of 4pl of stop solution: 95% formamide; 20mM EDTA; 0.1%
bromophenol blue; 0.1% xylene cyanol FF. The samples were heated to 95°C for 2
min prior to loading on a 6% denaturing polyacrylamide gel.
2.8.1. DENATURING POLYACRYLAMIDE GEL ELECTROPHORESIS
Thoroughly cleaned glass plates were assembled using wedge spacers (0.4mm at the
top to 1.2mm at the base) which improve the resolution and spacing of the
electrophoresed fragments enabling the reading of a greater number of bases. A 6%
gel was prepared by dissolving: 9g of acrylamide [BDH]; 0.45g bis-acrylamide
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[BDH]; 75g urea [IBI]; 15ml 10 X TBE (1.34M Tris HC1; 680mM boric acid; 25mM
EDTA; pHlO.O) in 50ml of distilled water, gentle heat is required to aid dissolution.
Polymerisation was initiated by the addition of 0.15g of ammonium persulphate
[Sigma] and 20pl of TEMED (N,N,N'N'-Tetramethylethylenediamine) [Sigma]
immediately prior to pouring the gel. Denatured samples were loaded onto the pre-
run gel (10 minutes at 75 watts) and electrophoresed for approximately 2.5 hours,
until the bromophenol blue marker reached the bottom of the gel. The gel was fixed
by soaking in 1 litre of 7% acetic acid and 7% methanol for 15 minutes followed by
another wash for 15 minutes. The gel was dried under vacuum on a dryer [Model
583 Gel Dryer, Bio-Rad] for 2-3 hours at 80°C and exposed to X-ray film [Kodak
XAR-2] in a light-tight cassette over-night. Films were developed by kind permission
of the X-ray department at the Royal Infirmary, Edinburgh. A typical sequencing gel
is shown in fig 2.3.
30
Figure 2.3. SEQUENCING GEL
2.8.2. SEQUENCE ANALYSIS
In phylogenetic studies, the evolutionary relationships among viral strains (or among
other groups of organisms) can be illustrated by means of a phylogenetic tree. Dr.
Eddie Holmes (now at the Univesity of Cambridge) carried out phylogenetic analysis
on sequences obtained in this thesis. Briefly, sequence data can be handled in two
different ways: (1) a statistical approach and (2) a method based on the principle of
parsimony (parsimony, invariants/evolutionary parsimony). Statistical approaches are
widely used and are usually either Distance based methods (for example Fitch-
Margoliash or Neighbour-joining) or the Maximum-Likelihood method. Both models
make a prediction on how the sequences have changed during evolution. Assumptions
are made by all approaches and are as follows:
(a) No variation in nucleotide frequencies during evolution (assumed in all methods).
(b) No between-lineages variation in the rate of evolution.
(c) No between-site variation in rate of evolution (assumed in most methods).
Maximum Likelihood methodology allows for some rate variation along the
sequence with different classes of site having different rates.
(d) Sites are independent (assumed in most methods). The Maximum Likelihood
method allows for 'patches' of correlated sites.
The Maximum-Likelihood model is used in analysis of data in this thesis and relies
on the following criteria:
(1) a model (M) (the Felsenstein model of molecular evolution)
(2) the data (D)
(3) the molecular sequence under comparison
32
(4) the competing hypotheses (H) - always assumed (ie: the alternative tree patterns
with associated time of divergence).
The likelihood theory states that hypotheses be judged on the basis of their
likelihood. If P(D/H) is the probability of obtaining the data D given the hypothesis
H, then the likelihood of an hypothesis H, given the experimentally determined data
D, on the given model, is: ^(H) = P(D/H). In effect, likelihood assesses the
probability of the data given the model under the various hypotheses, it does not
assess the likelihood of the model, however two competing hypotheses can be taken
into account by using the likelihood ratio: L^HD/L^ffi). The statistical method of
likelihood is not the critical element in the estimation of phylogeny, it is the
particular model of molecular evolution that is the biological consideration and it is
the model that can be altered if necessary.
Nucleotide sequences obtained were compiled by version 2.0 of the programs of
Staden (1984) and analysed by programs available in the University of Wisconsin
Genetics Computer Group sequence analysis package, version 7.0 (Devereux et al.,
1984). Sequences were aligned using PILEUP and LINEUP programs and
phylogenetic analysis performed using two different programs available in the
PHYLIP package of Felsenstein (version 3.4). A matrix of nucleotide sequence
distances were estimated using the program DNADIST, allowing for the calculation
of average sequence diversities both within and between samples. Phylogenetic trees
were then constructed using the program NEIGHBOR which clusters the matrix of
nucleotide distances created by DNADIST. The second PHYLIP program, DNAML
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finds the tree of the highest likelihood (the maximum likelihood tree) given a
particular stochastic model of molecular evolution and is probably the most reliable.
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2.9. QUANTITATION BY LIMITING DILUTION
The sensitivity of the nested PCR for single molecules of target DNA permits a
straightforward method of quantitation of viral sequences. Samples were titrated to
an end-point in serial ten-fold dilution steps, and the final concentration producing
a visible signal can be considered to contain at least one molecule of target sequence.
The accuracy of the titration was increased by increasing the number of replicates at
each dilution. In practice, the cut-off point was established from ten-fold dilutions
then five replicates were set-up at and around this cut-off value. As the distribution
of very dilute DNA between samples by macroscopic pipetting is a completely
random process, the Poisson formula can be used to calculate the likelihood of
positive samples having originally contained one or more molecules of target DNA
or RNA. The observed frequencies were converted into molecular concentrations of
target DNA by the Poisson formula, -(In f0), where fa is the frequency of negative
reactions (Simmonds et al., 1990a). Levels of RNA in a sample can be determined
by titration of cDNA prepared from a suitable concentration of viral RNA, however
as described in section 2.3. the efficiency of the reverse transcriptase reaction has to
be taken into account when making calculations of viral copy numbers (Zhang et al.,
1991). Comparisons made of the positivity rate over a range of concentrations of
RNA and the equivalent amount of cDNA showed that unless there was large
amounts of product DNA (>100ng) then the result obtained by titrating the RNA or





Following identification of a positive sample by the standard PCR procedure
described, the appropriate primary PCR product was retrieved from storage and DNA
was amplified in a second round PCR as before but with the modification of
supplementing the PCR buffer with 2pCi of [35S]-dATP (Amersham International,
Amersham, UK) and reducing the concentration of unlabelled nucleotide
triphosphates to 8.25pM. One microlitre of the product was digested with 10 units
of the appropriate enzyme. A total reaction volume of 30pl was used in the
appropriate restriction buffer supplied by the manufacturer, incubation was carried
out at 37°C for 18 hours (overnight). The cleaved product was heated to 65°C for 5
min and 6jal of loading buffer (2% sucrose; 0.1% bromophenol blue; 0.1% xylene
cyanol FF) added and mixed prior to loading. The digest products were
electrophoresed on a 12% polyacrylamide gel in 1 X TBE at 50 Volts for 18 hours
on the Protean II electrophoresis apparatus (Biorad). The gels were fixed in two
changes of 2% acetic acid, 10% methanol and 0.3% glycerol (BDH) for 30 min each,
and dried for 3 hours then exposed to X-ray film for 3 days prior to development.
Figure 2.4. shows a typical RFLP gel prepared by this method.
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Figure 2.4a. POLYACRYLAMIDE RFLP GEL : Haelll/Rsal DIGEST
Migration distances and sizes (in bp) of DNA Mr markers (Haelll-digested pBR322
DNA) stained separately by ethidium bromide are shown in M. Inferred sizes of
bands for the samples are shown on the right (in bp). Different electropherotypes
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2.10.2. MOLECULAR WEIGHT MARKERS
There were no commercially available standard DNA size markers in the range of
fragment sizes that were obtained. A method that produces 5' end-labelled DNA
markers prepared using y-[32P]dATP and polynucleotide kinases is available, however
it was inappropriate to use this method as radiolabel would have to have been
ordered specifically for this work. Due to the relatively short half-life of 32P it would
have been necessary to order amounts of radiolabel most of which would be wasted
making the technique too expensive for the number of samples examined. In addition,
the laboratory area where the gel electrophoresis was carried out was not an area
authorised for use of 32P and it is possible that the gel drier used would become
contaminated with 32P.
In order to overcome the problems associated with the use of 32P, DNA fragments
were sized by comparison with migration distances of standard-size DNA markers.
The two outermost tracks of the gel were run with a pBR322 digested with Haelll
(Boehringer Mannheim), after electrophoresis the marker tracks were excised and
stained with ethidium bromide and the migration distances measured. A plot of M,.
versus relative migration (Rf) was used to estimate the size of the bands on the
autoradiograph after exposure and development.
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2.10.3. IMPROVED RFLP METHOD
During the course of this work an agarose gel became available that was capable of
resolving DNA fragments down to 3 base pairs in size. Modification to the original
method was made which enabled a larger number of samples to be analysed in a
shorter period of time. Samples to be tested were amplified in a 25pl secondary PCR
reaction volume. The whole sample was then digested with the appropriate
combination of restriction enzymes as described in section 2.10.1. in a final volume
30pl. The whole sample was then run on a 4% METAPHOR [FMC Ltd] agarose gel
stained with ethidium bromide. Figures 2.5a and b. show typical RFLP agarose gels.
This method enabled a standard set markers to be run at the same time.
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Figure2.5a.AGAROSERFLPGEL:Haelll/RsalDIGE T
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2.11. DIGOXIGENIN LUMINESCENT DETECTION OF NUCLEIC ACIDS
Detection of digoxigenin (DIG)-labelled nucleic acids by enzyme immunoassay with
luminescence on nylon membranes has largely replaced detection systems using 32P
radiolabeled DNA, although the basic principle remains the same. The hapten DIG
is bound by a spacer arm to uridine-nucleotides and incorporated enzymatically into
the nucleic acid probe by random primed DNA labelling. Hybridisation and blocking
are carried out, followed by detection of DIG-labelled probes using high affinity anti-
DIG-antibody Fab-fragments conjugated to alkaline phosphatase (AP). The
chemiluminescent substrate AMPPD (3-(2'-spiroadamantane)-4-methoxy-4-(3"-
phosphoryloxy)-phenyl-l,2-dioxetane) is dephosphorylated by the alkaline
phosphatase, the resulting decomposition via an unstable intermediate produces light
as a glow which can be detected by X-ray film.
PCR positive samples were run on a 2% agarose gel stained with ethidium bromide
(as in section 2.6.). The DNA was denatured by incubating the gel in 100ml of
denaturing solution (0.5M NaOH; 1.5M NaCl) with gentle agitation for 1 hour.
Denaturing solution was removed and replaced with 300ml of neutralising solution
(1.5M NaCl; 0.5M Tris HC1; pH8.0) for a further 45 min, followed by two washes
with 2 X SSC (0.3M NaCl; 0.03M Na citrate; pH 7.0). Southern transfer was carried
out overnight to a nylon membrane [Boehringer Mannheim] and dried at 80°C for
2hours the following day. The filter was prehybridised in a roller bottle with 30ml
of hybridisation solution (50% formamide; 5 X SSC; 2% blocking reagent [supplied
in the Boehringer Mannheim DIG Luminescent Detection Kit]; 0.1% N-lauryl
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sulphate; 0.02% SDS [sodium-dodecyl sulphate]) for 1 hour at 42°C. Probe DNA was
labelled by mixing lOOng of DNA with 3.2pl dNTP mix (kit dCTP:dGTP:dATP);
1.8pl dTTP/dUTP mix (1:1; dTTP[0.5mM]:dig dUTP[0.3mM]); 2.0pl reaction mix
(kit); lpl of Klenow enzyme, in a total volume of 20pl and incubated at 37°C for 1
hour. The labelled probe was then added to the filter in the roller bottle containing
the hybridisation solution and incubated at 42°C overnight. The filter was then
washed two times with 2 X SSC + 0.1% SDS for 5 min at room temperature,
followed by a further two washes with 0.1 X SSC + 0.1% SDS for 5 min at 68°C.
Chemiluminescent detection of target was carried out at room temperature by
washing the filter in 30ml of washing buffer (0.1M Maleic Acid; 0.15M NaCl;
pH7.5) + 0.3% Tween 20 for 5 min. This buffer was removed and replaced with
20ml of washing buffer +1% blocking agent for 30 min, the anti-digoxigenin-AP,
Fab fragments were diluted into this solution at 1:10,000, and incubated for 30 min.
Unbound conjugate was removed by washing two times with 20ml washing buffer
+ 0.3% tween 20 for 15 min. Equilibration was carried out by incubation with 20ml
of buffer E (0.1M Tris HC1 pH9.5; 0.1M NaCl; 50mM MgCl2). Substrate solution
AMPPD was diluted 1:100 in buffer E and incubated with the filter for 5 min. The
filter was placed on a backing sheet of Whatman 3MM filter paper, sealed in Saran
Wrap and incubated at 37°C for 5 min then exposed to X-ray film for 30 min and
developed as section 2.8.1..
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CHAPTER 3
3. HEPATITIS C VIRUS : GENERAL INTRODUCTION
3.1 POST-TRANSFUSION NON-A NON-B HEPATITIS
The hepatitis C virus is recognised as the main cause of PT-NANBH worlwide. Until
recently the diagnosis of HCV infection was one of exclusion. Individuals presenting
to the clinician with symptoms of jaundice, hepatic tenderness, increased serum levels
of alanine aminotransferase (ALT) and aspartate aminotransferase were subjected to
routine diagnostic tests for hepatitis B virus (HBV), hepatitis A virus (HAV),
Epstein-Barr (EBV) and cytomegalovirus (CMV). In those cases where infection was
proven not to be caused by any of these agents the diagnosis of non-A non-B
hepatitis (NANBH) was made. Until recently the NANBH agent was responsible for
60 to 90% of cases of post-transfusion hepatitis (PTH) (Prince et al., 1974; Tabor et
al., 1978; Alter et al., 1975). The incidence of PTH-NANBH in recipients of blood
was reported to be very low in the UK at 0.26% (Contreras et al., 1991) and between
2 and 4% in Northern Europe, 6 and 18% for Southern Europe and between 10 and
12% in the United States in 1991 (van der Poel 1991a).
3.2. DISCOVERY OF THE HEPATITIS C VIRUS
For many years the agent responsible for NANBH remained elusive. Initial
characterisation and physical identification of the virus was made by using the
chimpanzee as an infectivity model. Sera proven to induce liver disease in
chimpanzees could be treated in different ways and the effect on subsequent
transmission measured. In this way it was shown that the agent was inactivated by
chloroform and the deduction made that the virus contained lipid and was likely to
be associated with the surface membrane. Filtration studies showed that the virus was
approximately 30 to 60 nm in diameter. With this information it was possible to
deduce that the NANBH agent was a small, lipid-enveloped virus possibly related to
the class of small arthropod-borne RNA viruses, and was provisionally classified with
the togaviridae (Bradley et al., 1985).
Identification of the NANBH agent proved difficult since conventional
immunological methods failed to identify specific antibodies or virus antigens. This
failure could have been due to a lack of virus-specific antibody or to insufficient
production of virus antigens in NANBH infections. A novel approach was taken by
Choo et al. (1989) in which the infectious agent was cloned without prior
characterisation. Large quantities of a highly infectious chimpanzee plasma were
subjected to ultracentrifugation in order to concentrate the virus. Nucleic acid was
extracted from the pellets and denatured, as the nature of the genome was unknown,
synthesis of cDNA from both RNA and DNA using random hexamers was attempted.
A cDNA library was constructed in the bacteriophage 9cgtl 1, a vector which allows
the efficient expression of cDNA-encoded polypeptides. This library was then
screened for expression of virus antigens using serum from a patient with chronic
NANBH. Screening of approximately one million clones led to the identification of
one positive cDNA clone, termed 5-1-1. The 155 base-pair insert in this clone was
then purified and used as a hybridisation probe on the same library and a larger
overlapping clone (353 base-pairs) was identified. The cloned DNAs did not
hybridise with human or chimpanzee DNA, however one of the strands was
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homologous with a 5-10 kb nucleotide single-stranded RNA. Binding to oligo(dT)-
cellulose occurred indicating the presence of either a 3' terminal polyadenylated
sequence or an A-rich tract within the molecule. Sequence analysis of this and two
other overlapping clones indicated that the immunoreactive peptide possessed one
continuous, translational open reading frame (ORF). In order to express the ORF in
a system that could generate large quantities of the resulting polypeptide, the DNA
sequence was inserted into a plasmid containing the human superoxide dismutase
gene. When expressed in bacteria the resultant fusion protein reacted on
immunoblotting with serum from 7 of 11 patients with NANBH, and none of 10
control sera from individuals with non-NANB induced hepatitis. In addition,
seroconversion was demonstrated in 4 chimpanzees experimentally inoculated with
the NANBH agent, but not in 7 animals infected with HAV or HBV.
This work led to the further characterisation of the agent of NANBH, now termed
hepatitis C virus (HCV), a positive stranded RNA genome of at least 10,000
nucleotides (Choo et al., 1989).
3.3. GENOME ORGANISATION AND FUNCTION
Following the identification and characterisation of the hepatitis C virus by Choo et
al.(1989; 1991) further reports confirmed that HCV exists as a positive-stranded RNA
genome containing a large open reading frame encoding 3010 to 3033 amino acids
(Kato et al.,1990; Takamizawa et al.,1991; Okamoto et al.,1991). The ORF is flanked
by a 5' non-coding region (5'NCR) of 341 nucleotide in length that is important in
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translation initiation (Yoo et al.,1992), and a short 3' NCR (Han et al.,1991)
(fig.3.1.). Eukaryotic mRNAs are translated by a mechanism known as ribosome
scanning. The 40S ribosomal subunit binds adjacent to the 5' end of the mRNA,
mediated by interaction between a 5'methylated cap structure and a cellular initiation
factor complex. HCV appears to have a mechanism for translation initiation that
enables cap-independant translation. Although the exact mechanism is yet to be
defined it is thought that translation is initiated from an AUG codon that is located
at an internal site from the 5'NCR (an internal ribosome entry site, IRES)
(Tsukiyama-Kohara et al.,1992). Several AUG codons are located upstream of the
translation initiation site, however it is unlikely that these function as alternative start
sites. If IRES initiated translation does occur, as is the case for picornaviruses, the
virus may gain a major selective advantage since viral infection could effectively
inactivate the cellular cap-binding protein by production of an inhibitory protein
which leads to the arrest of cellular protein synthesis. Computer analysis of the
5'NCR has shown that sequences form secondary structures indicative of a stable
stem-loop formation which may serve as a ribosome landing pad. In vitro studies
have shown that sequences immediately upstream of the initiator AUG codon play
a key role in efficient translation initiation (Wang et al., 1993).
Cloning of the HCV genome has enabled a proposed classification, however the
identification of the proteins derived from translation of the ORF and subsequent
processing until recently could only be inferred from related viruses. Identification
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in vitro studies on HCV to be done, expression of the full-length recombinant
genome in mammalian cells was required before particular domains of the ORF could
be accurately assigned to processed proteins. Using a vaccinia virus infection and
transfection system along with HCV antibody-positive human sera and monospecific
antibodies, the proteins encoded by the putative structural and non-structural regions
of the ORF of HCV were identified as core (p22), El (gp32-35), E2 (gp68-72), NS2
(p23), NS3 (p72), NS4a and b (plO and 27 respectively) and NS5a and b (p56 and
p70 respectively) (Selby et al.,1993) (fig 3.1. and 3.2.). Expression of the N-terminal
putative structural proteins in vitro and in vivo also enabled the identification of core
and envelope glycoproteins (Harada et al.,1991; Hijikata et al., 1991a; Kumar et
al.,1992; Matsuura et al.,1992), however it remains to be determined whether co-
expression of the non-structural proteins influences processing of the structural
proteins. The NS3 region encodes a protein of dual function, it has a potential
catalytic triad similar to that of trypsin-like serine proteases and contains a consensus
helicase domain thought to be involved in template replication and possibly
translation. The NS5 region is thought to correspond to the replicase protein as it
contains a domain highly conserved amongst all viral RNA-dependent RNA
polymerases (Choo et al., 1991). Figure 3.2 indicates the cleavage points of the HCV
polyprotein. The function of the NS2 and NS4 proteins have yet to be determined.
Identification and immunostaining of the proteins encoded by the HCV genome
suggests that most of them are present in the ER, and only NS3 and NS5a may be
soluble and therefore have a cytoplasmic location.
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Figure3.2.CLEAVAGEPOINTSOFTHEHCVOLYPROTEIN


















3.4. CLASSIFICATION OF HEPATITIS C VIRUS
As yet HCV has not been assigned to a particular virus group. In order to understand
the rationale behind the proposal to assign HCV to a separate genus within the
Flaviviridae, it is necessary to outline the basis of the classification system.
3.4.1. TAXONOMY OF RNA VIRUSES
Until recently virus groupings have been based on a variety of characteristics such
as the structure of the virion; the host range (especially for plants and animals); the
transmitting vector; the disease syndrome and antigenic cross-reaction (for closely
related viruses). A refinement to this method is a classification based on the physical
structure of virus particles, and their stability in the presence of various chemicals
and physical agents. A recent classification scheme recognises families of viruses and
"
super-groups " of families, which are thought to reflect ancestral relationships
among otherwise divergent viruses. The criteria for membership of a super-group is
mainly based on similarities in genome organisation and structure, for example in the
order, number, and type of genes along the genome, the nature of modifications at
the 3' and 5' ends of the RNA, and the RNA polarity (ie: (+) or (-) strand viruses).
Positive strand virus genomes serve as a messenger RNA, following entry into the
cell, virus RNA binds to ribosomes and is translated in its entirety. The product of
this translation, the polyprotein, is then cleaved into proteins the main function of
which is to serve as structural components of the virion. The (+) strand also serves
as a template for synthesis of complementary (-) strand RNA by a polymerase
derived from cleavage of the polyprotein. Negative strand RNA then serves as a
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template to make more (+) strands. Progeny (+) strands then serve as mRNA
templates to make more (-) strands and constituents of progeny virus particles. The
genome of (-) strand RNA viruses function alternatively as templates for transcription
and replication. The virus genome must be transcribed to make mRNA, since the cell
lacks the appropriate enzymes all (-) strand viruses package in the virion an RNA
dependent RNA polymerase along with the viral genome. Transcription of the virus
genome is the first event after entry of the virus into cells. This yields functionally
monocistronic mRNAs, (+) strands, each specifying a single protein. Replication
begins under the direction of newly synthesised virus proteins, a full-length (+) strand
is made and serves as a template for the synthesis of (-) strand genomic RNAs. Other
factors include the occurrence of post-translational processing; the production of
subgenomic RNAs and readthrough of stop codons.
At present four super families of RNA viruses are recognised:
SUPERFAMILY I : Alphavirus-like families
SUPERFAMILY II : Picornavirus-like families
SUPERFAMILY III : Negative stranded viruses
SUPERFAMILY IV : Double stranded viruses
Sequence data has shown that there are regions of amino acid sequence similarity in
the replicase proteins of certain groups of viruses of plants and animals (Alquist et
al., 1985; Franssen et ah, 1984; Haseloff et ah, 1984), suggesting that the different
superfamilies have each descended from a common ancestor. On the basis of
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sequence similarities and genome order it is proposed that all positive-stranded RNA
viruses, ie: those that contain the messenger sense RNA as their genome have
evolved from a common ancestor. Members of these superfamilies include viruses
that infect many different hosts (eg: plants, insects and higher animals) and have a
variety of divergent morphologies.
3.4.2. RELATIONSHIP OF HCV TO OTHER VIRUSES
The structure and organisation of the HCV genome shows similarities to other
positive-stranded RNA viruses and in particular, based on genome organisation and
hydrophobicity plots, it has been suggested that HCV be classified in the family
Flaviviridae (Choo et al., 1991; Han et al., 1991). The Flaviviruses were previously
grouped within the Togaviridae (which includes the genera Alphavirus and
Rubivirus), but have recently been classified as a single genus of the family
Flaviviridae. Currently there are sixty-eight members of the Flaviviridae which can
be divided into three different groups based on their mode of transmission; fifty are
transmitted by mosquitos, eleven by ticks with the remainder having an unknown
vector. The mosquito borne members can be divided into several sub-groups based
on serological cross reaction. The Flavivirus virions contain a nucleocapsid of 25-30
nm diameter, surrounded by a lipid bilayer derived from the host cell membranes
containing the envelope proteins E and M. The diameter of the virion is
approximately 40nm with surface projections of 5-10 nm. The genomes of Yellow
Fever Virus, West Nile Virus, Murray Valley Virus, St. Louis Encephalitis, Kunjin,
Japanese encephalitis, Tickborne encephalitis and Dengue serotypes 1, 2 and 4 are
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single stranded RNA of positive polarity and approximately 11 kilobases in length.
The RNA has a cap at the 5' terminus (m7GpppAmp) (Chambers et al., 1990), in
common with the genomes of negative strand viruses and reoviruses it lacks a 3'
terminal poly (A) stretch. The RNA forms a stable hydrogen-bonded stem-and-loop
structure at the 3' terminus (similar to a plant-virus 3' termini). Short self-
complementary nucleotide sequences at the extreme 5' and 3' termini of the genome
RNA are observed (similar to that found in negative strand viruses). The Flavivirus
genome contains a single long open reading frame (ORF) of over 10000 bases,
translated as one polyprotein, from which virus proteins are produced by post-
translational cleavage (fig.3.3.). Structural proteins are found at the 5' end and the
non-structural components including the RNA polymerase at the 3' end, a similar
arrangement to that found in picornaviruses. Several regions of the genome are
conserved in sequence and structure, ninety nucleotides at the 3' terminus form a
stable hairpinloop with the 3' terminal dinucleotide being hydrogen bonded making
it inaccessible to end labelling. Short stretches of conserved and repeated regions in
the 3' non-coding region are found, one stretch of eight contiguous nucleotides in the
3' untranslated region is complementary to eight nucleotides at the 5' end (although
there is no extensive sequence conservation at the 5' termini). These conserved
sequences are possibly important in cyclisation of the RNA in a similar manner as
alphaviruses and bunyaviruses undergo cyclisation which may be important in
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3.4.3. SIMILARITIES TO OTHER POSITIVE STRAND VIRUSES
Virus specified proteinases are common to many positive strand virus families as
well as sequence characteristics of NTP-binding domains, helicase enzymes and RNA
dependent RNA polymerase activity. Flaviviruses were originally grouped with
alphaviruses based on similarities in morphology and their mode of transmission.
Genome organisation and expression of the flaviviruses indicate that a similar
strategy to picorna-like viruses is used. Both virus genomes encode a single
polyprotein that begins with the structural proteins and is processed by proteolytic
cleavage to yield the mature viral proteins. In contrast, virion morphogenesis and
structural protein processing of flaviviruses are very similar to rubella virus (Frey and
Marr 1988), which make up a separate genus in the togaviridae family along with the
alphaviruses (see section 3.4.1.). A membrane anchored precursor form of the C
protein is probably utilised by both viruses and envelopes are acquired by budding
through intracellular membranes. The pestiviruses are probably the most closely
related to the flaviviruses, genome sequences for bovine viral diarrhoea virus
(BVDV) and hog cholera virus (HoCV) suggest a similar genome arrangement and
replication strategy to flaviviruses (see section 3.4.4.). Homology between the
flaviviruses and the pestiviruses is mainly confined to certain motifs in the NS3 and
NS5 domains with little amino acid sequence homology seen elsewhere. (Figure 3.4.
shows the aligned sequences of flavivirus NS3 proteins and cellular proteases with
HCV added as a comparison).
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Figure3.4.
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3.4.4. COMPARISON OF THE PESTIVIRUS BOVINE VIRAL DIARRHOEA
VIRUS WITH MEMBERS OF THE FLAVIVIRIDAE
Table 3.1. highlights some of the main differences and similarities between
pestiviruses, rubiviruses, flaviviruses and hepatitis C virus. Nucleotide sequence
comparisons of BVDV with the three sub-groups of flaviviruses show that there are
no extensive regions of sequence similarity although several small tracts of 17 to 30
nucleotides are similar in BVDV and YFV. More information is gained from
comparisons of the genetic organisation and detailed information from the protein
coding regions. Hydropathic profiles of BVDV and YFV show striking similarities
and also the organisation of BVDV protein coding domains along the ORF is
paralleled by YFV. The similarity in hydropathic profiles in the absence of nucleotide
homology is important. The several short similarly aligned regions of highly
homologous amino acids in two NS proteins may indicate that the representative
proteins share similar functions for which the conserved sequences may be essential.
The available data is sufficient to distinguish BVDV from members of the
Togaviridae however it still remains to be defined if it is more appropriate to classify
BVDV and pestiviruses as part of the family Flaviviridae. Definition of the
nature of the actual virion structural polypeptides of BVDV would assist in drawing



















































3.4.5. CURRENT CLASSIFICATION OF HCV
As indicated in the introduction to this section 3.4. the current proposal is to assign
HCV to a separate genus within the family Flaviviridae. Section 3.4.4. then showed
how the pestivirus BVDV is closely related to the flaviviruses. HCV shows a very
close relationship to the pestiviruses with significant sequence similarities in the NS-3
and NS-5 proteins, in addition to regions of nucleotide homology in the 5' NCR.
Similarities in the secondary RNA structure adopted by the respective RNAs during
internal base-pairing (Brown et al.,1992) are observed. The stem-loop structure within
the 5' NCR of HCV that has been shown to be necessary for internal ribosomal
binding or entry (IRES) in HCV (Tsukiyama Kohara et al.,1992) is almost identical
in shape to that in the equivalent region of pestiviral RNA genomes (Brown et
al.,1992). In contrast, flaviviruses have a short 5' NCR and a cap-dependent
ribosomal scanning mechanism of translation initiation (Chambers et al.,1990). Both
pestiviruses and HCV show sequence diversity in the region of the genome encoding
the highly glycosylated envelope proteins. Comparison of the gene sequences for the
E2/NS-1 protein of HCV (Hijikata et al., 1991a; Weiner et al.,1991; Kato et al.,1992)
and the equivalent gp53 proteins of the pestiviruses (BVDV and HoCV) indicate
alternating constant and hypervariable regions not observed with flaviviruses.
Frequent potential N-linked glycosylation sites are observed in the El and E2/NS-1
protein of HCV and gp48, gp25 and gp53 proteins of pestiviruses and it is possible
that this contributes to their low buoyant densities on gradient centrifugation
(approximately 1.08- 1.11 g/cm3 for HCV and 1.09-1.16 g/cm3 for pestiviruses, in
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comparison to 1.20 g/cm3 for flaviviruses (Miyamoto et al.,1992; Takahashi et
al.,1992)).
3.5. RNA VIRUS VARIABILITY
3.5.1. RATE OF DIVERGENCE OF RNA VIRUSES
The genomes of RNA viruses diverge very rapidly. The mutation rate is thought to
be approximately 10"4 per nucleotide per round of replication (Steinhauer and
Holland, 1987). This rapidity of evolution may be a consequence of the lack of
proofreading activity in the RNA dependent RNA polymerases. The size of an RNA
virus genome may be limited by this high mutation rate (Reanney, 1982). The
potential and the actual rates of divergence tend to differ. Potentially, the rate of
divergence could be very rapid due to the high mutation rate and the large number
of rounds of replication of an RNA virus per year. However a limit is imposed on
the actual rate of divergence (ie: mutation of residues in the genome) by selection
pressures since most mutations are deleterious or incur disadvantages to the parental
population. Studies on RNA viruses estimate divergence rates of 0.03 to 2.0 % per
year (Smith and Inglis 1987); although this figure probably overestimates the basal
rate of divergence, it is significantly higher than the rate of divergence in animals
which is 1 % per million years (Britten 1986). The implications of such a high rate
of RNA sequence divergence are considered in relation to HCV in the next section.
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3.5.2 IMPLICATIONS OF HIGH MUTATION RATES
The degree of variation observed within the HCV genome is comparable to that of
other RNA \ iruses. However HCV, in contrast with most other RNA viruses, is able
to establish a chronic infection which results in a progressive disease in many
exposed individuals. The relatively high rate of nucleotide mis-incorporation in the
replication of the HCV genome may contibute to the generation of novel antigenic
variants and therefore provide a mechanism for " immune escape ". This theory is
supported by evidence of a high degree of envelope sequence variability in discrete
hypervariable regions of the El and E2 genes (Kato et al., 1992). Changes in these
regions would possibly alter the antigenicity of the virus and allow " escape " from
the hosts neutralising antibodies enabling persistent infection. However, there is
evidence that some persistently infected individuals show little change in envelope
sequence over a period of time (Kumar et al., 1993). In others, antibody levels are
detected that are similar or greater in frequency in individuals who are chronic
carriers of HCV compared with those who have cleared the virus and become non-
viraemic (Chein et al.,1993). These observations would argue against the " immune
escape " hypothesis. Microheterogeneity of virus sequences within an infected
individual is proposed as the basis of the mechanism of chronic virus infection for
HIV as well as HCV. The extent to which the immune system plays a role in the
evolution of the envelope proteins and in the prevention of re-infection are important
questions that await answer, and are undoubtedly of importance in the quest to
develope vaccines.
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3.6. HEPATITIS C VIRUS SEQUENCE VARIABILITY
3.6.1. INTRODUCTION
Hepatitis C viruses are heterogeneous, comprising several distinct major "types"
(Enomoto et al., 1990; Tsukiyama Kohara et al., 1991) that display in the region of
70% nucleotide sequence homology overall between types. This corresponds
approximately to the degree of variability which exists between different serotypes
of other flaviviruses (Chambers et al., 1990). Comparison of nucleotide and amino
acid sequences of different variants of HCV suggests the existence of distinct
sequence groups. Analysis of the complete genome sequences of HCV variants from
Japan (HCV-J, Kato et al., 1990 and HCV-BK, Takamizawa et al., 1991) show
ninety-two percent nucleotide sequence identity, compared with only 79% between
HCV-J and HCV-1 from the USA (Choo et al., 1991). Nucleotide sequence
comparisons in the NS-5 region of HCV between a series of isolates from infected
individuals in Japan (Enomoto et al.,1990) divides viruses into two main types that
differ by 33%, both of which can be further divided into two sub-types each differing
by 20%. The sub-divisions of the first group K1 and PT corresponded to the genome
sequences HCV-J/HCV-BK and HCV-1 respectively. Complete genome sequences
of the other major type (K2) have also been obtained (HC-J6, Okamoto et al., 1991;
and HC-J8, Okamoto et al., 1992a). Comparisons show a similar sequence
interrelationship as found in NS-5. HC-J6 differs from HC-J8 by only 23%, while
both differ from the other major type by 32-33%. Although different regions of the
HCV genome display varying degrees of diversity, the distinction between type and
sub-type is consistent. In the core and NS-3 regions differences between types range
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from 15-22% and 34-49% respectively, in the NS-4 region variability between HCV
types 1 and 2 is 25-27%, with the regions encoding the putative envelope proteins
(El, E2/NS-1) being the most variable with greater than 50% sequence divergence
in certain hypervariable regions (Weiner et al., 1991; Hijikata et al., 1991a).
The 3' untranslated region is highly variable with variation in both sequence and
length between different HCV types (Han et al., 1992) and within different clones
from the same isolate (Okamoto et al., 1991). However it is possible that the
published sequences are not complete and have yet to reach the end of the genome.
There is also dispute as to whether a polyadenaline or a polyuridine tract is present
(Han et al., 1991; Kato et al., 1990; Chen et al., 1992). By analogy with other
positive-sense RNA viruses, it is likely that HCV forms secondary structures at the
3' end of the genome for initiation of minus-sense RNA synthesis (Han et al., 1992)
although the details have yet to be elucidated.
The 5' non-coding region (5'NCR) or untranslated region (UTR) shows much less
variability between HCV types than the coding regions. There are very few
nucleotide differences in this region between HCV types, with a maximum sequence
divergence of 10%. The sequence conservation of the 5'NCR may reflect functional
constraints. In vitro studies have implicated the 5'NCR as having a regulatory role
in virus replication or initiation of translation (section 3.3.) The HCV 5'NCR has the
potential to form stable and complex secondary structures, containing stem loop
structures. These structures may be required for virus replication and initiation of
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translation and may considerably restrict the degree of sequence variability in the
5'NCR. In a recent study (Simmonds et al., 1993b), comparison of eight HCV
sequences revealed five covariant positions within the 17 base paired residues
forming one of the stems. This frequency of compensatory substitutions which
maintain base pairing would be unlikely to have arisen by chance. In addition, the
positions of single or double nucleotide insertions localise to the non-base-paired
terminal loop and would therefore have no effect on base pairing within the stem
structure. In this way secondary structures for different variants of HCV are highly
conserved.
3.6.2. CLASSIFICATION OF HCV VARIANTS
There have been several attempts to classify HCV sequence variants into different
types. Phylogenetic analysis of nucleotide sequences amplified in the region of the
genome encoding the core protein and parts of the NS3 and NS5 proteins showed
that although different degrees of variability were found in various parts of the
genome, analysis of each produced phylogenetic trees topologically identical to those
obtained upon analysis of complete genome sequences (Chan et al., 1992).
Phylogenetic analysis of seventy-six nucleotide sequences, with a world wide
distribution, derived from part of the gene encoding the non-structural protein (NS5)
indicated that HCV variants could be grouped into six major genotypes. Many of the
HCV types comprised a number of closely related subtypes, resulting in a total of
eleven genetically distinct viral populations (Simmonds et al., 1993c). A classification
system has been proposed that would allow for new types and subtypes to be added
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as they are discovered (table 3.2.). In general, the consensus sequence of each type
and subtype may be used to identify and classify new HCV variants. The NS5 region
is a useful region for virus identification since it is sufficiently variable to allow this
distinction to be made. Sequence similarities of less than 72% with any of the
consensus nucleotide sequences would indicate the designation of a new type. Those
showing sequence similarities of between 75% and 86% with particular variants and
less than 72% with others would be assigned as a new subtype.
Enomoto et al., (1990) classified sequences as Kl/PT and K2, the first being
subdivided along the geographical lines indicated in section 3.6.1., and K2
comprising the K2a and 2b subgroups. Houghton et al., (1991) classified sequences
as type I (sequences of USA/European origin), type II (Far East sequences) and type
III (sequences of Japanese origin). Any new sequences discovered would then be
designated type IV. However, this classification is uneven in that the difference
between type I and II sequences in each protein coding region is consistently less
than that between I and III. Fewer amino acid substitutions exist between type I and
II sequences than between other variants, and type I and II sequences cannot be
differentiated in the 5'NCR. Alternative classifications have identified the existence
of distinct genotypes but fail to take into account the two-tiered nature of sequence
differences (Okamoto et al., 1991; Okamoto et al., 1992b; Mori et al., 1992). The
scheme described by Okamoto et al. and Mori et al. describes HCV types I, II, III,
IV, V and VI which correspond to types la, lb, 2a, 3a and 3b respectively in the
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Table.3.2.COMPARISONFNOMENCLATUREFHCVTYPE
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system proposed by Simmonds et al., 1993c. Cha et al. (1992) described five groups
of HCV variants, where I corresponds to la, II to lb, III to 2a, 2b and 2c, IV to 3a
and 3b and V to type 5a. These classification systems would be difficult to extend
to incorporate types and subtypes as they are discovered (eg: lc and 2c). Differences
between the various schemes have made it difficult to compare results from different
laboratories. Table 3.2. shows a comparison of the nomenclature systems for HCV,
the system proposed by Simmonds et al. (1993c) is now widely used in the literature
and will be the system referred to in subsequent chapters.
3.6.3. PHYLOGENETIC ANALYSIS OF HCV VARIANTS
The discovery of HCV variants (Enomoto et al., 1990; Nakao et al., 1991; Okamoto
et al., 1991) that differed markedly in sequence from the original prototype HCV
(HCV-1; Choo et al., 1991) and others found in Japanese patients (Kato et al.,1990;
Takamizawa et al., 1991) raised the possibility that further HCV variants may exist.
A study to examine nucleotide sequence diversity in naturally infected individuals
(blood donors) in Scotland (Chan et al., 1992) revealed the existence of a group of
5'NCR sequence variants that differed from all previously published data.
Direct sequence analysis revealed constant as well as variable regions. Six sequences
(E-bl3 through E-bl8) (fig. 3.5) closely resembled HCV-1 (sequence no.l) and the
other type 1 sequences listed in table 3.3., while four others (E-b9 to E-bl2) were
more closely related to "K2" and HC-J6 sequences (nos. 24, 27, 28). However, eight
sequences (E-bl through E-b8) were distinct from the others (fig 3.5.). Sequence
71
variability within the three groups was considerably less than that which separates
them, and no sequence intermediate between the three groups was found. Division
of these and previously published sequences into three groups was supported by
formal phylogenetic analysis shown in fig 3.6.. This tree shows that the third group
is equally distinct from group 1 as is group 2. The group labelled "1" contains
sequences of HCV with a worldwide distribution (sequences 1-15; table 3.3), while
group "2" contains K2 and J6 sequences first observed in Japan (nos. 24, 27, 28).
The corrected distances between sequences within each group were in each case less
than 3%. Between groups, they ranged from 9% (between 1 and 3, and between 1
and 2), to 13% between 2 and 3 (Chan et al., 1992). Further analysis in the core,
NS3 and NS5 regions confirmed that the new group of sequences were also distant
from the other two previously identified groups.
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Figure3.5.
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Figure 3.6.
Phylogenetic analysis of the 5'NCR sequences using the maximum likelihood
algorithm, shown as an unrooted tree. Symbol •, nosl - 18 correspond to blood
donor sequences E-bl through E-bl8. Symbol O, nos 1- 28 correspond to the
previously published sequences identified in Table 3.3.
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Table 3.3.
SOURCE AND CITATION OF PUBLISHED HCV SEQUENCES
Geographical
No. Type Abbreviation Source Reference
1 la HCV-1 U.S.A. Choo et al. (1991)
2 la Pt-1 Japan Nakao et al. (1991)
Enomoto et al. (1990)
3,4 la H77, H90 U.S.A. Ogata et al. (1991)
5, 6 la GM-UGM-2 Germany Fuchs et al. (1991)
7 1 J1 Japan Han et al. (1991)
8 1 A1 Australia Han et al. (1991)
9 1 SI S. Africa Han et al. (1991)
10 1 T1 Taiwan Han et al. (1991)
11 1 U18/124 U.S.A/Italy Han et al. (1991)
12 lb HCV-J Japan Kato et al. (1990)
13 lb HCV-BK Japan Takamizawa et al. (1991)
14,15 la,b HC-J1, -J4 Japan Okamoto et al. (1990b)
16-20 lb Kl, Kl- 1-4 Japan Enomoto et al. (1990)
21 lb JH Japan Kubo et al. (1989)
22 lb J7 Japan Takeuchi et al. (1990)
23 lb T3 Taiwan Chen et al. (1991)
24-27 2a K2a, K2a-1, Japan Nakao et al. (1991)
2b K2b, K2b-1 Enomoto et al. (1990)
28 2a HC-J6 Japan Okamoto et al. (1991)
29 2 Clone A Japan Tsukiyama-Kohara et al.
(1991)
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From the published data there is considerable evidence for an overlapping distribution
of HCV types in a single geographic area. The existence of different hepatitis C viral
types may be related to distinct clinical disease syndromes associated with HCV
infection. Differences in the pathogenicity of the different types of the virus may be
related to the extent of disease observed and varying response to interferon treatment.
The degree of sequence variability found between HCV types would be expected to
affect the antigenicity of many of the putative proteins of HCV. In the following
chapter (4) the relationship between detection of antibody and HCV viraemia is
investigated in the blood donating population. The distribution and the effect of




4. BLOOD DONOR SCREENING FOR HEPATITIS C VIRUS
4.1. GENERAL INTRODUCTION
HCV is recognised as the main cause of PT-NANBH worldwide. Relying on the
results of antibody screening alone for counselling of donors and elimination of
donations from use is problematic since false positive reactions may occur and the
relationship between an antibody response and HCV viraemia is not clearly defined.
In the following sections the relationship between antibody result and viraemia
detected by RT-PCR is examined.
4.1.1. ANTI-HCV ANTIBODY ASSAYS : FIRST GENERATION ASSAYS
The first HCV antigen to become available for antibody screening assays was the 5-1-
1 antigen derived from the NS4 gene. Further cloning led to the purification of the
clOO antigen from the same region of the genome (location shown in fig 3.1., section
3.3.). This antigen was used to coat microtitre plates with the subsequent development
of a radioimmunoassay that specifically detected anti-HCV antibodies in a panel of
well characterised serum samples. Using this newly developed assay system, anti-
HCV antibodies were detected in patients with chronic PT-NANBH whose blood had
proven to be infectious to chimpanzees, and also in the implicated donors to these
patients (Kuo et al.,1989). The development of a commercially available enzyme-
linked immunoassay (anti-HCV clOO ELISA) enabled the widespread screening of
blood donors and anti-HCV testing in certain diagnostic situations.
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Several countries in Europe and the United States initiated programs of blood donor
screening relying on these first generation assays. However sensitivity and specificity
were low, resulting in the reporting of false positive and negative results. Analysis of
stored sera from prospective studies showed that the anti-HCV assay had a sensitivity
of more than 90% when used to test blood recipients who developed NANBH or in
their implicated donors (van der Poel et al., 1990a). However, when used to test
random, non-implicated donors, only 30% to 50% of the donors with repeatedly
reactive serum could be detected by a secondary test such as the recombinant
immunoblot assay (RIBA). One reason for false negative results may be that a
response to the clOO antigen is sometimes not detected for up to three months
following infection (Alter et al., 1989). In addition some polymerase chain reaction
(PCR) proven infections have been shown not to produce an antibody response to
clOO (Weiner et al., 1990). It has also been demonstrated that the clOO RIBA/clOO
EIA combination is less sensitive than the clOO ELA alone (van der Poel et
al.,1990a,b). Another factor contributing towards false negative results may be a
difference in antigenicity due to sequence variablity between different types of
hepatitis C virus.
At this time the only alternative test available was the RIBA with the 5-1-1 and clOO
antigens immobilised on nitrocellulose strips. This assay therefore does not provide
independent confirmation of a positive result as both antigens are derived from the
NS4 region of the genome and is considered to be a supplemental test. To provide
confirmation of a positive result, antigens derived from a different region of the
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genome should be used in the assay system. Alternatively, direct detection using
hybridization or reverse transcription followed by PCR (RT-PCR) should be carried
out in a highly conserved region of the genome such as the 5' ron-coding region
(NCR).
4.1.2. ANTI-HCV ANTIBODY ASSAYS : SECOND GENERATION ASSAYS
In response to these problems a second generation anti-HCV EIA was subsequently
developed which detects antibodies against part of the core polypeptide (c22-3) and
part of the NS3 region (c33c), in addition to anti-clOO. A second generation RIBA
(RIBA-2) was developed containing five recombinant antigens, 5-1-1 and c33c
produced in Escherichia coli, and c 100-3, c22-3 and SOD (superoxide dismutase, a
control) produced in yeast. Donations are classified as positive which show significant
reactivity with two or more HCV antigens (band strength of 1+ to 4+), or
indeterminate when reactivity is with one antigen only. Comparison of the sensitivity
of the second generation EIA with the c 100 EIA and RIBA-2 confirmed the increased
sensitivity of the second generation assays. A retrospective study on PT-NANBH
patients showed that 26 weeks post transfusion, seroconversion was detected in 100%
of patients using the 2nd generation EIA while only 67% were detected with the clOO
EIA (Bresters et al. 1992). In addition, early detection of antibody was observed with
the second generation assay (van der Poel et al., 1992; Wang et al. 1992). The RIBA-
2 gave an increased sensitivity of HCV antibody detection in blood donors, and
transfusion recipients with PT-NANBH and patients with chronic NANBH (Ebling
et al., 1990; Marcellin et al., 1991). The use of second generation tests has
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significantly lowered the risk of transmission of HCV infection via blood transfusion
(Donahue et al., 1992).
4.1.3. ANTI-HCV ANTIBODY ASSAYS : THIRD GENERATION ASSAYS
In an attempt to further increase the sensitivity and specificity of tests, an EIA
containing antigen derived from the NS5 region of the HCV genome in addition to
c 100-3, c33c and c22-3, found in the second generation tests was developed. The
RIBA-3 utilizes three recombinant antigens and two synthetic peptide bands. The
recombinant antigens are c33c produced in Escherichia coli, in addition to NS-5 and
SOD produced in yeast. The synthetic peptide bands consist of peptides derived from
the core and NS4 region of the HCV genome, c22-3 and c 100-3 respectively. Third
generation assays have only recently become available. It is anticipated that the
RIBA-3 will provide additional information on donations determined as indeterminate
by RIBA-2.
4.1.4. DIFFICULTIES ASSOCIATED WITH SCREENING FOR HCV
INFECTION
It has been difficult to predict the prevalence of HCV in blood donors in the UK
since there is a shortage of data on the incidence of post-transfusion hepatitis. A study
carried out in North London suggested a rate of post-transfusion hepatitis which was
much lower that that reported in other parts of the world (Contreras et al., 1991). It
was estimated that transmission occured at a rate of 1 in 1,300 donors in the UK. In
Scotland testing of plasma pools suggested a frequency of < 1 PCR-positive
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donation/1,000 in the local donor population (Simmonds et al., 1990c). Concerns
about the effectiveness of the second generation tests for anti-HCV screening
followed the reporting of data showing continued transmission of HCV by screened
donations (Esteban et al., 1990; Japanese Red Cross Non-A Non-B Hepatitis Research
Group, 1991). Although screening of blood donors in an attempt to prevent PT-
NANBH has greatly reduced the incidence of transmission cases there remain
donations that transmit HCV but which are seronegative or indeterminate in
commercial serological tests (Esteban et al., 1990; van der Poel et al., 1991b). Some
of these false negative serological results may be the result of infection by extreme
sequence variants of HCV that elicit an antibody response that has limited or no cross
reactivity with the peptide antigens used in the serological assays. Such failures may
sometimes be due to infectious donations that are collected in the period between
infection and seroconversion in the donor. In addition, the humoral response to HCV
antigens may be abnormally restricted or reduced in immunocompromised individuals.
In the following sections 4.2.3.- 4.2.4 the relationship between detection of antibody
and HCV viraemia in the blood donating population is considered. An HCV typing
assay is described in section 4.3. which enables the HCV genotype to be determined
without the need for direct sequence analysis. Using such an assay the HCV genotype
may be determined on a large number of samples in a short period of time. The
newly developed HCV typing assay was used to investigate whether sequence
heterogeneity might influence the effectiveness of serological screening for HCV in
blood donors and the extent of nucleotide sequence diversity and distribution of HCV
types worldwide in naturally infected individuals (described in section 4.4.).
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4.2. CORRELATION OF RIBA REACTIVITY AND THE PRESENCE OF
HCV RNA
4.2.1. INTRODUCTION
In September 1991 routine screening of all blood donations in the UK for HCV
antibody was implemented. Screening of low risk populations such as blood donors
produces a significant number of indeterminate results with the REBA-2 assay, which
gives rise to the problem of how to interpret this result in relation to HCV viraemia
and counselling of the donor. Like the first generation HCV tests, the second
generation tests may produce false positive reactions (Kolho et al., 1992; Bresters et
ah, 1992; Garson et ah, 1992). A similar problem of obtaining confirmation of the
initial screening results (EIA) exists as the supplemental tests (RIBA) rely on antigens
derived from the same regions of the genome. Information on the relationship
between RIBA-2 and RIBA-3 positive and indeterminate results and HCV viraemia
was obtained by reverse transcription followed by the polymerase chain reaction (RT-
PCR) to detect HCV RNA in the donating population in Scotland. An accurate value
for the prevalence of HCV infection in Scottish blood donors could then be obtained





A total of 103,203 volunteer blood donations collected in Scotland and Northern
Ireland in the first three months after the introduction of HCV screening (between
September and November 1991) were used in the RIBA-2 study. No repeat donations
should be present as three months is the minimum period between which whole blood
may be donated. Blood donor samples were screened at the Regional Transfusion
Centres (RTCs) for antibody to HCV using second-generation HCV ELISA, (Abbott
GmBH, Wiesbaden-Delkenhein, Germany; Ortho Diagnostic Systems, Raritan, NJ.).
Glasgow, Edinburgh, Aberdeen and Belfast RTCs used the Abbott anti-HCV kit and
referred 275 repeatedly reactive donations from screening 89,708 donations (0.31%),
while the Inverness and Dundee Centres used Ortho kits and referred 65 donations
from screening 13,495 donations (0.48%).
(2) RIBA-3 TESTING
All RIBA-2 indeterminate samples from the first 3 months of screening were tested
by RIBA-3. In addition, between October 1992 and April 1994 a total of 2787
repeatedly reactive donations from screening for anti-HCV by ELISA were referred
to Ruchill Hospital by RTCs. Only new donors and those previously screened giving
a RIBA-2 indeterminate and PCR negative result were included in this number since
all RIBA-2 positive and PCR positive donors would be excluded from further
donation.
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Referred donations were tested by RIBA-2 or RIBA-3 (Chiron Corporation,
Emeryville, California) by Dr. Brian Dow and staff at The SNBTS Microbiology
Reference Unit, Regional Virus Laboratory, Ruchill Hospital, Glasgow. Donations that
were RIBA positive (reactivity with two or more HCV antigens) or indeterminate
(reactivity with only one antigen), were tested for virus RNA by RT-PCR (chapter 2,
sections 2.5. and 2.6.)
4.2.3. RESULTS
(1) SUPPLEMENTARY TESTING : RIBA-2
Of the 340 referred donations, 77 (22.6%) were positive by RIBA-2, 130 (38.2%)
were indeterminate, and the remaining 133 (39.1%) were negative. All RIBA-2
positive samples exhibited reactivity to c33c and c22-3 bands, except for one sample
which only reacted to the 5-1-1 and cl00-3 bands (table 4.1.). Of the 130 samples
indeterminate by RIBA-2, most showed only weak reactivity (scored 1+ or 2+) to one
of the four antigens, 5-1-1, c 100-3, c33c and c22-3 with few strong bands (of 4+)
seen except to the c22-3 antigen (table 4.2.).
(2) CONFIRMATORY TESTING : PCR
During the study period, 65/77 (84.4%) of RIBA-2 positive samples were PCR
positive (table 4.1.), compared to only 7 (5.5%) of the 130 RIBA-2 indeterminate
samples (table 4.2.). None of the indeterminate samples with reactivity to either the
c 100-3 or 5-1-1 antigens were PCR positive, but virus RNA was detected in one
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Table 4.1. RIBA-2 CONFIRMED PATTERNS AND PCR RESULTS OF
REFERRED SAMPLES
RIBA-2 Pattern Total
5-1-1 cl00-3 c33c c22-3 Number PCR+
+ + + + 35 30(86%)
+ + + 2 1(50%)
+ + + 13 10(77%)
- + + 26 24(92%)
+ + - - 1 0
Total no. 77 65(84%)
Table 4.2. PCR RESULTS OF RIBA-2 INDETERMINATES ACCORDING TO
BAND INTENSITY
RIBA-2 No. Intensity PCR+
band
5-1-1 1 1+ 0




c33c 6 1+ 0
2 2+ 1
1 3+ 0




Total no. 130 7
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sample with reactivity to c33c (scored as 2+) and in 6 samples that were strongly
reactive (4+) with the c22-3 antigen. The 133 RIBA-2 negative samples were tested
by PCR in pools of 10, but all were PCR negative. The average virus titre in a unit
of plasma has been reported to be between 5 X 105 and 108 HCV copies/ml (Garson
et al., 1992;). This range was confirmed for Scottish blood donors by titration of ten
samples (section 2.9.). The limit of sensitivity of this RT-PCR assay was 200
copies/ml (Simmonds et al., 1990c). Therefore, introducing a dilution factor of 1:10
by pooling samples would still enable the detection of all but a few infected
donations with extremely low titres of virus.
(3) SUPPLEMENTARY TESTING : RIBA-3
Testing all 130 RIBA-2 indeterminate samples by RIBA-3 produced 14 positive, 28
indeterminate and 88 negative results. Two samples showed reactivity with NS-5
only, and 3 were classified as positive due to additional NS-5 reactivity.
Of the 2787 referred donations, 159 (5.7%) were positive by RIBA-3, 643 (23%)
were indeterminate, and the remaining 1985 (71.3%) were negative. Sixty-seven and
51 RIBA-3 positive samples showed reactivity to 4 and 3 bands respectively, all but
7 had reactivity to the c33c and c22-3 antigens. Forty-one samples (26%) showed
reactiviy to 2 bands only, 17/41 (41%) were reactive to both c33c and c22-3 with
7/41 (17%) and 14/41 (34%) showing reactivity with c33c and c22-3 respectively
(plus one other band) (table 4.3.). Of the 643 indeterminate samples 23%, 23%, 18%
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and 36% showed reactivity to cl00-3, c33c, c22-3 and NS-5 antigens alone
respectively.
(4) CONFIRMATORY TESTING : PCR
Testing all new donors and those with previously RIBA-2 indeterminate RT-PCR
negative results by RIBA-3 identified 159 RIBA-3 positive donors, 114 (71.7%) of
which were also RT-PCR positive (table 4.3.). Five out of 643 (0.78%) RIBA-3
indeterminate samples were RT-PCR positive. Of the RIBA-3 indeterminate samples,
1 sample that showed reactivity to the cl00-3 antigen was RT-PCR positive which
is unusual. One other sample which showed reactivity to the c33c antigen (with a
score of 2+), and RT-PCR positive was identified. This sample was from the same
individual that had shown similar reactivity in the RIBA-2 in the first 3 months of
screening. Of the remaining indeterminate samples 3/16 were RT-PCR positive and
showed reactivity to the c22-3 antigen (table 4.4.).
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+ + + + 67 57(85%)
+ + + - 36 26(72%)
+ + + 3 3(100%)
+ + + 4 4(100%)
- + + + 8 8(100%)
Total no. 51 41(80%)
+ + - 6 2(33%)
+ + - 11 3(27%)
+ - + 3 0
- + + - 17 11(65%)
- + + 1 0
- + + 3 0
Total no. 41 16(39%)
Total no. 159 114(72%)
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Table 4.4. PCR RESULTS OF RIBA-3 INDETERMINATES ACCORDING TO
BAND INTENSITY
RIBA-3 No. Intensity PCR+
band
















Total no. 643 5(0.78%)
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4.2.4. DISCUSSION
Of the 340 referred samples from Scottish and Northern Ireland Blood Transfusion
Centres 72 (21.2%) samples (ie: ELISA repeat reactive samples) were shown to have
HCV RNA in the plasma. The majority of RIBA-2 positive samples were PCR
positive (84%). This finding is consistent with other studies that have demonstrated
the RIBA-2 assay is efficient in detecting donations reactive in first generation EIAs
that were viraemic (Garson et al., 1992; van der Poel et al., 1991c;). In contrast, the
majority of RIBA indeterminate donations failed to react by PCR and only 7 out of
130 (5.4%) were found to contain HCV RNA. All of these samples exhibited a single
band in the RIBA-2 indicating reactivity to the core antigen (c22-3), except for one
sample with reactivity only to the c33c antigen. Twelve of the 77 RIBA-2 positive
samples (15.6%) were PCR negative. These samples and an unknown number of
indeterminate samples may contain HCV antibody and may represent donors that
have recovered from HCV infection. Alternatively, PCR negative samples may be a
result of the PCR assay not being sufficiently sensitive. Fluctuations in the levels of
viraemia may be another possible explanation for these antibody positive and
seemingly PCR negative donations.
The confirmatory strategy used by the SNBTS involves the use of RIBA-2, a
supplementary test incorporating the same antigens as used in the screening tests,
followed by PCR. The use of RIBA-2 as a confirmatory test is therefore less than
ideal. A confirmatory test should be at least as sensitive as the screening test and use
antigens from a different source. For example, confirmation of reactivity in HIV-1
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recombinant antigen ELISAs is made by using Western blots of whole virus lysate
and containing additional antigens. Information from PT-NANBH patient samples
have confirmed that the RIBA-2 system is less sensitive than the screening EIAs in
the early stages of seroconversion (pers. comm. Dr. B. Dow; van der Poel et al.,
1992). However, no PCR positives were found in the ELISA reactive, RIBA-2
negative samples in this study. Although the pooling strategy and the sensitivity of
the RT-PCR would not permit detection of donations with virus titres of less than
200 copies per ml, it is unlikely that significant numbers of specific HCV antibody
containing donations failed to be detected because of any comparative insensitivity
of RIBA-2.
Testing 130 RIBA-2 indeterminate samples by RIBA-3 reduced the numbers reacting
as positive and/or indeterminate to 42. RIBA-3 testing of samples over the initial 3
month period would have reduced the number sent for RT-PCR testing from 207 to
119. It is not possible to compare the RIBA-2 results from the first 3 months of
testing with RIBA-3 results obtained after this date as a different donor population
is being tested. However, since the RIBA-3 incorporates improved recombinant
antigens and synthetic peptides from 4 different regions of the HCV genome it is
anticipated that an increase in sensitivity will be observed. The importance of the
NS-5 component is uncertain, none of the RIBA-3 and RT-PCR positive samples that
showed reactivity to 2 antigens were reactive with the NS-5 antigen and none of the
indeterminate samples that were reactive to this antigen alone were RT-PCR positive.
While reactivity to the c33c and c22-3 antigens appears to have a predictive value
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for RT-PCR positivity the greater sensitivity provided by the RIBA-3 should reduce
further the number of samples that need to be tested by RT-PCR.
The prevalence of HCV infection in the blood donor population in Scotland and
Northern Ireland is 0.07% (no. of PCR positive, RIBA-2 positive or indeterminate
samples/no. of donations screened; 72/103,203) which is relatively low in comparison
with other countries (Stevens et al.,1990; Richards et al., 1991; Alberti et al., 1991).
The prevalence of HCV infected donors is expected to fall in the future as HCV
infected individuals are excluded from further donation. Extrapolation of these figures
to the whole of the UK would suggest that aproximately 3,000 HCV infected donors
would have been identified in the first year of testing.
This study indicates that the only method of determining whether an HCV antibody
positive sample is likely to transmit HCV is to carry out a direct test for HCV
viraemia using the PCR. However, the use of the RT-PCR as a routine screen for
HCV adds significantly to the cost, time and is difficult to standardise. Exclusion of
all RIBA-2 positive donations from further use would eliminate 77 out of 65 PCR
positive donations and thus provide an improvement in the safety of blood and blood
products. However, the RIBA-2 indeterminate donation represents a significant
problem. Most are likely to be nonspecific reactions since they are PCR negative and
may have non-specific antibody reactivity with the antigens used in the assays. A
small number probably represent specific antibody following HCV infection and
some (7 out of 130) may be viraemic. Where funding or access to PCR analysis is
94
limited, routine testing by RT-PCR of REBA-2 or RIBA-3 indeterminate samples
would be the most efficient approach. Alternatively, a combination of alternative
antigen EIAs and/or RIBA-3/line immunoassays could reduce the number of samples
that would require PCR testing (Dow et al., 1993). However, irrespective of the
combination of tests used, PCR remains the only method of identifying a viraemic
donor and the only independent confirmation of viraemic HCV infection.
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4.3. DEVELOPMENT OF AN HCV TYPING ASSAY
4.3.1. INTRODUCTION
There is little information on the effect of virus sequence variation on the
effectiveness of screening for antibody to HCV. The original anti-HCV enzyme
immunoassay (EIA) used a recombinant protein, c 100-3, derived from the NS-4
region of the viral genome as the solid phase antigen in an indirect ELISA, and
proved capable of detecting most, but not all, donations implicated in the
transmission of HCV to recipients (Houghton et al., 1991; Mori et al., 1992). Second
generation EIAs include recombinant antigens from the core and NS-3 regions of
HCV and are capable of much higher detection rates of HCV antibody in blood
donors and haemophiliacs (Bresters et al., 1992; Craxi et al., 1991). However, some
HCV infected blood donors may not be detected because of the delay between
primary infection and seroconversion for antibody to HCV. However, infection with
HCV genotypes divergent in sequence from HCV type 1 might elicit antibodies that
do not cross-react with the antigens used in current screening assays. In order to
investigate this possibility, an RFLP typing system was developed and used to screen
HCV infected blood donors. This information was then used to correlate serological
response with HCV genotype. This assay also led to the identification of novel HCV
genotypes (section 4.3.3.(2)) and allowed their geographical distribution to be
identified (section 4.4.). Sequence information on all HCV variants would assist in
the development of serological tests that are equally sensitive in detecting all HCV
types, not only type 1.
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4.3.2. DEVELOPMENT OF A RFLP ASSAY TO DETECT
HCV TYPES 1 TO 3.
Several different methods have been developed for the typing of HCV variants: direct
sequence analysis (Cha et al., 1992; Chan et al.,1992; Kato et al.,1990), slot-blot
hybridization analysis of RT-PCR products using cDNA probes specific to each HCV
genotype (Takada et al., 1993) and PCR amplification using type specific primers
that are designed to match only viral sequences of a defined HCV type and will fail
to amplify sequences of other types (Okamoto et al., 1992). An alternative method
is the non-selective amplification of virus cDNA using conserved primers followed
by restriction endonuclease cleavage and electrophoresis of the DNA fragments to
detect restriction fragment length polymorphisms (RFLP) (Nakao et al., 1991). The
coding regions of the HCV genome are so variable that reliable amplification of all
HCV types with the same set of PCR primers is difficult. For this reason, typing
methods based on the analysis of amplified DNA are only reliable if carried out in
the highly conserved 5'NCR. It is possible that the RFLP system could be extended
to identify subtypes of the major genotypes since there are certain consistent
differences in the 5' NCR of subtypes within a single genotype. The first combination
of enzymes described were concerned with the identification of HCV type 1 and type
2 (Nakao et al., 1991) specifically. A recently discovered third HCV type (Chan et
al., 1992) would remain undetected by this system.
Predicted cleavage patterns produced by all common restriction enzymes of blood
donor and haemophiliac sequences obtained in a study by Chan et al.(1992) and
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sequences reported elsewhere (Choo et al.,1991; Okamoto et al.,1991; Nakao et
al.,1991; Kato et al.,1990; Takamizawa et al.,1991; Ogata et al.,1991; Fuch et
al.,1991; Han et al.,1991) were computed with standard sequence-analysis software
(Devereux et al.,1984). Restriction enzymes were identified that produced patterns
that were clearly resolved by polyaerylam ide gel electrophoresis. Using the
combination of enzymes HaeHI and Rsal in one reaction along with ScrFI in a
separate reaction it was possible to differentiate HCV types 1, 2 and 3 from each
other by the unique cleavage patterns obtained (see chapter 2, section 2.10. for
experimental details).
A total of 78 HCV sequences in the 5'NCR were compared using phylogenetic
methods (see chapter 2, section 2.8.2.), and assigned into HCV types 1, 2 and 3. A
total of 7 distinct cleavage patterns were predicted for the restriction endonucleases
HaelH and Rsal in combination (fig.4.1a.). All of the type 1 sequences obtained in
this and the study described in chapter 3, section 3.6.3., as well as all published type
1 sequences produced restriction patterns a and b, type 2 sequences patterns c, d and
e, and all type 3 sequences produced patterns f and g (fig.4.1a. and fig.4.2a.).
ScrFI independently differentiates all known type 1 sequences (pattern A, B) from
type 2 (C, D, E and F) and from type 3 (G; fig. 4.1b. and fig. 4.2a). The two
adjacent ScrFI sites present in all but two of the sequence variants (pattern B) could
not be simultaneously cleaved, so patterns A and B are for practical purposes
equivalent, and are referred to as A/B.
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Figure 4.1a.
PREDICTED CLEAVAGE PATTERNS FOR Haein/Rsal DIGEST
a 44 58 114/5 9 26
b 102 114/5 9 26
c 44 12 46 58 56 9 26
d 44 12 46 114 9 26
e 56 46 114 9 26
f 33 69 114 9 26
g 33 23 46 114 9 26
Figure 4.1b.
PREDICTED CLEAVAGE PATTERNS FOR ScrFI DIGEST
A 53 15 48 9 32 94
C 53 15 57 32 94
D 53 15 48 41 94
E 53 15 183
F 53 15 48 135
G 53 15 41 16 126
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Figure 4.2a.
Predicted combinations of RFLP patterns obtained from cleavage with Haelll/Rsal
and ScrFI associated with sequences of HCV types 1 to 3.
ScrFI
A/B C D E F G Type
a 9 _ _ _
1
b 35 1 - - - -
c - 5 -
Haelll d - 1 2 - 2
/Rsal e - 1-1 -
f — — _ _ _ 15
3
g - - - - - 8
Type 1 23
Figure 4.2b.
Observed RFLP patterns of HCV variants amplified from 100 blood donor samples,
showing inferred HCV type.
ScrFI
A/B C D E F G Type
a 3 _ _ _ —
1
b 47 - - - - -
c - 3 -
Haelll d - 1 3 - 2
/Rsal e - 1 2 -
f — _ _ _ _ 38
3




(1) SCOTTISH BLOOD DONORS
Amplified and radiolabeled 5'NCR sequences from a total of 100 PCR-positive,
RIBA confirmed or indeterminate subjects were typed by RFLP with both ScrFI and
HaelH/Rsal. Observed combinations of restriction patterns and therefore the inferred
HCV type for each sample are shown in fig 4.2b. No sample produced restriction
patterns incompatible with the combinations of published or sequences derived as
part of this study (fig. 4.2a). Types 1 and 3 are the predominant variants in Scotland
(table 4.5.); 50% of donors are infected with type 1, 40% with type 3, while type 2
accounts for the remaining 10%.
(2) IDENTIFICATION OF HCV VARIANTS
Using the RFLP system described the distribution of HCV types worldwide was
explored in order to carry out a search for new variants outside the existing
classification. Blood donor samples from nine different countries were available
(described in section 4.4.2.) and previously published sequences from another
worldwide survey (Bukh et al., 1992).
RFLP analysis of plasma samples of Egyptian blood donors indicated that all
infections were of the same type, HCV type 1. In a previous study on Scottish blood
donors (McOmish et al., 1993a), those infected with type 1 showed broad reactivity
with all four antigens in the RIBA-2, while those infected with HCV types 2 and 3
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Table 4.5.
FREQUENCY OF INFECTION WITH HCV TYPES 1 TO 3 IN
SCOTTISH BLOOD DONORS




Total PCR pos 100/113 (88%)
Total PCR neg 13/133 (12%)
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showed reactivity restricted to the NS4 derived antigens (cl00-3 and 5-1-1) only
(see also section 4.4.3(2). and 4.4.4.). RIBA-2 results for the Egyptian blood donor
samples varied, broad and restricted serological reactivity with the antigens in the
RIBA-2 was observed, which would be expected with donors infected with the three
different HCV genotypes, not with type 1 alone, the genotype determined by RFLP.
To further investigate this apparently unusual serological profile, direct sequence
analysis was carried out on all PCR positive donations from Egyptian donors. One
sample from a blood donor in Holland (IN-26; sequence no.7) produced a la
electropherotype with the HaelH/Rsal digest which is not common. This sample was
investigated further also by direct sequence analysis.
Sequences of the 5'NCR (fig.4.3.) are presented as a phylogenetic tree (fig.4.4.). This
analysis reveals sequences 1-10 form a separate cluster from variants previously
typed as 1, 2, and 3. This new group of sequences was assigned as HCV type 4
(Simmonds et al., 1993b). Mean nucleotide distances within type 4, and between type
4 and the other HCV types in the 5'NCR are comparable to those previously
described for intra and inter-type distances for other types (table 4.6a.). The majority
of sequences within type 4 form a close group, but sequences 11, 12, and 13 differ
considerably from any of the known HCV types. Comparison with published
sequences from Zaire (shown as hollow squares) (Bukh et al., 1992) reveals that they
group closely with type 4 sequences described here. However, the relatively small
numbers of substitutions that differentiated these sequences from those of type 1 and
3 meant that an analysis of more variable regions of the genome was neccessary.
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RNA from three representative type 4 variants (EG 29, 33, 21; corresponding to
5'NCR sequences nos. 1-3) was amplified using primers in the core region of HCV
polyprotein (chapter 2, section 2.6., table 2.1.). All three sequences differed
considerably at both the nucleotide and amino acid level from HCV types 1 to 3
(fig.4.5. and 4.7.). Phylogenetic analysis of HCV sequences in the core region gave
further support to the proposal that the sequences designated type 4 did in fact
constitute a new type of HCV (fig.4.6). The unrooted maximum likelihood tree for
core sequences suggests that the three Egyptian-derived sequences form an
independent phylogenetic group since they are separated by long branch-lengths from
the other sequences. Nucleotide distances between type 4 and types 1 to 3 were
comparable to those that exist between the three known HCV types (table 4.6b.).
Although most of the nucleotide sequence changes were silent, there were between

















la lb 2a 2b 3a
HCV-1 HCV-J HC-J6 HC-J8 E-bl EG-16 EG-29 EG-33 EG-3 EG-9 EG-12 EG-13 EG-21 EG-14 EG-23 EG-32 EG-27 IN-26 EG-30 EG-15 EG-1 EG-22 EG-24 EG-25
(1) (1) (2) (3) (3) (3) (3) (3) (4) (5) (5) (6) (7) (8) (9) (10) (10) (10) (10)
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Table 4.6a.
MEAN NUCLEOTIDE DISTANCES BETWEEN THE FOUR MAJOR GROUPS
OF SEQUENCES VARIANTS IN THE 5' NC REGION
n* If 2 3 4
1 14 0.018
2 13 0.091 0.020
3 9 0.095 0.145 0.012
4 13 0.054 0.089 0.080 0.022
* Numbers of non-identical sequences in each group.
t Sequences 14-17 (HK- 1-4) that group with type 1 sequences excluded from
comparison (see section 4.3.3(2).).
Table 4.6b.
NUCLEOTIDE DISTANCES BETWEEN HCV
SEQUENCE VARIANTS IN THE CORE REGION
n* la lb 2a 2b 3a 4f
la 6 0.023
lb 5 0.086 0.036
2a 1 0.223 0.205 0
2b 1 0.193 0.206 0.130 0
3a 1 0.151 0.180 0.219 0.220 0
4 3 0.161 0.157 0.222 0.196 0.223 0.042
* Numbers of non-identical sequences in each group.
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Figure 4.6.
PHYLOGENETIC TREE OF NUCLEOTIDE SEQUENCES
OF PART OF THE CORE REGION
Phylogenetic analysis of nucleotide sequences of part of the core region (positions
13 to 380) using DNAML, shown as an unrooted tree. Sequences numbered as in Fig
4.4.. Sequence 30 corresponds to isolate HC-J8 (Okamoto et al., 1992). All branch
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RFLP analysis carried out on the blood donor samples from Hong Kong showed that
the majority of HCV infections were of HCV type 1. However the remaining samples
displayed an RFLP pattern that was similar to that expected for a 2d electropherotype
with the HaelH/Rsal digest but showed a slightly larger band in the 114bp fragment.
Direct sequence analysis was carried out on 4 representative samples (sequences 14-
17 in fig.4.3. and fig.4.4.). All four 5'NCR sequences from Hong Kong blood donors
and EG-28 and EG-96, showed a single base insertion between position -138 and -
137. In addition the Hong Kong sequences had a two base insertion 5 bp upstream
between position -144 and -143 (numbering as in the HCV-1 sequence; see fig 4.3.).
Apart from these insertions, the Hong Kong sequences differed little from type 1
5'NCR sequences, and cluster relatively closely to the main group of type 1
sequences in the phylogenetic tree (nos. 14-17; fig.4.4.). Sequence data obtained by
Dr. S-W. Chan in the NS-5 region confirmed that these samples from Hong-Kong
also represent a new HCV type, designated type 6 (Simmonds et al., 1993b).
Comparison of these newly identified HCV types with other published sequences
(Buhk et al., 1992; Simmonds et al.,1993b,c) revealed a number of other sequences
that appeared to be of ambiguous status. Two sequences, EG-96 (12) and EG-28 (13)
are linked to the other sequences by long branch lengths (fig 4.4), in addition to
sequence IQ-48 (Simmonds et al., 1993b). Three sequences from South African
patients (hollow circles fig 4.4.; Buhk et al., 1992) appear to be distinct from those
of any of the other HCV types and have been classified as HCV type 5 (Simmonds
et al., 1993c).
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4.3.4. MODIFICATION OF THE RFLP ASSAY TO DETECT
HCV TYPES 1 TO 6
Sequence analysis in the NS-5 region of HCV amplified from plasma of Egyptian and
Hong Kong blood donors revealed a relatively homogeneous group of novel sequence
variants which were as distinct from HCV types 1, 2, and 3 as these types were from
each other. These new sequences were designated HCV type 4 and 6 respectively.
Another group of variants, found in plasma samples from South Africa (Buhk et al.,
1992), were designated HCV type 5. By using the combination of restriction enzymes
HaeEII/Rsal and ScrFI it is possible to identify HCV types 1, 2, and 3. However,
HCV types 4 and 5 would be indistinguishable from HCV type 1 using this
combination of enzymes. Type 1 and type 4 (and type 3) sequences differ in the
number of Hinfl sites present. Type 4 sequences showed a U->C change at position -
166 that creates a novel Hinfl site that is absent in all type 1 (and type 2) sequences.
Using the combination of HaelH/Rsal followed by ScrFI/Hinfl the bands produced
and the nomenclature system used broadly follows that described in section 4.3.2., but
with additional patterns for the two novel genotypes 4 and 6. For simplicity, the two
patterns with ScrFI/Hinfl which are not distinguishable (A and B) by electrophoresis
are referred to as A. Similarly, a rare C->T change found in a type 3 and a type 4
sequence at position -220 (eg. E-bl, Chan et al., 1992; EG-33, Simmonds et al.,
1993b) creates a new Hinfl site, but the position of cleavage is 3 base pairs (bps)
downstream from a conserved ScrFI (or Mval site). As these two sites could not be
simultaneously cleaved, the polymorphism would not affect the overall pattern of
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bands. Since there are no other variable Hinfl or ScrFI sites in type 3 and 4
sequences, a single letter (G, H) has been assigned to each respectively.
Using the combination Haelll/Rsal, patterns designated a and b are predicted for
published type 1, type 4 and type 5 sequences, while patterns designated c, d and e
were uniquely associated with type 2 (fig.4.8a.). Patterns f and g should be produced
by all known type 3 sequences, and pattern h by type 6. The latter pattern differs
from pattern d (type 2) by the two insertions (total 3 bp) in the 114 bp fragment. This
size difference can be readily resolved by polyacrylamide gel electrophoresis of the
cleaved DNA.
The second set of restriction enzymes (ScrFI/ Hinfl) produces different bands for five
of the six HCV genotypes (fig.4.8b.). For type 6 sequences, a 3 bp insertion in the
35 bp fragment (pattern I) distinguishes them from type 1 sequences (pattern A; 32
bps). With neither combination of enzymes is it possible to distinguish type 5 from
type 1 sequences. The type 5 sequences can be distinguished from type 1 by replacing
ScrFI (GGnCC) with Mval (GG[A/T]CC) to identify an A/G polymorphism at
position -162, and a U/C polymorphism at position -121. Further studies using
Mval/Hinfl indicate that this combination can be used to entirely replace the
ScrFI/Hinfl combination for identification of all six genotypes (section 4.4.6.), as
suggested by analysis of predicted fragment patterns of the published sequences
(fig.4.8a.and 4.8c.). Out of a total of four possible electropherotypes, all type 1
115
sequences produce pattern A, and type 5 produces pattern D. RFLP gels are shown
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4.4. GEOGRAPHICAL DISTRIBUTION OF HEPATITIS C VIRUS
GENOTYPES IN BLOOD DONORS
4.4.1. INTRODUCTION
The six major genotypes of HCV have distinct nucleotide sequences in the 5'NCR
(Buhk et al.,1992; Simmonds et al.,1993), and so viruses can be typed by RFLP
analysis of DNA amplified from this region of the viral genome by reverse
transcription of RNA followed by PCR (McOmish et al., 1993a; Nakao et al., 1991).
Developing a typing assay based on RFLP requires considerable amounts of
comparative sequence data, as there is also some intratypic sequence variability that
may lead each genotype to show more than one electropherotype. Furthermore,
assays may need to be modified as more HCV genotypes are discovered.
The distribution of the six recognised genotypes in 447 anti-HCV positive volunteer
blood donors from nine different countries; Scotland, Finland, the Netherlands,
Australia, Egypt, Hungary, Japan, Hong Kong and Taiwan was examined. Serological
reactivities to the structural and non-structural HCV type 1 antigens in the
recombinant immunoblot assay (RIBA-2) assay of samples from donors infected with
different genotypes were assessed in parallel.
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4.4.2. SAMPLES
Samples from blood donors from Scotland, Egypt (expatriates working in Riyadh,
Saudi Arabia), Finland, Netherlands, Hungary, Australia, and Hong Kong were
available from routine 2nd Generation anti-HCV ELISA screening (Ortho or Abbott).
Samples from Japan were screened by anti-HCV passive haemagglutination assay
(HCV-PHA) using red blood cells coated with PHCV-34 and PHCV-31 antigens
(Dainabot Co. Ltd., Abbott, Japan). Samples from Taiwan were screened using a
second generation ELISA with HCV antigens equivalent to c22-3, c33c and c 100-3.
All screening assays were carried out in the country of origin.
Donations from Finland, Netherlands, Hungary, Australia, Egypt that were repeatedly
reactive on screening by Abbott (Abbott GmBH, Wiesbaden-Delkenheim, Germany)
or Ortho (Ortho Diagnostics Systems, Raritan, NJ), 2nd generation assays were tested
further by the RIBA-2 (Chiron Corporation, Emeryville, CA.) (table 4.7.). Samples
that were confirmed positive or indeterminate were shipped frozen to Edinburgh for
further analysis by polymerase chain reaction (PCR). In Hong Kong, the Abbott
Matrix assay was used for supplementary testing. Samples reactive on screening from
Japanese donors that showed titres of > 212 in the HCV-PHA assay were referred to
Scotland, while those from Taiwanese donors were referred without prior confirma¬
tory testing. In interpreting the RIBA-2 results, reactivity with the 5-1-1 and c100-3
antigens, and no other bands, were considered as an indeterminate result. Both
antigens are derived from the same region of NS-4 and could be reacting with the




Amplified sequences from each of the 447 PCR-positive donations were cleaved with
two sets of restriction endonucleases (Haelll/Rsal and ScrFI/Hinfl). A wide range of
electrophoretic patterns were found in the study samples, but almost all could be
assigned to those predicted for published sequences (n=443; table 4.8.). In no cases
were there incompatible combinations of RFLP pattern between the two sets of
enzymes (fig. 9a.), and all 443 sequences could be assigned as types 1 or type 5, 2,
3, 4, and 6. As sequences of genotype 5 produce the same RFLP patterns with both
sets of restriction endonucleases as type 1 (fig. 4.8a. and 4.8.b.), a third cleavage
reaction with Mval/Hinfl was carried out on the 252 samples showing the aA or bA
electropherotypes (fig. 4.9b.). All but one sample showed the A electropherotype
indicating type 1, while the exception showed the D pattern consistent with a type
5 sequence.
Types 1, 2 and 3 were found in the three western European countries surveyed and
in Australia, with types 1 and 3 being similar in prevalence and type 2 forming
approximately 20% of the total (table 4.9.). One Dutch donor was infected with a
variant that showed an RFLP pattern with ScrFI/Hinfl normally associated with type
4; this sample was sequenced and found to be similar to those obtained from the
Middle East and Egypt (section 4.3.4.) (Simmonds et al., 1993b), Zaire (Bukh et
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Table4.7.
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Table4.8.
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al., 1992), and Burundi (Stuyver et al.,1993) and which had previously been assigned
to the type 4 genotype (Simmonds et al., 1993b,c; Stuyver et al.,1993). Upon
checking of donor records, this individual was found to have originated from
Indonesia and may have acquired infection there. The one sample identified by RFLP
as type 5 (bA, D with Mval/Hinfl) originated from Australia; direct nucleotide
sequence analysis confirmed its identity as type 5, as it was identical to the 574CR
sequences of the previously identified type 5 variants SA1, SA3, SA7 and SA11
(Buhk et al., 1992; Simmonds et al., 1993c). This donor was of French/Polish
ancestry. Her only admitted risk factor for HCV infection was blood transfusion in
France. No history of travel to South Africa was reported. The distribution of HCV
genotypes was markedly different in Hungary where all but one were infected with
type 1. The one exception produced an RFLP pattern consistent with type 4 (aH), an
identification also confirmed by direct sequence analysis.
Type 1 was also the most frequent found genotype in countries in the Far East,
although these countries differed from many of those in Europe by the complete
absence of HCV type 3. Approximately a quarter of donors from Hong Kong were
infected with a novel HCV type, designated type 6 (Buhk et al., 1992; Simmonds et
al., 1993b,c). A completely different distribution of HCV infection was found in
Egypt, where all donors who could be typed (17/19) were found to be infected with
HCV type 4 (table 4.9.).
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Only two of the donors showed evidence of infection with more than one genotype.
Both of these were from Hong Kong and showed a mixed pattern of type 1 and type
6 electropherotypes. Co-infection with two genotypes was confirmed by limiting
dilution of cDNA amplification of single molecules by nested PCR (Simmonds et al.,
1990a). RFLP analysis of DNA amplified from five single molecules yielded 3 type
1 and 2 type 6 sequences from one of the two donors who showed this type of mixed
pattern.
Two of the nineteen samples from Egypt produced anomalous RFLP patterns
producing bands with HaelH/Rsal larger than any of those predicted in fig.4.8a..
Sequence analysis confirmed that a A->U or an A->C change at position -177
eliminated the normally well conserved Rsal site to produce bands of 44, 173 (ie. 58
+ 115; see pattern a), 9 and 26 bps, or 217 (ie. 102 + 115; see pattern b), 9 and 26
bps. Although the first sequence showed substantial similarity to type 4 variants, they
have both been left unassigned, sequence data in the NS-5 region is currently being
obtained to allow formal classification.
(2) SEROLOGY
Irrespective of the geographic origin of the donor, sera from those infected with HCV
type 1 showed broad reactivity with all four antigens in the 2nd generation RIBA-2
with a high mean score in all cases (fig.4.10; table 4.10.). The antibody response
elicited by infection with HCV types 2, 3, 4 and 6 showed reactivity that was largely
restricted to c33c and c22-3 antigens (fig. 4.10.) (HCV type 5 is represented by 1
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sample only in this study, serological reactivity of type 5 infected donors is
considered separately in section 4.4.4.). Reactivity to 5-1-1 was found in 79%, 17%,
7%, 42% and 33% in donors infected with types 1, 2, 3, 4 and 6, respectively, and
to cl00-3 in 78%, 34%, 33%, 58% and 58% respectively (table 4.10). There was a
significant difference between the proportion of type 1 samples reactive with 5-1-1
compared with the other four genotypes either individually (type 2, /?<0.0001; type
3, p<0.0001; type 4,/?<0.001 and type 6,/?<0.001) or collectively (%2=176, 4 degrees
of freedom on a 2 x 2 contingency table; p<0.0001). There were also significant
differences between type 1 and type 2, 3, 4 and 6 in the frequency of reactivity to
cl00-3 (p<0.0001, p<0.0001,p<0.05,/?=0.1). Between type 1 and the four genotypes
together there was a highly significant difference (%2=82, 4 degrees of freedom,
p<0.0001).
Only 26 out of 430 RIBA-indeterminate samples were PCR positive (6%) compared
with 421 PCR-positive out of 526 RIBA-2 confirmed samples (80%) (table 4.10.).
All indeterminate donations reactive with the NS-4 derived proteins clOO-3 or 5-1-1
were PCR negative, while a significant proportion of those showing an indeterminate
reaction with c33c or c22-3 were PCR positive (2/24, 23/339 respectively).
Approximately 20% of donors infected with type 3 were reactive with c22-3 only,
compared with 3% of those infected with type 1 (%2=23; p<0.0001). However,
sequence variability was not the only cause of restricted serological reactivity, as
many of the samples that failed to react with c 100-3 and 5-1-1 were obtained from
donors infected with type 1 (10 of 430 RIBA-indeterminate samples and 33 of the
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166 samples reactive with c22-3 and c33c only). Whether this restricted pattern of
reactivity is associated with proximity to seroconversion is currently being assesed
by testing previous donations and follow-up samples from the donors. Retrospective
testing of stored samples has shown that the type 1-infected donor with reactivity to
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Frequency of reactivities to antigens in the RIBA-2 assay by samples from blood
donors infected with different genotypes of HCV. The values above the histogram
indicate the mean score for each type with each antigen, from 0 (nonreactive) to 4+.
Samples from 252 type 1, 86 type 2, 73 type 3, 19 type 4, 1 type 5, and 12 type 6
infected donors were used for comparison.
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4.4.4. INVESTIGATION OF THE PREVALENCE AND DISTRIBUTION OF
HCV TYPE 5.
The study described in section 4.4. examined the distribution of HCV genotypes in
blood donors from nine different countries, some genotypes (types 1, 2, and 3)
showed a broad distribution while others were detected in one country only (types
4 and 6). Infection with HCV type 5 has been reported to occur in South Africa
(Bukh et al., 1992) and has only rarely been found in Europe or elsewhere (section
4.4.3.; McOmish et al., 1994). To further investigate the prevalence and distribution
of HCV type 5, blood donor samples from two different areas in South Africa were
tested using an RFLP system that detects the six known genotypes of HCV (section
4.3.4.; McOmish et al., 1994).
4.4.5. SAMPLES
Eighty four blood donor plasma samples (42 black donors and 42 Caucasian donors)
from the Johannesburg area and 29 samples from the Durban area that had been
screened by second generation ELISA and found to be repeatedly reactive were
shipped frozen to Edinburgh for RT-PCR testing (kindly provided by Dr. Kew,
University ofWitwatersrand, Johannesburg and Dr. Conradie, The Natal Institute of
Immunology, Division of The Natal Blood Transfusion Service, Durban,
respectively). PCR positive samples were tested by RIBA-2 by Dr. Brian Dow at
Ruchill Hospital. In interpreting the RIBA-2 results plasma with reactivity to both
5-1-1 and cl00-3 antigens were considered as indeterminate (see section 4.4.2.).
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4.4.6. RESULTS
(1) PCR AND HCV TYPING
Sixty three of the 84 (75%) and 25 out of 29 (86%) samples were PCR positive from
Johannesburg and Durban respectively. HCV genotype was determined by RFLP
analysis using the restriction endonucleases HaelH/Rsal and Mval/Hinfl which
enables all six known HCV genotypes to be identified (section 4.3.4.; McOmish et
al.,1994). Electrophoretic patterns obtained could be assigned to one of the six
genotypes in all but 3 of the samples from Johannesburg (table 4.11.). Sequence
analysis in the 5'NCR in three of the samples showed that a A—>U change at position
-177 eliminated the usually well conserved Rsal restriction site producing bands of
217, 9 and 26 bp. All three sequences show similarities to type 4 sequences in the
5'NCR but await sequence analysis in core and NS5 regions to allow classification.
In both centres types 1 and 5 were the predominant genotypes found with some
infections attributed to types 2, 3, and 4 (table 4.12.). It was not possible to obtain
information on the geographical origin of the donors infected with types 3 and 4,
however the one donor from Durban that was infected with HCV type 2 had a
surname consistent with a Far Eastern ethnic origin.
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Table4.11.
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The distribution of the HCV types was similar in black and Caucasian blood donors,
of the 26 type 1 sequences identified 12 and 14 were from Caucasian and black
donors respectively. The 49 HCV type 5 sequences identified were similarly split
between 20 Caucasian donors and 29 black donors.
(2) SEROLOGY
RIBA-2 results were available on all 25 of the PCR positive samples from Durban
and on 46 of the 60 PCR positive samples from Johannesburg (table 4.13.). A similar
trend was found as before (section 4.4.3.(2)), those infected with HCV type 1 showed
broad reactivities with all four antigens in the RIBA-2 with a high mean score in all
cases (fig. 4.11. and table 4.13.). Of the 39 donors infected with HCV type 5
reactivity to the 5-1-1, cl00-3, c33c, and c22-3 antigens was 53%, 67%, 75%, and
95% repectively (fig. 4.11. and table 4.13.). The mean score for reactivity to the NS4
encoded antigens was low. Such a response is similar to the serological profile found
in individuals infected with HCV types other than type 1. The antibody response
produced by the 7 donors infected with HCV type 3 showed reactivity to the c33c
and c22-3 antigens only. (HCV types 2 and 4 were represented by 1 sample each in
this study, both samples showed reactivity with the c33c and c22-3 antigens only).
Of the 18 PCR positive samples that were indeterminate in the RIBA-2, all but one
showed reactivity to the c22-3 antigen only. Antibody elicited by one type 5 sample




Frequency of reactivity to antigens in the RIBA-2 by samples from 22 and 39 blood
donors infected with HCV type 1 and 5 respectively. The values above the histogram
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4.4.7. DISCUSSION
The main problem with any HCV typing assay is the need for continual modifica¬
tions as new HCV genotypes are discovered. Many of the assays that use type-
specific primers could be predicted to either fail to differentiate genotypes, or fail to
amplify sequences unrecognised when the primers were originally designed. For
example, none of the primers used for identification of genotypes I, II, III, and IV
(types la, lb, 2a, 2b) described by Okamoto et al., (1990) would be likely to amplify
either type 3 and type 4 sequences. Similarly, type-specific probes for amplified NS-5
or 5'NCR based on these genotypes would fail to hybridise or hybridise
inappropriately to many of the newly recognised genotypes (Enomoto et al., 1990;
Stuyver et al., 1993; Takada et al., 1993).
There is now a considerable amount of comparative sequence data from several
geographical regions in the 5TMCR of HCV types 1, 2 and 3. It is therefore possible
to predict a comprehensive range of possible electropherotypes with the restriction
enzymes used, and to reliably differentiate these genotypes from each other. It is
likely that a wider range of electropherotypes will be found for genotypes, and
continuous modification of fig.4.8. will be required as new data accumulates. Some
of the sequences closely resembling type 4 (Simmonds et al., 1993b,c), but which
were obtained from West Africa rather than the Middle East (Bukh et al., 1992;
Stuyver et al., 1993) would produce patterns with Haelll/Rsal other than a and b,
although all would produce the C electropherotype with Mval/Hinfl.
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The RFLP method described only detects the majority circulating sequence of HCV;
co-infection with two or more genotypes is only apparent when approximately
equimolar concentrations of different sequences are present within a sample. Only
two co-infections (both from Hong Kong donors infected with type 1 and type 6)
were detected and could be an underestimate of the true rate of mixed infection.
Assays based on type-specific amplification of different genotypes would be expected
to be more sensitive indicators of multiple infection (Kato et al., 1991; Okamoto et
al., 1993), provided that separate amplification reactions were carried out for each
pair of type-specific primers.
This large scale survey of blood donors shows that major differences exist in the
geographical distribution of HCV variants. Donors in western European countries
(Scotland, Holland and Finland) were almost exclusively infected with types 1, 2 and
3 while those in the Far East (Japan, Taiwan, Hong Kong) were mainly infected with
type 1, with lower frequencies of type 2 and type 6 in Hong Kong. The situation is
highly complex and difficult to interpret as there are genotypes with world-wide
distributions (eg. type 1, 2) co-existing with those which are apparently confined to
specific geographical areas (type 4, 5, and 6).
The data from blood donors in this survey is consistent with that obtained from
smaller surveys of a variety of different patient groups with non-A, non-B hepatitis
or hepatocellular carcinoma (Kato et al., 1991; Takada et al., 1992a,b; Takada et al.,
1993). However, these latter studies are potentially biased towards those genotypes
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that are more likely to cause more severe liver disease. Current evidence suggests
that genotype 1 is associated with a higher rate of chronic active hepatitis or cirrhosis
than genotypes 2, 3 or 4 (Dusheiko et al., 1994), and a much poorer response to
treatment with a-interferon compared with type 2 (Kanai et al., 1992; Takada et al.,
1992b; Yoshioka et al., 1992) and type 3 (Dusheiko et al., 1994). It is possibly
significant that amongst the asymptomatic blood donors in this study, a much higher
rate of non-type 1 variants (43%) was found than in previous surveys.
More complex distributions of HCV genotypes may be found as more countries are
surveyed. HCV type 3 has been found in Thailand and India (pers comm. Dr. L.
Jarvis, Dept. Medical Microbiology, Edinburgh). In the former country, type 3
accounts for approximately two thirds of HCV infections in haemophiliacs treated
with locally prepared factor VIII concentrate (Jarvis et al., 1994 manuscript in press
JID). Type 5 is only commonly found in South Africa (this study, section 4.4.4.;
Bukh et al., 1992), although it does occur sporadically elsewhere (one donor
identified in Australia in this study and another in Northern Ireland detected when
screening blood donations).
Any attempt at interpretation of these geographical differences is hampered by
current ignorance surrounding the method of virus transmission. Needle sharing,
transfusion of blood and blood products, tattooing and other forms of parenteral
exposure have been implicated in the transmission of HCV, while the current
evidence suggests that intra-familial, mother-to-child, sexual or inter-familial
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transmission are relatively inefficient modes of virus spread. There is therefore little
understanding of how or whether HCV might spread in societies where blood
transfusion and parenteral drug abuse are uncommon. It is difficult to interpret the
data obtained, similarity in distribution of HCV genotypes in Australia compared
with western Europe (and its difference from other Far East countries) could be
explained by assuming an ancient origin for HCV, and relating the distribution of
genotypes to the original European ancestry of the majority of Australian blood
donors. On the other hand, it may be that HCV was relatively recently introduced by
importation of contaminated commercial blood products manufactured from paid
donations collected in North and Central America, or by needle sharing with HCV-
infected individuals from Europe or the USA.
The existence of distinct HCV genotypes with up to 30% sequence diversity could
potentially result in significant antigenic variation among homologous proteins
encoded by the different genotypes of HCV. The effect that this sequence variation
would have on the effectiveness of antibody screening for HCV has not been widely
studied. All current assays use antigens derived from HCV type 1 sequences, and rely
on cross-reacting antibody to detect infection with other HCV genotypes. This is
illustrated by the first generation assays that used the c 100-3 recombinant protein
derived from NS-4. The antigenic region was found to be particularly variable in
sequence between HCV types 1, 2 and 3 (Simmonds et al., 1993a), and led to a low
rate of detection of infection with variants other than type 1 (Chan et al., 1991;
McOmish et al., 1993a). In this study, the majority of individuals infected with
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genotypes 2 to 6 show weak or absent reactivity to c 100-3, confirming similar
observations for types 2 and 3 on a relatively smaller number of individuals
(McOmish et al., 1993a). This lack of cross-reactivity provides at least one
explanation for the continued transmission of HCV by blood screened by anti-ClOO
assays alone (Esteban et al.,1990; Japanese Red Cross NANBH Research Group,
1991).
All donors infected with types 2 to 6 reacted with the recombinant core protein, c22-
3 reflecting its greater degree of amino acid sequence conservation (90%) than the
non-structural proteins (75-80%). However, this observation is misleading because
c22-3 is a component of screening and confirmatory assays for HCV infection. In
interpreting these results, the pre-selection by the screening assays precluded an
analysis of the proportion of infections with divergent HCV types that elicited an
even more restricted serological response so as to be undetectable by current blood
donor screening. The actual frequency with which samples from individuals infected
with variants other than type 1 are missed by current 2nd generation screening assays
(that contain c33c and c22-3 as well as NS-4 proteins) is unknown, but probably low.
However, it is recognised that the serological response to HCV-encoded antigens is
often narrow in specificity, and is generally of low titre. Acute infection with HCV
following transfusion of infectious blood or blood products may fail to elicit antibody
for several months (van der Poel et al.,1992). Furthermore, individuals who are only
marginally immunosuppressed (such as renal dialysis patients, the elderly,
haemophiliacs and neonates) generally show extremely restricted and idiosyncratic
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patterns of serological reactivity, often to only one (or possibly none) of the four
antigens used in current screening assays (Lelie et al., 1992). In all of these cases,
it would be beneficial to have a test that is optimally sensitive for all variants of
HCV. Evaluation of assays that incorporate additional peptide antigens corresponding
to epitopes of other HCV types not shared with type 1 may represent a first step in
improving current assays.
4.5. COMPARISON AND VALIDATION OF A TYPE SPECIFIC ANTIBODY
ASSAY WITH AN RFLP ASSAY
4.5.1. INTRODUCTION
The NS-4 region encoding the c 100-3 antigen is variable between different isolates
of HCV, showing only 75-77% sequence similarity between HCV types 1 and 2.
There is evidence that this affects serological recognition demonstrated by the relative
infrequent serological reactivity of sera from blood donors infected with HCV types
2 and 3 with NS-4-derived antigens in immunoblot assays (section 4.2., McOmish
et al., 1993a; McOmish et al., 1994), and frequent negative results in the original 1st
generation blood donor screening assays. An investigation of the distribution of
epitopes in the NS-4 region encoding c 100-3 for HCV types 1, 2 and 3 was carried
out (Simmonds et al., 1993a). The frequency of serological reactivity to synthetic
peptides corresponding to two antigenic regions of the sequenced region of the three
HCV types was examined using samples from blood donors infected with known
HCV types determined by RFLP. This enabled an investigation of the frequency of
type-specific and cross-reactive antibody specificities to be determined in naturally
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infected individuals. The newly developed assay for type-specific antibody was used
to detect infection with different HCV types in anti-HCV positive blood donors, and
the incidence of mixed infection in haemophiliacs multiply exposed to HCV and
compared with the genotype determined by RFLP analysis.
4.5.2. SAMPLES
Plasma samples were obtained from 137 HCV-infected blood donors identified by
screening with Abbott or Ortho second generation ELISA. Plasma samples were also
obtained from 27 HIV-uninfected haemophiliacs treated with non-heat inactivated
factor VIII and IX concentrates and who had been infected with HCV for several
years. All samples were anti-HCV positive by several second generation screening
and confirmatory assays (Dow et al., 1993; section 4.2.3.). Control samples were
obtained from anti-HCV negative blood donors. All samples from anti-HCV positive
blood donors were screened for antibody to the recombinant c 100-3 recombinant
protein using the Abbott 1st generation EIA, according to the manufacturer's
instructions.
Development of the type-specific antibody assay and serological typing of samples
was carried out by Ken Rose and is described in Simmonds et al, 1993. RFLP




A total of 137 samples from donors typed by RFLP analysis of sequences amplified
by PCR in the 5'NCR were assayed blind for the presence of type-specific antibodies
using the HCV-TSAA (table 4.14.). Upon de-coding the results, it was found that
there was good correlation between the results of the two assays. Almost all samples
that could be serologically typed contained antibody of a single type-specificity
corresponding to the HCV type detected by PCR (118/122). Antibody to one of the
HCV types found in the four samples with dual specificity also corresponded to the
%
circulating HCV type identified by PCR. Only 15 samples could not be typed using
the serological assay; 7 were non-reactive with the NS-4 antigens at either 1/40 or
upon retesting at a 1/10 test dilution, while the remaining 8 contained no detectable
type-specific antibody.
To investigate whether the HCV-TSAA could reliably detect multiple infection,
samples were tested from 27 HCV-infected haemophiliacs treated for several years
with non-heat treated factor VIII or IX, and who have potentially been exposed to
all three types of HCV over the years of treatment (Ludlam et al., 1989; Watson et
al., 1992). It was found that a higher proportion of samples showed type-specific
antibody to multiple HCV types. In blood donors, only 4 samples out of 122 showed
evidence of multiple infection (3%), dual or even triple antibody specificities were
found in 8 of the 20 haemophiliac samples typed by HCV-TSAA (40%; table 4.14.).
Antibody to types 1 and 3 was most frequently found in the haemophiliacs. Most had
only been treated with factor VIII or EX concentrates derived from local plasma
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Table 4.14.
COMPARISON OF SEROLOGICAL TYPING BY HCV-TSAA WITH PCR
Number TYPE-SPECIFIC ANTIBODY
PCRa tested 1 2 3 1+2 1+3 2+3 1+2+3 NTSb N?
1 68 61 - - - 1 - - 3 3
2 13 - 11 - - - 1 - 1 0
3 56 1 - 45 - 2 - - 4 4
Hemd 27 10 - 2 1 6 - 1 2 5
a Genotype of HCV sequences amplified by PCR and typed by RFLP
b NTS : No type-specific antibody detected
c NR : non-reactive with NS-4 peptides
d Samples from HCV-infected haemophiliacs, un-typed by PCR.
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donations, and is consistent with previous observations these two types are the
predominant HCV variants detected in Scottish blood donors (section 4.3.3. and
McOmish et al., 1993a).
4.5.4. DISCUSSION
The amino acid sequences of the antigenic regions of the three HCV types differed
considerably from each other. In the attempt to develop a type-specific antibody
assay (TSAA) it was assumed that serological reactivity to them would be type-
specific. However, substantial degrees of cross-reactivity were observed upon epitope
mapping and ELISA with branched peptides (Simmonds et al., 1993a). To detect
type-specific antibody, it was necessary to absorb out cross-reactive antibody with
a molar excess of heterologous peptides in solution, on the basis that the only
antibody that could bind to the solid phase was that which reacted with epitopes not
shared with other HCV types. Using this modification to the assay, in general, the
circulating HCV genotype detected by PCR/RFLP in samples from HCV-infected
blood donors corresponded to the detection of type-specific antibody to the
corresponding HCV serotype (table 4.14.). The detection of dual antibody specificity
in samples from four donors suggested that they had been exposed and infected with
more than one HCV type; in such cases the PCR type corresponded to one of the
HCV types for which type-specific antibody was detected. A total of 122 of 137
blood donor samples were successfully typed (89%) serologically, of which all but
one were consistent with HCV genotyping by PCR. Although the serological assay
for type-specific antibody to different HCV types does not necessarily reflect actively
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replicating virus in cases of recent infection, it is possible that this could provide a
practical alternative to the PCR-based typing assays (Enomoto et al.,1990; McOmish
et al., 1993a; Nakao et al., 1991; Okamoto et al., 1991) currently available, and the
only possible assay in those who are anti-HCV positive, but PCR negative.
In this study it was found that almost all blood donors had antibody to only a single
type. This is perhaps surprising in view of previous observations that the major risk
factor for HCV infection in this particular group of blood donors is past intravenous
drug abuse by needlesharing and that both HCV type 1 and 3 are approximately
equally prevalent in this particular risk group in Scotland (section 4.3.3.; McOmish
et al., 1993; Crawford et al., 1994). A higher rate of multiple infection was detected
in haemophiliacs treated with non-inactivated factor VIII or IX (40%), higher than
that detected by PCR-based typing of circulating RNA sequences (Okamoto et al.,
1992b), but which still does not reflect the full extent of their exposure to HCV over
the years of treatment with factor VIII. It is possible that past infection with HCV
completely or partially protects the individual from further infection, or attenuates the
secondary immune response to the extent that type-specific antibody to the re¬
infecting virus type remains undetectable.
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CHAPTER 5
5. HEPATITIS C VIRUS TRANSMISSION BY INTRAVENOUS
IMMUNOGLOBULIN
5.1. GENERAL INTRODUCTION
Until recently intravenous immunoglobulin (IVIG) preparations had a very good
safety record with respect to transmission of viruses. Even in the absence of specific
virus inactivation procedures, immunoglobulins prepared by the Cohn procedure have
been free of disease transmission. In this process, serum proteins are separated by a
sequence of precipitations with ethanol at low temperature, ionic strength and pH.
Contaminating viruses partition into the precipitated fractions which are discarded in
the production procedure (Louie et al., 1994). Immunoglobulin G constitutes 95 to
99 percent of the protein in Cohn Fraction II with varying small quantities of IgA,
IgM, IgD, IgE and other proteins. In the final stages of production contaminating
ethanol is removed under conditions designed to prevent the formation of aggregated
immunoglobulin, while further processing (finishing steps) reduces the levels of
spontaneous anticomplementary activity and vasoactive substances. Finishing steps
used by different manufacturers are DEAE sephadex filtration or treatment at pH4.0
with low concentrations of pepsin, the latter treatment providing a degree of virus
inactivation (Louie et al., 1994; pers comm Dr.H.Hart, Protein Fractionation Centre,
Edinburgh).
The following sections describe and investigate HCV transmission by two different
immunoglobulin preparations. The first, from normal human immunoglobulin used
in the treatment of immunodeficient patients and the second, from a specific
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immunoglobulin (anti-D immunoglobulin) administered to RhD- women after
pregnancy. Different manufacturing processes were used in the preparation of these
different batches of immunoglobulin and is relevant in considering how HCV
transmission by these products may have occurred.
5.2. A RETROSPECTIVE STUDY OF IMMUNODEFICIENT PATIENTS
5.2.1. INTRODUCTION
Intravenous immunoglobulin (IVIG) preparations allow large amounts of
immunoglobulin to be administered rapidly and painlessly to patients with
deficiencies in antibody production. Individuals with primary immunodeficiency
diseases such as X-linked agammaglobulinemia (XLA), common variable
immunodeficiency (CVI) and X-linked immunodeficiency with
hyperimmunoglobulinemia M are characterised by low or undetectable amounts of
all five serum immunoglobulin classes. Another group of patients who benefit from
IVIG administration are those with normal or near-normal immunoglobulin levels but
who have marked impairment in their ability to produce specific antibodies after
immunization. Such patients include males with the Wiskott-Aldrich syndrome who
are unable to produce antibodies to polysaccharide antigens and have blunted
anamnestic responses to protein antigens, and patients with ataxia telangiectasia, a
hereditary degenerative disease of the spinal cord, cerebellum and other parts of the
nervous system. Children with transient hypogammaglobulinemia of infancy may
have low serum concentrations of all or some immunoglobulins during the first few
months of life, although normal amounts of specific antibodies in response to
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immunization are often observed. The administration of exogenous antibody may
inhibit endogenous antibody formation in these patients (Tiller et al., 1978). The only
clear indication for replacement therapy with intravenous immunoglobulin in patients
with selective IgG subclass deficiency is a demonstrated deficiency in the ability to
form antibodies against a variety of polysaccharide and protein antigens.
Secondary immunodeficiency may be the result of disease or trauma (Berkman et al.,
1990). Haematological cancer patients or individuals receiving immunosuppressive
agents for the treatment of cancer may be antibody deficient. Those with HIV
infection, particularly infants, may have defects in their ability to form specific
antibodies, even though serum immunoglobulin levels are usually elevated.
Administration of intravenous immunoglobulin to HIV infected individuals may
prolong survival by reducing the risk of opportunistic infection.
IVIG produced by Cohn fractionation using mild manufacturing methods in the
finishing step, such as gel chromatography and ultrafiltration (or none at all), have
been implicated in the transmission of NANBH (Lane, 1983; Lever et al., 1984; Ochs
et al., 1985; Ochs et al., 1986; Weiland et al., 1986; Hammarstrom and Smith, 1986;
Bjorkander et al., 1988; Quinti et al., 1990), and also from one product treated at
pH4 with low concentrations of pepsin in the final stage (Williams et al., 1989). At
the time of publication of these reports the agent of NANBH was yet to be confirmed
as the hepatitis C virus (HCV) and reliable serological assays were not readily
available. As a result the diagnosis of NANBH was generally one of exclusion (of
154
HBV and CMV) in the presence of abnormal liver function tests or histological
appearance in liver biopsies. In addition most of the patients involved suffered from
either X-linked agammaglobulinaemia (XLA) or common variable immunodeficiency
(CVI) (Lever et al., 1984; Ochs et al., 1985; Ochs et al., 1986; Weiland et al., 1986;
Hammarstrom and Smith, 1986; Bjorkander et al., 1988; Williams et al., 1989; Quinti
et al., 1990) and therefore were unable to mount an antibody response. Direct
detection of virus nucleic acid would be the definitive method of diagnosis.
Plasma or serum samples from many of the patients reported in these transmission
events had been stored at -20°C or colder and were made available for HCV RNA
detection using RT-PCR. The original IVIG batches possibly associated with the
NANBH transmission were also tested in order to establish the nature of the
contaminating infective agent.
5.2.2. SAMPLES
Plasma samples from 33 patients who had developed NANBH (as defined either by
symptoms of hepatitis and/or an elevation of liver enzyme levels indicative of a viral
hepatitis infection) after receiving one of four different IVIG preparations from
different manufacturers (preparations A - D, table 5.1.). Another group of 18 patients
had received implicated, or suspected IVIG batches but had normal liver enzymes
and no symptoms of hepatitis. In 25 of the patients with IVIG associated NANBH,
samples were available prior to the administration of the implicated or suspect IVIG
batches. Due to the study being carried out retrospectively, it was possible to obtain
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Table 5.1.
INTRAVENOUS IMMUNOGLOBULIN PREPARATIONS TESTED
Product Manufacturer Finishing Step

















Note : All preparations used cold ethanol fractionation (Cohn Method) as the primary
manufacturing procedure. The finishing step is the final stage of production.
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samples that had been collected at varying periods before and after exposure to the
IVIG preparations. All samples were received coded and tested blind with the code
being broken when results were available.
Patient details are described and summarised in table 5.2..
(i) Five patients (2 XLA, 2 CVI and 1 hyper IgM syndrome; cases 1-5). All
developed NANBH after receiving pilot batches of experimental IVIG preparation
A in 1982 (Lever et al„ 1983).
(ii) Five patients with CVI (cases 6-9) who developed NANBH in 1985 after therapy
with IVIG preparation B. For this group it was not possible to identify specific IVIG
batches associated with NANBH transmission, however these patients could be
compared with samples from six other patients with CVI (cases 10-15) who were
treated with IVIG batches manufactured at the same time but who did not appear to
develop NANBH.
(iii) Ten patients (8 CVI and 2 IgG subclass deficiency; cases 16-21 and 23-26) who
developed NANBH after therapy with IVIG preparation B in 1983-1985. Four of
these patients (cases 23-26) had previously been treated in 1978-1979 with an
experimental IVIG preparation manufactured in Sweden (Bjorkander, unpublished
data). One patient (case 22) was treated with IVIG preparation B at the same time
but did not develop NANBH.
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(iv) Ten patients (3 possible XLA and 7 CVI; cases 27-36) who developed NANBH
following exposure to two pilot batches of experimental IVIG preparation C in 1983
were compared with seven patients (1 possible XLA, 1 X-linked immunodeficiency
with hyper-IgM and 5 CVI; cases 37-43) who did not develop NANBH despite
exposure to the same two experimental batches of the IVIG preparation. An
additional patient (case 28) received a single transfusion of the contaminated IVIG
batch, and increase in ALT values was observed and the patient developed the
symptoms of chronic active hepatitis. Another patient (cases 43) died in 1983 four
months after receiving the contaminated batch of IVIG. Although the ALT values
remained normal for this patient, chicken pox and idiopathic thrombocytopenia were
thought to be complicating factors.
(v) Four patients (2 XLA and 2 CVI; cases 44-47) who developed NANBH after
treatment with a single batch of IVIG preparation D in 1988. Liver tissue stored at -
20°C after necropsy was available from one of the patients with NANBH (case 44).
Samples were also available from 4 patients (3 CVI and 1 with drug induced
hypogammaglobulinaemia; cases 48-51) who were treated with the implicated IVIG
batch D, but did not develop NANBH.
5.2.3. INTRAVENOUS IMMUNOGLOBULIN PREPARATIONS
Only three of four implicated preparations of IVIG were available for testing for the
presence of HCV RNA. Fourteen batches of IVIG preparation B, possibly associated
with NANBH transmission, and two batches of IVIG preparation C, definitely
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implicated in NANBH transmission, were stored as a freeze dried powder at 4°C
prior to reconstitution according to the manufacturers instructions immediately before
RNA extraction. One batch of IVIG preparation D, definitely associated with
NANBH transmission had previously been reconstituted as a 50g/l solution after
manufacture and stored at -20°C prior to being used in this study, together with 9
other IVIG batches manufactured and stored in the same way.
5.2.4. RESULTS
Samples were available for testing for the presence of HCV RNA by PCR from 33
patients who had developed hepatitis after exposure to one of four different IVIG
preparations (table 5.2.). For 24 (73%) of these patients, samples were available that
had been taken prior to therapy with IVIG batches implicated or suspected of
transmitting NANBH, 7 (29%) were found to be HCV positive by PCR prior to IVIG
administration. This suggests that they had already been infected with HCV by a
source other than the implicated or suspected batches of IVIG.
Fifteen out of 17 patients, who were initially negative for HCV RNA, were found to
be positive after IVIG therapy and all 15 developed NANBH. Eight of 9 patients
(89%) for whom a sample was not available prior to IVIG therapy were also found
to be positive for HCV RNA after IVIG treatment. This implies that HCV is the
virus that is most likely to be responsible for the NANBH in these two groups of
patients. HCV RNA could also be detected in liver tissue from one patient who had
received IVIG preparation D and subsequently developed NANBH. Six patients who
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Table 5.2. PATIENT DETAILS
Prep Patient Control HCV PCR + /-
case case Pre IVIG Post IVIG
no. no. months(m) and years(y)
A 1 + (7y)
2 + (7y)
3 - (9m) + (ly)
4 + (ly)
5 +(3y,4y)
B 6 + (2y)









16 - (lm) + (7m)
17 -(lm) + (6m)
18 -(ly) + (3y)
19 - (lm) + (10m)
20 - (lm) - (4m)
21 + (lm) - (4m)
22 -(4y,5y)
23 + (lm) + (6m)
24 + (lm) + (6m)
25 + (2y) + (2y, 2y6m)
26 + (lm) +(ly,5y, 5y4m)
C 27 - (5y, lm) +(4y,5y,7y)
28 -(4y,2y) + (4m)
29 - (2y) + (15m)
30 -(3m) + (lm, 2y, 5y)
31 - (10m) + (2m, 15m, 5y)
32 - (7m, lm) + (4y, 5y, 6y)
33 - (3y) - (17m) , + (6y)
34 - (2y) - (14m)
35 + (5m) + (4m, 8y)
36 + (5y, 5m) + (lm)
37 - (3y, lm) -(3y,6y)
38 - (2y) -(3m,lOy)
39 - (14y) -(16m,8y)
40 -(ly) + (5y)
41 - (ly) + (2m)
42 -(ly) +(ly,8y)










Pre IVIG Post IVIG
months(m) and years(y)
D 44 -(2m) +(2m,2y)








were negative for HCV RNA prior to IVIG therapy had more than one sample
available after the development of NANBH. Five of these samples were repeatedly
positive (with an interval of up to eight years) suggesting that once HCV infection
occurs it persists (in this patient category). Another group of eighteen patients had
received implicated or suspected IVIG batches but had not developed NANBH.
Samples were available from 7 of these patients prior to the administration of
implicated or suspected IVIG batches; 2 patients were positive for HCV RNA before
IVIG therapy (cases 42 and 43). Four of the 7 were HCV RNA negative after IVIG
therapy but three patients became HCV RNA positive despite the absence of
symptoms of NANBH. Of the eleven patients for which there was no sample for RT-
PCR analysis prior to IVIG therapy, all were found to be negative for HCV RNA in
the post-treatment sample.
Eight out of 9 patients who were positive for HCV RNA prior to receiving an
implicated or suspected batch of IVIG, remained positive over a period of up to 8
years (except case 21). This is a similar trend to that found with the patients who
were negative for HCV RNA prior to IVIG therapy, supporting the hypothesis that
once infected by HCV, immunodeficient patients remain so. Four patients (cases 23-
26) were found to be positive for HCV RNA. At first the route of exposure was not
clear (these patient should have been in a group that had no previous IVIG
treatment), on investigation it was found that they had been exposed to an
experimental IVIG batch in 1978-1979 which was manufactured in Sweden
(Bjorkander, unpublished data). Samples from these four patients prior to 1979 were
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retrieved from storage and found to be negative for HCV RNA (data not shown).
Five patients were positive for HCV RNA (cases 21, 35, 36, 42 and 43) in which a
definite source of exposure to HCV could not be identified. However, 1 patient (case
35) had blood transfusions related to surgery; 1 (case 36) had symptoms of hepatitis
10 years earlier, 1 (case 42) was a Vietnam Veteran and 1 (case 43) had received
multiple red blood cell and platelet transfusions during the preceding year.
HCV RNA could not be detected in four patients who had NANBH after IVIG
therapy (cases 20, 33, 34 and 47). One of these patients (case 47) was subsequently
found to have had a spontaneous improvement in plasma ALT levels, and so may no
longer have been viraemic.
Of the 3 (out of 4) different IVIG preparations available, 2 batches of preparation C
implicated in NANBH and 6 out of 14 batches of preparation B which were strongly
suspected of transmitting NANBH, had detectable levels of HCV RNA. The
implicated batch of IVIG preparation D, and another 9 batches of the same
preparation manufactured at the same time but not implicated in NANBH
transmission, were found to negative for HCV RNA.
5.2.5. DISCUSSION
A retrospective study was carried out to identify the agent responsible for causing
NANBH in a group of patients who had been treated with IVIG. The use of RT-PCR
has been shown to be effective for detecting HCV RNA in plasma, serum, factor
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concentrate and IVIG preparations that have been stored over a number of years
(Simmonds et al., 1990; Garson et al., 1990). The 5' NCR primers used are capable
of detecting the presence of all currently known HCV types (chapter 4, section 4.4.).
Serum or plasma samples that had been collected prior to the development of
NANBH were also tested. A separate group were patients who had been exposed to
IVIG batches which were implicated (or strongly suspected) of causing NANBH
transmission, but these patients had not developed NANBH.
Thirty three patients who had developed NANBH associated with the administration
of IVIG were studied. However, 7 of these patients (and two patients, cases 42 and
43, who had no symptoms of hepatitis) were positive for HCV RNA prior to
exposure to IVIG, implying that the source of infection was other than the implicated
or suspected IVIG batches. Four of these patients (cases 23-26) were exposed to an
experimental IVIG preparation in 1978-1979, 2 patients had previously been
transfused with whole blood and another had a history of hepatitis and had served
in the Vietnam War. Of the remaining patients, 17 were negative for HCV RNA
prior to exposure to IVIG batches associated with NANBH and of these HCV RNA
could be detected in 15 patients post-exposure. In the group where no sample was
available prior to the development of NANBH, 8/9 patients were positive for HCV
RNA, suggesting that HCV is the causative agent for the NANBH associated with
IVIG administration.
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Testing the implicated batches of IVIG showed that 6 batches of IVIG preparation
B and 2 batches of IVIG preparation C contained HCV RNA. The batches of IVIG
preparation B were routine production batches by the Cohn fractionation method with
albumin stabiliser added and DEAE-purification as the finishing step. In a
prospective study over twelve months of follow-up of immunodeficient recipients
receiving monthly infusions of IVIG preparation B, there was no evidence of
NANBH transmission (Bjorkander et al., 1991) for this preparation in which a
solvent-detergent virucidal treatment step had been incorporated into the
manufacturing procedure. The batches of IVIG preparation C were produced in a
pilot plant. A study on liver enzyme levels in patients who had received the FDA
licensed version produced in a large scale manufacturing facility, did not indicate that
any transmission of NANBH (Lee et al. 1988). HCV RNA was not detected in IVIG
preparation D and a follow up of immunodeficient recipients of subsequent batches
of this preparation over a 2 year period did not find any further cases of NANBH
(pers comm Dr.Yap, Scottish National Blood Transfusion Service, Edinburgh).
Studies assessing the safety of IVIG preparations have been difficult due to the
sporadic nature of transmission episodes, the lack of a serological response by
immunodeficient patients with IVIG associated NANBH and the small number of
cases available for study. The patient group used in this study is of a reasonable size,
their cases are well documented and the causative agent has been identified by
detection of virus nucleic acid.
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5.3. HCV TRANSMISSION BY ANTI-D IMMUNOGLOBULIN
5.3.1. INTRODUCTION
The membranes of human red cells contain a variety of antigens and can be divided
into four major blood types; A, B, AB, and O based on the presence of the A and
B antigens on the red blood cells (RBCs). Antibodies against these antigens can be
produced by exposure to the red cells of another individual. Exposure is most likely
to occur via blood transfusion, or during pregnancy when foetal red cells cross the
placenta and enter the circulation of the mother. The A and B antigens and those of
the Rhesus (Rh) system are of greatest clinical importance. The Rh system is made
up of many antigens, the most antigenic being the D antigen. The term RhD+ denotes
a person who has the D antigen on their RBCs while a RhD- individual has no D
antigen. Eighty-five percent of the UK population are RhD+, with the remainder
RhD-. The Rh factor is especially important in pregnancy when a mother with a
RhD- blood group can be sensitized by RBCs from a RhD+ baby. This occurs most
often at the birth of the first child when bleeding of the placenta can release a large
number of the baby's RBCs into the mother. The mother produces antibodies which
are predominantly of the IgG class and will be able to cross the placenta in any
subsequent pregnancy. Reaction of maternal antibodies with the D-antigen on the
RBCs of a second RhD+ baby leads to cell lysis. The resulting haemolytic disease
of the newborn (HDN) can vary in severity from mild anaemia to death in utero.
Prophylactic treatment with small amounts of IgG anti-D at the time of birth of the
first child greatly reduces the risk of sensitization. This is effective because if the
mother has circulating IgG anti-D, sensitization to the D antigen is less likely due to
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lysis of the foetal RBCs before they encounter antigen sensitive cells and trigger an
immune resonse.
Anti-D immunoglobulin is prepared from plasma containing high levels of anti Rh
D antibody. Such plasma is obtained by hyperimmunising RhD- volunteers with
RhD+ RBCs and anti-D IVIG is usually manufactured by Cohn fractionation as
outlined in section 5.1.. The risk of transmission of viruses by anti-D IVIG
preparations is low due to the manufacturing methods used and because the products
are manufactured from small pools of donors which reduces the chance of
introducing viraemic plasma into the pool. There has only been one previous reported
outbreak of NANBH from anti-D IVIG which occurred in East Germany following
the administration of anti-D IVIG manufactured in 1978 (Dittman et al., 1991). This
preparation had not been prepared by Cohn fractionation and the only purification
step carried out on the plasma was passage through a DEAE sephadex column.
Retrospective testing of sera taken 6-12 months after the administration of the anti-D
IVIG confirmed HCV as the infecting agent. Ten years later, 60% of these women
have developed chronic hepatitis, and 82.7% of these are anti-HCV positive.
The Blood Transfusion Service Board in Eire introduced routine testing of blood
donors for anti-HCV in 1991, in line with procedures in the UK (chapter 4, section
4.2.). A disproportionate number of anti-HCV positive donors in Eire were found to
be RhD- female donors, who had children aged 17. On tracing donor records of these
individuals most were found to have been administered anti-D immunoglobulin in
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1977. A national initiative has recently been undertaken to recall and offer HCV
testing to all women who have received anti-D IVIG since its introduction in 1970.
The following section describes the results of the first three months of this screen,
and provides evidence for a phylogenetic link between the infected batch of IVIG,
the original donor and the anti-D IVIG recipients.
5.3.2. SAMPLES
Sixty thousand samples were screened for anti-HCV at centres in Dublin and Cork
(by Mr.T.Finch and Mr.J.Willis and staff respectively). All samples repeatedly
reactive in the 2nd generation ELISA screening assay (Abbott GmBH, Wiesbade-
Delkenhein, Germany) were tested by 3rd generation RIBA (RIBA-3, Chiron
Corporation, Emeryville, California). Eight hundred and ninety-seven samples that
were positive or indeterminate (chapter 4, section 4.2.) in the RIBA-3 were tested for
virus by RT-PCR. Dr.L.Jarvis and J.Daub assisted in the extraction and RT-PCR of
these samples.
Four batches of anti-D IVIG were available for testing and a plasma sample from the
HCV positive donor whose plasma was present in the pool from which implicated
anti-D IVIG batches were manufactured.
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5.3.3. RESULTS
Of the 897 samples tested by RIBA-3, 577 (64%) were positive and 320 (36%)
indeterminate. Of the RIBA-3 positive samples, 371/577 (64%) were RT-PCR
positive compared to 15/320 (4.7%) of the RIBA-3 indeterminate samples. HCV
RNA could be detected in all four of the batches of anti-D IVIG tested using primers
specific for the 5'NCR.
HCV genotype was determined by RFLP analysis (chapter 4, section 4.3.4.) for 100
RT-PCR positive samples of recipients of anti-D IVIG and all were genotype 1. In
contrast, 11 blood donor samples that had risk factors other than anti-D IVIG
administration (table 5.3.), infection with genotypes 1, 2 and 3 was detected in 4, 3,
and 4 donors respectively demonstrating that HCV types 1, 2 and 3 are present in the
donating population in Eire.
To establish that the HCV type 1 infection in the anti-D recipients were related,
direct nucleotide sequence analysis of the NS-5 region of the HCV genome was
carried out. Single molecules for each sample were obtained by titration to limiting
dilution. HCV nucleotide sequences could be amplified in the NS-5 region for sera
from 10 anti-D IVIG recipients, 6 blood donors with other risk factors, the implicated
batch of anti-D IVIG and from sera from the original HCV infected donor. These
sequences were compared with representative la, lb and 2b sequences (fig.5.1.).
Their relationship with published NS-5 sequences was investigated by phylogenetic
analysis, the results of which are presented in a rooted phylogenetic tree (fig.5.2.).
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The sequences from the non anti-D recipient blood donors infected with HCV type
2 (cork B and cork 11), showed similarities to subtype 2b. HCV sequences obtained
from 4 non anti-D recipient blood donors infected with type 1 grouped closely to
other published sequences within subtype la (cork 1, 5, 13 and A). All 10 anti-D IgG
recipients (cork 2, 3, 4, 6, 9, 12, 14, 15, 16, and 17), the anti-D IVIG (cork B250)
and the implicated donor (labelled : DONOR) grouped with the subtype lb group of
published sequences (fig.5.1. and 5.2.).
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Table 5.3.
RIBA-2/PCR POSITIVE SAMPLES AND ASSOCIATED RISK FACTORS
HCV No. of Risk Factor
Genotype Samples
1 2 IVDA*
1 1 Sexual partner IVDA
1 1 Not known
2 1 Blood Transfusion
2 2 Not known
3 3 IVDA
3 1 Blood Transfusion
1 100 Anti-D IgG
*
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Comparison of nucleotide sequences in the NS-5 region from recipients of anti-D
immunoglobulin and blood donors in Eire (all samples prefixed " cork "). Cork 2, 3,
4, 6, 9, 12, 14, 15, 16, and 17 : anti-D recipients. Cork 1, 5, 11, 13, A and B : non
anti-D recipient blood donors (A and B donated blood in Dublin, all other samples
sequenced were donated in Cork). Cork DONOR : suspected source of HCV infected
plasma incorporated in plasma pool used to make batch 250; Cork B250 : sequences
from the batch of anti-D IVIG implicated in HCV transmission. " . " indicates
identity with J (Kato et al., 1990), nucleotide substitutions are indicated. PT and
K2BN1 (Enomoto et al., 1990) are shown for comparison. Nucleotide numbering as
in Choo et al., 1991.
Figure 5.2. LEGEND
Phylogenetic analysis of NS-5 sequences, shown as a rooted tree. Nucleotide
sequences from recipients of anti-D IVIG group closely together with published
sequences of type lb. Non anti-D recipient blood donor nucleotide sequences group
with published sequences of type la and 2b. Samples numbered as in fig. 5.1.
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Figure 5.2.
PHYLOGENETIC TREE OF NS-5 SEQUENCES
T104-
5.3.4. DISCUSSION
Of 897 plasma samples that showed reactivity with antigens in the RIBA-3, 371/577
(64%) were RIBA-3 positive and RT-PCR positive, compared to a figure of 72% in
the blood donating population in Scotland (chapter 4, section 4.2.3.(3)). The lower
rate of RT-PCR positivity in RIBA-3 confirmed samples in this group may be due
to individuals who have cleared the virus but have a persistent antibody response.
In a retrospective study of women in East Germany who were infected with HCV by
the administration of contaminated anti-D IVIG (Dittmann et al., 1991), anti-HCV
was demonstrated in 90% of serum samples collected 6-12 months after infection and
10 years later, 69.2% were anti-HCV positive. It will not be possible to carry out
retrospective testing on women infected in Eire since there are no archived plasma
samples.
It has been estimated that 8000 women in Eire received anti-D IVIG in 1977, and
projecting from current findings approximately 10% of these will now be positive for
anti-HCV. The prevalence of anti-HCV among women who received anti-D IVIG in
years other than 1977 is much lower at approximately 1%.
The rate of anti-HCV in anti-D recipients 17 years after infection is lower than the
69.2% anti-HCV positive individuals at 10 years after infection reported in East
Germany. One explanation for this is that the infecting dose of HCV was higher in
East Germany since plasma from 2 HCV infected donors was incorporated into a
pool of ten donors which was then used to make different immunoglobulin batches.
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In Eire one HCV infected donor contributed to a pool containing 200 donations and
used to make a single batch. Fewer vials from the contaminated batch in Eire may
have contained HCV (a limiting dilution effect) resulting in fewer women being
infected from the one batch. The number of batches containing plasma from the HCV
infected donor is currently being investigated, of the four batches available, all were
positive for HCV RNA. A common factor between the two transmission events is the
manufacturing method used in the production of the anti-D IVIG. Cohn fractionation
was not used in either country and the only IgG purification step was passage of the
plasma through a DEAE-Sephadex column.
Phylogenetic analysis of NS-5 HCV sequences derived from virus present in the
recipients of implicated batches of anti-D IVIG revealed that all sequences grouped
very closely together indicating a common origin. Sequences from the HCV infected
anti-D donor and the implicated batch of anti-D IVIG also grouped amongst those
of the recipients although they were most closely related to each other. The similarity
between these sequences was retained despite the 20 year period of separate
evolution. Rates of sequence change for HCV have been estimated by studies of
HCV infection in humans and experimentally infected chimpanzees (Ogata et al.,
1991; Abe et al., 1992; Okamoto et al., 1992c). Different regions of the genome
appear to evolve at different rates and variants of the same genotype have been
predicted to differ by up to 9% over the complete genome in a 30 year period (pers
comm Dr.P.Simmonds, Dept Medical Microbiology, Edinburgh). A study of the
evolution of the HCV genome in a chronically infected patient showed a 2.7%
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difference between isolates over a 13 year period in the same part of the NS-5 region
amplified in this study (Ogata et al., 1991). Pairwise comparison of the donor
sequence and recipients, showed differences of 2.7%, 1.8% and 0.4% for recipients
cork 15, 17 and B250 respectively, with 0 to 0.9% differences in the other 8 recipient
samples. The NS-5 region is thought to code for the virus replicase and is relatively
well conserved amongst all viral RNA-dependent RNA polymerases (chapter 3,
section 3.3.). It is likely that sequences in this region are conserved to keep the
functional domains of these proteins intact.
The genotype of the virus infecting all the anti-D recipients is lb, a genotype
commonly found in Scotland, Europe and also detected in recipients of anti-D IVIG
in Germany (Hohne et al., in press). Sequences obtained in the same region of the
HCV genome from 6 blood donors infected via other parenteral routes grouped
separately with previously published sequences for genotypes la and 2b. This
confirms that the anti-D recipients are infected with virus that is phylogenetically
distant from other HCV isolates in Eire.
There have been few reports of the persistence of HCV viraemia over long periods
of time. The majority of studies correlating viraemia and antibody response have
been on blood donors where the route and time of exposure is often unknown
(Bresters et al., 1993; Tobler et al., 1994) or on patients with symptomatic chronic
hepatitis due to HCV infection via blood transfusion (Wang et al.,1992; Lelie et al.,
1992). Further studies on these women who were infected 20 years ago will provide
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valuable information on the epidemiology and natural course of HCV infection since
the date and time of exposure is known and it should be possible to make estimates
of the approximate infective dose of HCV received. All women who are found to be
RT-PCR positive are to be counselled and offered liver biopsy with the intention of
offering interferon treatment to those showing histological evidence of chronic
hepatitis.
The results obtained in the studies reported here (sections 5.2. and 5.3.) and the East
German report indicate that HCV can be transmitted by IVIG preparations, in a
manner similar to HCV transmission by coagulation factor concentrates. A recent
report by Yei et al. (1992) described how cold ethanol fractionation of a plasma pool,
prepared exclusively form anti-HCV antibody reactive donations resulted in
detectable levels of HCV RNA in Fraction II, the fraction used for IVIG preparation.
In general, licensed IVIG preparations have a good record for safety, but the report
by Yei et al. and the work presented here indicates that routine anti-HCV screening
of plasma donors and the incorporation of specific procedures that are virucidal in
IVIG manufacture are essential to prevent any further cases of transmission of
NANBH by IVIG preparations. There is always the possibility that a failure may
occur in The Good Manufacturing Practice (GMP) but even then HCV screening of
plasma donors would increase the safety of the product by reducing the possibility





Parvoviruses are DNA viruses that infect a number of animal hosts and humans may
become infected with parvovirus B19. Infection in normal indivduals causes mild flu¬
like symptoms but in those with underlying haemolytic disease it can lead to aplastic
crisis as the virus targets erythroid precursor cells (Morfini et al., 1992).
Transmission of parvovirus B19 by blood and blood products has been reported
(Mortimer, 1983). Standard immunological screening methods are not useful for
screening blood donations for B19; detection of virus nucleic acid is an alternative,
however at present there is no suitable technique for screening large numbers of
blood donations on a routine basis. In the following sections, the physical and
epidemiological characteristics of B19 are considered which highlight the problems
associated with prevention by iatrogenic transmission. A method for screening a large
number of samples for the presence of B19 virus nucleic acid is described and
applied to the screening of blood donations.
6.2. THE VIRION
The parvovirus family consist of a large number of physically and chemically similar
viruses which infect many animal species (table 6.1.). The parvovirus virion has a
relatively simple structure and is among the smallest of the DNA animal viruses. The
particle has icosahedral symmetry, a diameter of 18 to 26 nm and is non-enveloped.
When purified from human plasma the B19 virion is found to contain two major






H-l Virus (rat) H-l
RT Virus (rat) RT
TVX (unknown) TVX






Species host range variants:




Aleutian Disease Virus (mink) ADV
Goose Parvovirus GPV
Possible members:
Minute Virus of Canines MVC
HB Virus (human?) HB
RA-1 (human) RA-1
Dependovirus Subgroup
Adeno-associated type 1 (monkey) AAV-1
Adeno-associated type 2 (human) AAV-2
Adeno-associated type 3 (human) AAV-3
Adeno-associated type 4 (monkey) AAV-4
Adeno-associated type 5 (human) AAV-5
Bovine Adeno-associated Virus BAAV
Canine Adeno-associated Virus CAAV
Avian Adeno-associated Virus AAAV
Possible members:
Equine Adeno-associated Virus EAAV
Ovine Adeno-associated Virus OAAV
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species. Approximately 80% of the mass is protein and the remainder is DNA. The
buoyant density of the intact virion in caesium chloride is 1.39 - 1.42 g/cm3 which
is due to the relatively high DNA to protein ratio. The particles do not appear to
contain lipids, carbohydrates, cellular or virally coded enzymes, or low molecular
weight histone-type proteins. The virion is extremely resistant to inactivation, being
resistant to extraction with lipid solvents, pH ranges between 3 and 9, heating to
56°C for 60 minutes and exposure to relatively high salt concentrations (which are
used in caesium chloride isopycnic gradients). The stability of the particle is probably
due to its relatively simple structure. However, the virus can be inactivated by
formalin, p-propiolactone, hydroxylamine and oxidising agents; prolonged storage
and repeated freeze-thawing may compromise virus integrity resulting in reduced
stability to extremes of temperature or salt concentration although remaining
infectious.
6.3. THE GENOME
6.3.1. DNA STRUCTURE AND SEQUENCE
The B19 genome appears to have features in common with both autonomous and
helper dependant viruses, sequencing studies have shown the genome to be highly
conserved (Mori et al., 1987). Computer analysis of the putative viral polypeptides
from MVM(p), AAV2 and B19Au have identified extensive regions of homology
between the polypeptides encoded by all three genomes. However B19 replicates in
erythropoietin-stimulated human bone marrow cultures without the aid of a helper
virus which suggests it is probably an autonomous virus. For the purposes of this
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chapter B19 is considered to be an autonomous virus. The autonomous parvovirus
virion contains a single-stranded polydeoxynucleotide chain of M.W. 1.55 - 1.97 x
106 daltons (Crawford et al., 1969; Gardiner et al., 1988). Several parvovirus DNAs
have been sequenced and in general the DNA molecule is about 5 kilobases in
length, H-l and MVM being 5176 and 5084 nucleotides respectively, (Astell et al.,
1983; Astell et al., 1986; Sahli et al., 1985; Rhode et al., 1983), AAV2 DNA
contains 4,680 bases. Strands of one polarity, those that are complementary to the
mRNA, are encapsidated in the autonomous parvoviruses (Bourguignon et al.,1976)
while strands of both polarities are encapsidated with equal frequencies in AAV
strains (Mayor et al., 1969). Since the study presented in this chapter is on parvovirus
B19 the human autonomous parvovirus infection, discussion of virus structure and
replication will be directed towards autonomous virus particles. Adeno associated
virus should be considered separately as sufficient differences exist for it to remain
outwith the scope of this chapter.
Both the 3' and 5' termini of all parvovirus genomes analysed to date contain
palindromic nucleotide sequences which can exist in the form of relatively stable
hairpin duplexes in the single-stranded form of viral DNA. At the 3' end of the virion
strand of most autonomous parvovirus DNAs the palindromic sequence is
approximately 115 bases long (Salzman et al., 1970). In the human parvovirus B19,
these sequences appear to be more than 300 nucleotides in length. This segment of
the DNA can fold back on itself to form a hairpin structure stabilised by hydrogen
bonding between the self-complementary sequences fig.6.1. Comparison of the 3'
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nucleotide sequence of MVM(p), H-l, KRV and H-3 have been made (Astell et al.,
1979), although there are some minor differences, the sequence of the first 150
nucleotides of each virus is essentially the same. Since sequence homology at this
level is not maintained throughout the viral DNA, this suggests a strong pressure to
conserve this particular region. A total of 104 of the first 115 nucleotides of MVM
can be base-paired to form a stable Y-shaped hairpin, it is possible that is the
constraint implied in maintaining this overall conformation which resists genetic drift,
rather than absolute linear sequence requirements. A bubble in the duplex stem
created by a mismatch between nucleotides 23 to 26 and 88 to 91 is a common
feature in all four viruses which suggests that it may also be an essential element of
the terminal structure (fig 6.1.). Of particular note is the fact that for each DNA
sequenced almost every base pair in the short arms of the T structure is a G*C base
pair. The 5' end of the human B19 genome appears to be unique in that its nucleotide
sequence is a terminal repeat of the sequence at the 3' end, where as in other
autonomous parvoviruses the 5'-terminal sequence is also palindromic and can form
a hairpin, but the sequence is completely unrelated to that at the 3' end. The 5'
terminal sequence is not a perfect palindrome (as found at the 3' end), there are
short, self-contained internal palindromic sequences. Two sequences that represent
an inversion of the terminal segment of the genome are found with equal frequency,
these arise from the fact that the 5'-terminal hairpin is not perfectly symmetric.
Terminal sequence organisation gives valuable information on the correct mechanism
of DNA replication and thus mature virion formation.
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6.3.2. ORGANISATION OF THE GENOME
In all parvoviruses analysed to date, all of the protein coding regions appear to be
clustered on one of the DNA strands, which is, by definition, the plus strand. The
autonomous parvovirus genome contains two large ORFs. The first spans map
position (mp) 6-42 (at the left half of the genome) and encodes two non-structural
(NS) proteins NS1 and NS2. Mutations occurring within this ORF block viral
replication and gene expression. The ORF spanning mp 45 - 90 (covering much of
the right half of the genome) encodes the coat proteins. Autonomous parvoviruses
contain three coat proteins (the exception being Aleutian disease virus ADV which
contain only two coat proteins). VP1 (M.W. 80000 - 86000) and VP2 (64000 -
75000) have identical amino acid sequence except for additional amino acids at the
NH2 terminus of VP1. This implies that synthesis of VP1 involves splicing to add
a second (smaller) ORF to the 5' end of the major ORF. VP3 is the major coat
protein (except in ADV) (M.W. 60000 - 62000) and represents approximately 80%
of the total mass.
6.4. PRODUCTIVE INFECTION
6.4.1. THE PRODUCTIVE LIFE CYCLE
The autonomous parvoviruses display a high degree of host specificity and replication
is tightly regulated by the parvovirus itself. B19 virus shows a strict tropism for
erythroid precursor cells, and it has been established that the target cells of B19 are
limited to the erythroid lineage, the susceptibility of which increases with
differentiation (Takahashi et al., 1990). The productive life cycle is always lytic, and
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DNA replication takes place in the nucleus. For parvovirus replication to occur it is
necessary for infected cells to be in S phase of division as parvoviruses do not have
the ability to stimulate or turn on host DNA synthesis (Walter et al.,1980).
The productive infection is initiated by absorption of the virion to specific cell-
surface receptors. It is thought that the receptors involve or are displayed on a protein
backbone. The receptor for a particular virus sero-type could be a single molecular
species of a number of different molecules which carry specific carbohydrate chains.
There is little information regarding the next stages of infection. Translocation of the
virion across the plasma membrane occurs and cytoplasmic virus becomes clustered
within multivesicular bodies and heterophagosomes arranging themselves in an array
lining the membrane in aggregates. The capsid is thought to play a role in the
initiation of viral gene expression so it is likely that the virion arrives in the nucleus
as an intact entity.
It is yet to be determined whether the parvovirus B19 genome becomes integrated
into the host cell DNA or not. The MVM genome does not integrate into the host
DNA however it is not known what occurs during prolonged nonlytic interactions
such as restrictive infections. In contrast AAV genomes integrate with high
efficiency. The fact that B19 have closely related terminal repeat sequences at each
end of their genomes, rather than having unique termini as in MVM and H-l,
suggests that integration may be possible.
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6.4.2. AUTONOMOUS VIRUS DNA REPLICATION
Viral DNA replication occurs in three distinct phases :
(i) synthesis of a parenteral complementary DNA strand
(ii) amplification of duplex DNA forms
(iii) excision and concomitant packaging of progeny single-stranded
viral DNA.
Viral and cellular replication are closely associated, cellular DNA polymerases are
used, although it is yet to be defined whether the involvement of cellular DNA
polymerase a or 8 or a combination of both (and the participation of p) are active
in replication. For polymerisation to take place a primer with a 3'OH group in
addition to a template is necessary for enzyme action. As mentioned in section 6.2.1.
the terminal sequence of the autonomous parvovirus genome are palindromic. In
order for the linear DNA genome to replicate the 3' terminus of the virion strand
folds back on itself and thus serves as a primer, with the complement of the 5'
terminus (ie: the 3' terminus of the complementary strand) forms a similar hairpin
structure providing a primer.
The replication events have been proposed by Astell et al. modified by Tattersall and
Cotmore, as a model for autonomous parvovirus replication. However the events for
human B19 replication are probably more complex due to the repetition of terminal
nucleotide sequences. The determination of the details of replication would require
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the development of an in vitro system for DNA replication which is hampered by the
presence of the palindromic 3' terminal hairpin primer. This structure could
potentially be used as a primer by almost any DNA polymerase in vitro and thus the
signal-to-noise ratio would be very small.
A simplified version of the overall scheme is presented in fig. 6.2.. The scheme
outlined is typical of viruses such as MVM and H-l which package predominantly
(>99%) single sense DNA strand which is the complement of that encoded into RNA,
and are thus (-) strand DNA viruses. However studies have shown that LuIII and B19
encapsidate both strands with approximately equal efficiency (Cotmore and Tattersall
1984; Bates et al., 1984). Selection of strands for packaging appears to be a virus-
coded rather than a host-specified function. However, few of the preformed viral
capsids are used to package DNA and mature into infectious virus particles (as
demonstrated in in vitro virus host cell systems), a mixture of empty capsids and full
















6.5. HUMAN PARVOVIRUS INFECTION
Infection with the human parvovirus B19 is common with approximately 50% of
adults having antibody. It is known to cause several pathological conditions and can
become a persistent infection (Frickhofen and Young, 1989). Infection of healthy
individuals is generally asymptomatic, B19 can cause non-specific respiratory tract
infection and is usually spread by the respiratory route. Acute infection in children
results in "fifth disease" or erythema infectosium (Anderson et al., 1984), in adults
it manifests as an arthralgia-arthritis syndrome (White et al., 1985). In patients with
underlying haemolytic disease, transient aplastic crisis or anaemia may result
(Pattison et al., 1981; Serjeant et ah, 1981). The aplastic crisis results from a halt in
erythropoiesis in the bone marrow for five to seven days. Individuals with a normal
immune system clear the virus, however infection of the immunocompromised can
cause pure red cell aplasia and bone marrow failure (Kurtzman et ah, 1989; Kurtzman
et al. 1987). The underlying cause is the weak humoral immune response in such
patients. Administration of intravenous immunoglobulin generally assists in transient
or permanent clearance of the virus and improvement of the anaemia. Studies have
shown that in utero infection of the foetus in the second or third trimester may result
in hydrops fetalis (Anand et ah, 1987; Porter et ah, 1988). The hydrops may be
transient and is often associated with anaemia and sometimes with myocarditis in the
foetus, or ultimately fatal. It has not yet been established whether B19 infection is
a cause of infrequent anatomical or functional abnormalities such as congenital red
cell aplasia or central nervous sytem disorders.
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Although B19 is spread via the respiratory route, parenteral transmission is possible
via transfusion of blood products made from plasma pools containing blood donated
during the viraemic stage of B19 infection. Recent evidence shows that parvovirus
B19 can be transmitted by coagulation factors VIII and IX (Mortimer, 1983;
Williams et al., 1990; Bartolomei Corsi et al., 1988; Lyon et al., 1989; Azzi et al.,
1992). Haemophiliacs receiving coagulation factors prepared from large plasma pools
show a higher prevalence of anti-B19 antibodies than individuals of the same age.
In addition, some haemophiliacs are HIV infected, which may result in them being
immunocompromised and therefore at increased risk if receiving a contaminated
batch of factor concentrate.
6.6. DETECTION OF PARVOVIRUS B19
B19 was first discovered in 1974 by Cossart et al. while carrying out routine
evaluation on tests for hepatitis B surface antigen (HBsAg). Current biophysical
methods for detection of B19 vary in specificity, sensitivity and ease of application.
To date B19 has been identified by electron microscopy (E.M.) (Bond et al., 1986;
Clewley et al., 1987) radioimmunoassay (RIA) (Westmorland and Cohen 1991),
counterimmunoelectrophoresis (CIE) (Cohen et al.,1981), nucleic acid hybridisation
(Nascimento et al.,1991; Anderson et al., 1988; Porter et al., 1988; Salimans et al.,
1989a,b) and polymerase chain reaction (PCR) (Clewley, 1989; Salimans et al.,
1989a,b). In the clinical situation routine diagnosis is made on the detection of IgM
only, however in immunocompromised patients serological assays may not be
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informative as the serum concentration of B19 antigen and specific antibodies may
be too weak to be detectable.
At present routine serological diagnosis of B19 infection is hampered by the
availability of viral antigen. Recent attempts to produce sufficient antigen have
included transfection of B19 DNA into Chinese Hamster Ovary cells (CHO) or Cos-7
cells (Kajigaya et al., 1989), production of recombinant antigen in E.coli (Sisk and
Bergman 1987) and in baculovirus (Kajigaya et al.,1991). Tissue culture systems
using infected early gestation aborted foetal liver for primary culture production
(Brown 1991) provide higher levels of B19 DNA released into the supernatant than
previously reported, greater than lpg/ml compared with 20 ng/ml (Yaegashi et al.,
1989). Bone marrow culture systems provide one hundred fold less (Ozawa et al.,
1987). It is unlikely that a tissue culture system will provide a source of diagnostic
antigen as foetal tissue is not readily available, cultures are viable for a short time
and the technique is labour intensive. Recently Satoshi et al. (1992) reported
propagation of B19 in an erythropoietin-dependent strain of megakaryoblastic
leukemia cell line called UT-7. Virus was detected in cultures for up to three months
at approximately 1000 copies per cell which at optimal multiplicity of infection was
20 to 50 fold greater than that amount of virus inoculated. This particular cell line
may prove to be more useful in the production of infectious virus and in the analysis
of B19 persistence, cytotoxicity and permissivity.
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Practically it is more probable that the use of synthetic B19 peptides will provide
larger amounts of antigen for diagnostic assays. In particular, enzyme-linked
immunoabsorbent assay (ELISA) for detection of B19 specific IgM and IgG (Fridell
et al., 1989; Schwarz et ah, 1991a). Currently the development of peptides for
immunogenetic reaction are those of the major structural proteins VP1 (Kajigaya et
al., 1991) and VP2 (Fridell et ah, 1989). A recently developed assay making use of
a synthetic VP2 peptide showed the degree of specificity and sensitivity of the
peptide antigen to be in the region of 90% (Fridell et ah, 1991). Considering the
evidence that it appears to be appropriate to test for IgM in diagnosis of recent B19
virus infection then the IgM peptide assay would be a choice for diagnosis of B19
infection in acute-phase serum samples.
However IgM detection is really only useful in determination of recent viral infection
by which time the patient is usually symptomatic. In addition, not all patients can
produce IgM or IgG, for instance those with congenital or acquired
immunodeficiency and patients with chronic haemolytic anaemia become
symptomatic during early viral infection prior to antibody production, the immature
immune system of the foetus only starts to produce antibody at eighteen weeks
gestation and then only in small amounts. Even if tests based on other sources of
antigen were introduced, native B19 antigen would still be required to provide
reference assays. Detection of the presence of B19 DNA and hence viraemia remains
the definitive diagnosis of infection. Dot-blot hybridisation techniques are generally
difficult to perform, require the use of radioisotope and are less sensitive than the
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PCR. Although PCR cannot distinguish between degraded or intact infectious viral
DNA, it may be of considerable benefit in screening plasma donations prior to
pooling for factor concentrate production.
6.7. BLOOD DONOR SCREENING
6.7.1. INTRODUCTION
There is a seasonal pattern to B19 infections. In temperate climates it is endemic
throughout the year with infection occurring most frequently in late winter, spring,
and early summer months. Long-term cycles of B19 infection have been observed in
the U.K. to occur at 4 to 5 year intervals (information supplied by the Centre for
Disease Control, Scotland.).
Previous attempts at screening blood donors for B19 infection have concentrated on
identifying a donation that could be used as a source of viral antigen for diagnostic
serology and secondly to establish the incidence of viraemia in the donating
population (Cohen et al., 1990). In order to prevent any viraemic donations being
used it is necessary to use rapid screening techniques that can be applied to a large
number of samples on a daily basis. Cohen et al. (1990) screened 24000 donor
samples from January to May 1990 using a dot-blot hybridisation assay and counter-
immunoelectrophoresis (CIE). The dot-blot hybridisation assay was found to be too
labour intensive and time consuming and was not used further after screening 6500
donations.
195
The PCR has previously been applied for detection of B19 in clinical samples
(Clewley, 1989; Salimans et al., 1989a,b; Koch and Adler, 1990; Cassinotti et al.,
1993). A study was undertaken to measure the frequency of B19 infection in the
donating population, to determine the feasibility of using the PCR to routinely
exclude B19 from blood products and to identify a highly viraemic donation that
would provide a source of antigen.
6.7.2. SAMPLES
Blood from 20000 volunteer donors in the Edinburgh area was collected over a three
month period from May to July 1991. 200pl aliquots of each donation was collected
in a microtitre plate, with pools of 100 donations being made at the time of
aliquoting and stored frozen at -20° C, these aliquots were then recombined in pools
of 500 donations and centrifuged followed by DNA extraction as described in chapter
2, section 2.2.. Samples making up the pools of 500 donations that were positive by
PCR, were reconstituted successively in pools of 100, 10 and 1 single donation in
order to identify the viraemic donor. Following identification of a positive blood
donation the plasma pack was retrieved and an aliquot tested by PCR, any previous
or follow-up donations were identified and tested by PCR. B19 quantification was
carried out by titration at limiting dilution, with 5 to 15 replicates tested at each 10
fold dilution (chapter 2, section 2.9., Simmonds et al., 1990a). On confirmation of
a positive PCR result the donor was contacted and B19 positive donors were asked
to attend an interview, at which time they were questioned about any symptoms they
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may have experienced and a blood sample was requested at this time. Fig.6.3. is a
flow chart showing the course of action.
The screening process was repeated in 1993. The main objective at this time was to
screen all donations that would be incorporated into a plasma pool used to produce
a batch of Factor VIII concentrate that would be B19 free. Donations were screened
at two different periods in the year in order to compare the incidence of viraemia.
Six thousand donations were screened in March 1993 and a further 6000 donations
in August and September 1993. During both collection periods in 1993 plasma packs
were segregated and stored at -40°C at the Protein Fractionation Centre prior to
Factor VIII production. Ten thousand donations are usually sufficient to produce a
batch of Factor VIII, however it was necessary to screen 12000 donations as not all
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6.7.3. PRIMERS
Primer sequences are shown in chapter 2, section 2.6., table 2.2.. Primers PV1 to
PV4 were derived from the previously published sequences ofWi and Au variants
of human parvovirus B19 (Blundell et al., 1987; Shade et al., 1986). This region
showed substantial nucleotide and sequence homology with adeno-associated virus
(Srivastava et al., 1983), minute virus of mice (Astell et al. 1983), HI (Rhode and
Paradiso, 1983) and feline parvovirus (Carlson et al., 1985). Primer sequences
derived independently for this study were similar in position to those used by
Clewely (Clewley, 1989) and represent one of the most highly conserved regions of
different parvovirus genomes. Primers PV1 and PV2 were used in the first round of
a nested PCR followed by amplification with PV3 and PV4 in the second round
stage. Sufficient volume of this second round product was made to allow for direct
sequencing to be carried out. Primers PV5 to PV8 amplified part of the genome
encoding an antigenic region within the B19 nucleocapsid (Fridell et al. 1989), PV5
and PV6 were used in the first round reaction then PV7 and PV8 used in the second
reaction. DNA extraction, PCR method and sequencing reactions are described in
chapter 2, sections 2.2, 2.6, and 2.8. respectively.
6.7.4. SEROLOGY
Plasma samples from PCR positive blood donations, stored previous donations and
follow up samples from infected donors obtained at recall were tested blind using
capture radioimmunoassay (Cohen et al., 1983). The tests were carried out by Dr.
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Bernard Cohen and staff at The Virus Reference Laboratory, Central Public Health
Laboratory, Colindale, London.
6.8. RESULTS
6.8.1. BLOOD DONOR SCREENING
Screening of 20,000 donations from volunteer donors in the Edinburgh and South
East Scotland area in May to July 1991 resulted in the identification of 6 B19
positive donations. In March 1993 and September 1993 screening of 6,000 donations
at each time resulted in the identification of 23 and 0 B19 positive donations
respectively. The limit of sensitivity of the screening method was 5 virions per ml
in a pool, and therefore 2,500 virions per ml in each component unit. All six
donations were positive with both primer sets, PV1 to PV4 and PV5 to PV8. The
procedure used in identifying a positive donation is shown in fig. 6.3. and 6.4. A
positive PCR result obtained in a pool of 500 donations was traced to an individual
donation by sub-dividing the initial pool into 5 pools of 100, a positive in this round
of screening indicates the 10 pools of 10 donations to be investigated, and each set
of 10 donations produced a single PCR positive sample thus identifying the viraemic
donor. The six packs of plasma corresponding to the positive samples in 1991 were
recalled from the Protein Fractionation Centre in Edinburgh, and all were confirmed
positive by PCR. A similar approach was taken in 1993, all screened packs were
segregated at the Protein Fractionation Centre, testing of the recalled packs confirmed
a positive donation in all 23 donations. The remaining B19 free packs are to be used
to manufacture a B19 free batch of factor VIE concentrate.
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6.8.2. SEQUENCING
The nucleotide sequences of the six B19 positive donations identified in 1991 were
determined using DNA amplified with primers PV1 and PV2, and abo PV5 and PV6.
The nucleotide sequence obtained from the six donors differed from published
sequences of B19 and from each other by 1 to 6 substitutions with one exception.
Two donors yielded the same viral sequence, on recall these two donors were found
to be husband and wife. The fact that different viral sequences were detected in each
donor confirms that the positive result obtained on screening is a true positive result
and not inadvertent contamination of samples or buffers. The nucleotide sequences
obtained are shown in table 6.2., and are compared with the B19-Au variant (Shade
et al., 1986).
6.8.3. CLINICAL AND VIROLOGICAL RESULTS
Previously donated blood samples and those obtained as follow-up samples as well
as the actual donation were tested for B19-specific IgG and IgM and for B19 DNA
by PCR (fig 6.5.). Five of the six donors, pi to p5, were negative for both IgM and
IgG in all samples prior to donation, and four of the five were still negative at the
time when viraemia was detected. When recalled these four donors were found to be
IgG positive and IgM positive 3 to 6 months after donation. Samples from p6 were
IgG positive before, during and after donation, with no B19-specific IgM detected
in follow-up samples from this particular donor. Unfortunately p5 did not wish to
attend for follow-up interview consequently there is no post donation sample
available. B19 DNA was undetectable in all samples collected from donors on recall
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which was generally 60 to 100 days after donation, in addition blood donated
previously by all six donors was PCR negative.
Symptoms experienced varied greatly between each individual. The two female
donors (pi and p2) reported rash, fever and arthropathy. The male donors were
generally asymptomatic, including p5, who had extremely high levels of circulating
virus (table 6.3.). Two of the donors were husband and wife (p2 and p3), and they
reported parvovirus-like symptoms of infection in their children.
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6.9. DETECTION OF PARVOVIRUS B19 IN BLOOD PRODUCTS
6.9.1. INTRODUCTION
Pools of 3,000 to 10,000 plasma donations are used as the raw material in the
manufacturing process for many blood products (chapter 1, Introduction). The
frequency of PCR-positive donations detected in the studies carried out in 1991 and
1993 of 0.03% and 0.4% respectively indicates that B19 might frequently
contaminate such blood products. Infection of the immunocompromised or a
haemophiliac with B19 through administration of these blood products may have
severe consequences (section 6.5.). B19 has no lipid envelope and is stable to most
chemical and physical treatments widely used in inactivation processes to eliminate
lipid enveloped viruses. There remains the possibility that B19 may persist in the
final product. Several blood products were tested for the presence of B19 DNA and
the effect of heat treatment on its survival in Factor VIII preparations was
investigated.
6.9.2. SAMPLES
Blood products were obtained from the U.K. National Institute of Biological
Standards and Controls (NIBSC) and the Protein Fractionation Centre (PFC),
Scottish National Blood Transfusion Service (SNBTS), Edinburgh. Preparation and
storage of Factor Concentrates is described in chapter 2, section 2.1. and 2.2..
Eighteen non-heat-treated batches of factor VIII, 9 non-heat-treated batches of factor
IX and 10 batches of IVIG were tested by PCR using primers PV1 to PV4. To
investigate the kinetics of B19 inactivation during heat treatment, intermediate-purity
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factor Vni was spiked at a ratio of 1:100 with B19-positive plasma, freeze dried, and
heated using model SNBTS production cycles. Additional levels of such proteins in
intermediate-purity factor VIII have been shown previously to have no effect on the
freeze-drying or heating characteristics of this product (pers comm Dr. Helena Hart,
PFC, Edinburgh).
6.9.3. RESULTS
Of the factor VIII and IX, 13 and 7 respectively were found to be PCR positive,
while none of the batches of IVIG contained detectable amounts of B19 DNA (table
6.4a.). Five of the PCR-positive batches of factor VIII were heat-treated by a
standard manufacturing process of 80°C for 72 hours and retested. Two of the five
batches remained PCR positive. The B19 DNA titre was determined before and after
heat treatment on the five available batches. In the two batches that remained PCR
positive there was at least 90% reduction in the amount of detectable viral DNA
(table 6.4b.).
To investigate the kinetics of virus inactivation, a batch of factor VIE was spiked at
a ratio of 1:100 with plasma from donor p5. During the lyophilisation step, the viral
DNA titre declined from 4.5 X 108 to 7 X 107 copies per ml. The lyophilised
material was then subjected to dry-heat-treatment for 24, 48 and 72 hours at 80°C.
A reduction to a final titre of 8 X 106 copies per ml was achieved with this process
(table 6.4c.). The overall reduction in the viral DNA titre is comparable to that
observed on heat treatment of nonspiked samples (table 6.4b.).
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Table 6.4a.
FREQUENCY OF DETECTION OF PARVOVIRUS B19 IN BLOOD PRODUCTS
Blood Product Source H.T. No. pos. No. tested
FACTOR VIII: NIBSC No 4 8
SNBTS No 7 10
SNBTS Yes 2 5
FACTOR IX: NIBSC No 3 4
SNBTS No 4 5
Intravenous IgG SNBTS 0 10
Table 6.4b.
EFFECT OF DRY HEAT TREATMENT AT 80°C FOR 72 HOURS






1 500 < 22 >95 %
2 50 < 22 >55 %
3 340 < 22 >93 %
4 1900 170 91 %
5 1400 50 96 %
Table 6.4c.
KINETICS OF REMOVAL OF B19 DNA DURING
HEAT TREATMENT OF FACTOR VIII
Virus titre %
Sample copies/ml Reduction
Spiked factor VIII 2.5 x 108
After lyophilisation 108 60%
24 hours 80°C (dry heat) 2.5 x 107 90%
48 hours .. 2.5 x 107 90%
72 hours .. 8 x 106 97%
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6.10. DISCUSSION
6.10.1. DETECTION OF PARVOVIRUS B19
INFECTION IN BLOOD DONORS
The incidence of parvovirus B19 viraemia in healthy blood donors in the studies
undertaken in both 1991 and 1993 (0.03% and 0.4% respectively), was considerably
higher than that reported by previous surveys in which antigen detection methods
were used (Cohen et al., 1990; Mortimer, 1983). One possible explanation for this
increased rate is the increased sensitivity of the PCR which is capable of detecting
5 copies per ml of plasma. Hybridisation methods typically detect 0.1 to lpg of B19
DNA which is equivalent to approximately 2 X 104 to 2 X 105 copies per ml. An
improved hybridisation assay with a chemiluminescent probe showed a sensitivity of
20fg of B19 DNA, or 4,000 copies (Musiani et al., 1991). While this method would
have detected all six donations in this study (unlike the former) it would still not
have been suitable for testing large pools due to its lack of sensitivity compared to
the PCR. Using the PCR it was possible to carry out direct sequence analysis of the
amplified DNA and to make a positive identification of B19 sequences and
distinguish B19 from other parvoviruses (or contaminants). Minor variations in
sequence between B19 in different blood donations confirmed that five independent
B19 infections in six donors had been identified. Sequence variability in the VP2
region was comparable to that observed among other epidemiologically unrelated
isolates of B19 (Umene and Nunoue, 1991).
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All the donors identified as being viraemic in the 1991 study were asymptomatic at
the time of donation, and three of the four male donors remained asymptomatic.
However both female donors reported symptoms of rash and arthropathy in the
following 5 to 14 days post-donation. A higher rate of symptomatic infection in
women has been reported previously (Woolf et al., 1989). Four of the five donors
recalled showed a specific IgM and IgG response to B19 following donation which
is consistent with primary infection (Anderson et al., 1985; Cohen et al.,1983). One
donor p6 was unusual in that he was anti-B19 IgG positive before donation and
before the time of viraemia and no IgM was detected at or after the time of donation.
One possible explanation would be that this individual was reinfected with
parvovirus; it has previously been shown that experimental inoculation of a healthy
adult volunteer with a low level of anti-B19 IgG led to reinfection, manifested by a
second IgM response and increased levels of anti-B19 IgG (Anderson et al., 1985).
However, neither serological response was observed in donor p6 in this study. Of
interest is that this individual had complained of recurrent polyarthralgia and flu-like
symptoms for several months both before and after donation. It is possible that he
had a chronic, low-grade infection with subclinical reactivation of B19 at the time
of donation.
6.10.2. PARVOVIRUS CONTAMINATION OF BLOOD PRODUCTS
Parvovirus B19 DNA was detected in two-thirds of the batches of noninactivated
clotting-factor concentrates tested. Considering the frequency of viraemic donors, the
size of the pools used for manufacture and the fractionation process used (Schwarz
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et al., 1991b) then this level of contamination could be expected. Although
parvovirus B19 DNA can be detected by PCR this does not necessarily imply
infectivity and more precise studies of B19 inactivation by different treatment
regimes will need to be carried out in the future using recently developed in vitro
culture systems (Brown et al., 1991; Schwarz et al., 1992). Whether these blood
products are infectious will depend on the stability of the virus, the possible
neutralisation of infectivity by mixture with antibody from other units in the pool
(Kurtzman et al., 1989), and the partitioning of the virus during cryoprecipitation and
cold ethanol precipitation during manufacture. However, these results contrast with
studies on other viruses, such as hepatitis C virus, in which the same treatment
eliminated infectivity and completely destroyed all traces of viral nucleic acid
(Garson et al., 1990a).
Several reports have provided serological evidence for transmission of B19 by non-
heat-treated factor VIII and prothrombin complex concentrates (Mortimer, 1983;
Rollag et al., 1991; Williams et al., 1990). Clinical data on recipients of " virally
inactivated " concentrates is contradictory and possibly reflects the variation in the
precise conditions used for virus removal. In one study, serological testing of
haemophiliacs who had received dry-heat-treated (72 hours at 80°C) factor VIII
showed that they had no increased risk of infection over age-matched controls
(Williams et al., 1990). However, elevated rates of infection were found in recipients
of dry heat-treated or steam-treated factor VIII (Bartolomei Corsi et al., 1988). In
addition, previously nontransfused haemophiliacs were reported to become acutely
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infected 7 to 14 days after the first infusion of detergent-treated (Azzi et al., 1992;
Morfini et al., 1992) or heat-treated (Azzi et al., 1992; Bartolomei Corsi et al., 1988;
Lyon et al., 1989) clotting factor.
6.10.3. DONOR SCREENING BY PCR : FEASIBILITY OF ROUTINE
TESTING FOR PARVOVIRUS B19
In order to identify a PCR-positive blood donation it was necessary to carry out four
sequential separate DNA extraction and nested PCR amplification reactions. In the
1991 study, in the initial pool of 500 donations the plasma that was found to be
negative (34 out of 40 tested) could have been safely transfused after only one
amplification reaction. An insignificant proportion of units (54 out of 20,000) would
need to subjected to four screens by PCR to rule out contamination. In this particular
study, no attempt was made to optimise the time taken for DNA extraction and PCR.
Despite this, it was possible to retrieve all six units of infected plasma from the PFC
before manufacture. Similarly in the 1993 study it was possible to retrieve all 23
positive packs identified and parvovirus DNA was confirmed in all. However it
proved to be more problematic to retrieve all previous and follow-up donations for
this particular study.
In theory, because the DNA extraction and amplification steps could be carried out
in a single working day, it should also be possible to prevent transfusion of all
contaminated units of erythrocytes and platelets without causing a significant delay
to the time of issue. Routine application of this method for virus detection in donor
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centres should be possible in the future with the development of rapid DNA




7. THE ROLE OF PCR IN THE DETECTION OF VIRUSES IN
BLOOD AND BLOOD PRODUCTS
7.1. GENER/ L INTRODUCTION
At present the diagnosis of microbial infection is generally based on the detection of
a specific antibody or antigen response. However detection of nucleic acid is
becoming widely used with the advent of recombinant DNA technology which has
enabled the production of nucleic acid probes for many microorganisms, including,
viruses, bacteria, fungi, spirochetes and rickettsia (Tenover, 1988). Culture methods
for diagnosis are often difficult or require long periods of cell growth to obtain
results. In addition, there may been a long window period (3 to 12 months) between
viraemia and antibody response, which is a specific problem in the detection of HIV
or HCV. Two methods of nucleic acid detection widely used are PCR and/or
hybridization. The use of nucleic acid hybridization for microbial diagnosis has been
limited by its insensitivity compared to immunological tests. However with the
development of the PCR, microbial nucleic acids may be " enriched " prior to
detection and a new level of sensitivity be obtained. Quantification of the amount of
the replicating virus is possible once the nucleic acid has been isolated. The ability
to detect small amounts of virus makes the PCR test prone to false-positive results
due to contamination of the specimen with the DNA to be detected and has made the
technique difficult to automate. False-negative results are rare, and are mainly due
to the presence of inhibitors of DNA polymerase in the specimen. Incorporation of
appropriate positive and negative controls allows for monitoring of these false
reactions. In addition, it has proved difficult to standardise the extraction and RT-
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PCR reactions (Zaaijer et al., 1993). Commercial kits are now available that enable
the detection by PCR of HCV, HIV and HBV virus particles in plasma and serum
samples.
A limitation to the number of samples that can be tested by PCR is the need to
extract nucleic acid from each sample to be tested. In the research situation this may
not represent a significant problem but for the routine screening of blood donors this
and the difficulty in automating the PCR has prevented the technique from becoming
widely us^d for the screening of blood donations. One way of overcoming the
problem associated with extraction is the pooling of samples to enable the screening
of a large number of samples. Such a method was developed and used to screen
blood donations for parvovirus B19 (McOmish et al., 1993b and chapter 6). The
following sections describe the extension of the pooling technique to other viruses
thus offering a step towards PCR screening of a large number of samples on a
routine basis. Comparison of a commercial HCV PCR detection system is made with
the RT-PCR technique described and used in this work (chapter 2, sections 2.5 and
2.6). The commercial kit and the RT-PCR technique are compared and validated
using a reference panel from the Eurohep Group whose aim is to standardise the PCR
used in laboratories across the world.
Manufacturers of blood products are required to prove the safety of their preparations
using validated fractionation and virus inactivation techniques. Infectivity assays are
cell culture based systems that are widely used for the detection of replicating virus
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particles and are often employed in studying virus inactivation procedures. However,
it takes several weeks to obtain a result from a cell culture system, whereas a PCR
result may be available within 2 days and can be performed on a larger number of
samples. The role of PCR as a replacement for infectivity assays in studying virus
inactivation is considered.
7.2. SCREENING OF BLOOD AND BLOOD PRODUCTS FOR HEPATITIS
A VIRUS
7.2.1. INTRODUCTION
Transmission of hepatitis A virus (HAV) to haemophiliacs by factor VIII
concentrates purified by ion-exchange chromatography and virally inactivated by
solvent-detergent (SD) treatment has been reported (Mannucci et al., 1992; Gerritzen
et al., 1992; Temperely et al., 1992; Peerlink et al., 1993). Transmission may have
occurred because HAV is a non-lipid enveloped virus and would not be destroyed
by the SD treatment. In addition, blood donation are not routinely screened for HAV
antibody. Normann et al. (1992) reported that HAV RNA could be detected in two
of four batches of factor VIII (produced by the S/D process) tested by PCR and one
of the four PCR-positive batches had been administered to four haemophiliacs who
had acute HAV infection following factor VIII treatment. Since many manufacturers
use the SD method of virus inactivation a study was undertaken to examine the
presence of HAV RNA in factor VIII concentrate produced by the SD method
Chromatography material used in the purification steps was also examined since it
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is possible that HAV could preferentially adsorb to the chromatography material and
be subsequently eluted.
Using the pooling method described in chapter 6, 12,000 blood donors were tested
for HAV infection by RT-PCR to measure the prevalence of HAV positive
individuals in the donating population in Scotland.
7.2.2. SAMPLES
Batches of high-purity factor VIII concentrate manufactured by the Scottish National
Blood Transfusion Service (SNBTS) and the New York Blood Centre were studied
(table 7.1.). In these preparations the SD process was incorporated into the
manufacturing procedure. In addition, three batches of high-purity factor VIII, one
manufactured by Octapharma, and implicated in HAV transmission (Peerlink and
Vermylen, 1993), and two manufactured by Biotransfusion, but not implicated in the
HAV transmission, were studied. These batches were also prepared by the SD
method. Three batches of high-purity factor VIE manufactured by the Bioproducts
Laboratory (Elstree, UK) using a high-purity monoclonal antibody purification
method after SD treatment were also tested. All factor VIE preparations were
supplied as lyophilised powder and reconstituted prior to testing according to the
manufacturer's instructions with final concentrations of factor VIII ranging from 25
to lOOIU/ml.
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Samples of chromatography gel used in the purification of factor VIE, the gel
material and a 2M sodium chloride (NaCl) eluate from it were obtained from
Biotransfusion, Lille (courtesy of Dr. T. Burnouf). Other samples were
chromatography gel that had been used in the purification of ten production batches
of factor VIII by the SNBTS, and a 2M NaCl and 50mM NaOH eluate.
Twelve thousand volunteer blood donations collected in Scotland at two time points
in the year (March and August 1992) were tested in pools of 100 donations as
described in chapter 6, section 6.7.2..
Twenty five coded batches of factor VIII concentrate (Melate) were also provided by
the New York Blood Centre. These batches had been produced using a mixture of
plasma from local volunteer donors and cryoprecipitate obtained from a commercial
company.
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7.2.3. PCR AND PRIMERS
Reverse transcription and PCR were carried out as described in chapter 2, sections
2.5 and 2.6.. HAV specific oligonucleotide primers (chapter 2, section 2.6., table 2.4.)
were designed from a consensus sequence of 6 HAV sequences in the 5' NCR which
is the most conserved region of the genome in all isolates. 5' nucleotide positions are
based on the wild type HM-175 strain (Cohen et al., 1987). Validation of the HAV
RT-PCR was based upon a panel of 26 plasma samples from patients with suspected
hepatitis A infection (kindly provided by Dr.S.Burns, City Hospital, Edinburgh). Five
out of 7 samples that were IgM anti-HAV positive were positive by RT-PCR; all the
remaining samples (7 IgM anti-HAV weak positive; 7 Ig M anti-HAV negative; 5
IgG anti-HAV positive) were all HAV negative by RT-PCR. HAV RNA could also
be detected in 1 sample of liver tissue from a patient with fulminant hepatitis A who
required a liver transplant. Direct nucleotide sequence analysis was carried out on
PCR products from three of the RT-PCR positive plasma samples and deduced
sequences were 100% identical to published HAV sequences. These plasma samples
were used as positive controls in further experiments.
The sensitivity of the PCR assay for the detection of HAV RNA in factor VIII
concentrates was determined by spiking experiments. HAV RNA copy number was
determined in a serum sample of a patient with hepatitis A infection by titration at
limiting dilution (chapter 2, section 2.9.). Five to fifteen replicates were tested at and
around the cut-off point of a serial 10-fold dilution set, and the copy number
calculated as described in chapter 2, section 2.9.. Varying volumes of this serum
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were added to a factor VIII concentrate reconstituted according to the manufacturers
instructions to 25IU/ml, previously tested and shown to be negative for HAV. The
number of copies of HAV RNA was determined by titration at limiting dilution and
compared to that obtained with the original serum sample used for spiking.
7.2.4. RESULTS
HAV RNA could not be detected by PCR in any of the batches of factor VIII
preparations studied (table 7.1), including the one batch of factor VIII that was
implicated in hepatitis A transmission in Belgium (Peerlink and Vermylen, 1993).
Also, HAV RNA could not be detected in the chromatography gel before or after use
in the purification of factor VIE, or in the eluates from these gels. A total of 12,000
blood donor plasma samples were tested as pools for HAV. No positive donations
were detected at either period of collection.
The failure to detect HAV RNA in any of the batches screened had two implications:
either it was not possible to detect HAV in factor concentrates in this way or the
batches tested were free from contamination with HAV. To continue the search for
HAV in factor concentrate, several batches were obtained from a manufacturer
outwith Europe. Two sets of batches of Melate were tested blind (table 7.1.). Two
out of 15 vials proved to be positive for HAV RNA, these were identified as batches
91C and 91D. A further 10 vials were tested and 2 positive vials were identified as
batches 9IB and 91C. A positive hybridisation signal was obtained on a filter
carrying PCR product from each of the three positive batches when incubated with
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a HAV-DIG labelled probe (fig 7.1; method: chapter 2, section 2.10.). In addition,
direct sequence analysis of PCR product from the three positive batches was carried
out. Sequences obtained showed 99% homology to the wild type HAV HM-175, the
only differences being an A—>T change at position 177, and a T—>A change at position
204 (numbering from wild type HAV HM-175, Cohen et al., 1987). Both of the
batch sets tested included all three PCR positive batches but batches 9IB and 91D
were not PCR positive in set one and set two respectively, whereas batch 91C
contained 100% cryoprecipitate obtained from a commercial source and was PCR
positive in both sets tested. Batches B and D were composed of 14% commercial
cryoprecipitate and 86% volunteer donor derived material.
A detection limit of HAV RNA was calculated by spiking experiments with human
plasma to be 266 copies of HAV RNA per ml of factor VIII concentrate. As an
independent test, factor VIII concentrates were spiked with a cell-culture-adapted
strain of HAV (HM175/18f) that had been titred by an infectivity assay on African
green monkey kidney cells by Dr. Stanley Lemon (University of North Carolina) and
obtained courtesy of Dr. Henrietta Margolis-Nunno (New York Blood Centre). A
factor VIII sample containing 50 radioimmunofocus assay units (RFU)/ml (Lemon
et al., 1991) was PCR negative, whereas samples containing 5,000 and 500,000
RFU/ml were PCR positive consistent with the estimated detection limit.
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Figure 7.1.
HYBRIDISATION SIGNAL OBTAINED WITH HAY PCR PRODUCT
1. Positive control (IgM anti-HAV positive, RT-PCR positive plasma sample)
2. Negative control (HCV RT-PCR positive plasma sample)
3. Batch 91C - from first test set
4. Batch 9ID - from first test set
5. Batch 9IB - from second test set
6. Batch 91C - from second test set
7. Melate batch 91C - uncoded vial
8. Positive control (as no.l)
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7.2.5. DISCUSSION
Reports of transmission of HAV by blood products have been rare and limited to
single donor products used in blood transfusion (Barbara, 1982; Skidmore et al,
1984). In 1992 and early 1993 there were four reports of HAV infection in
haemophiliacs treated with factor VIII concentrates produced from plasma using ion-
exchange chromatography with SD treatment as the virus inactivation method
(Mannucci, 1992; Gerritzen et al., 1992; Temperely et al., 1992; Peerlink et al.,
1993). Although in these cases the starting plasma was from a variety of different
sources the manufacture was performed by or under licence from a single company.
These HAV transmission reports caused some concern about the efficacy of the SD
treatment method in the inactivation of HAV in the manufacture of factor VIII
concentrates. In Scotland, factor concentrates produced using the SD method of virus
inactivation have been used since 1991.
The study was undertaken to establish if HAV RNA was present in factor VIII
concentrates produced using SD as the method of virus inactivation and to assess the
risk ofHAV infection in Scottish haemophiliacs who are receiving this product. HAV
RNA could not be detected in any of the factor VIII concentrates or chromatography
gel eluates studied, suggesting that the presence of HAV RNA in factor VIII
preparations is a rare event, consistent with the sporadic nature of the reported
transmission episodes. The negative results are also consistent with the lack of
detectable cases of HAV viraemia in the 12,000 blood donations tested.
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An alternative explanation for the negative RT-PCR results could be that the
detection limit for HAV RNA was not sufficiently low to detect an infecting HAV
dose. The detection limit established for the RT-PCR used in this study was 266
copies of HAV RNA per millilitre of reconstituted factor VIII concentrate solution.
The concentration of factor VIII in a single experiment was 25 IU/ml, which is
equivalent to a detection limit of approximately 10 copies of HAV RNA per IU of
factor VIII. Another explanation might be that HAV RNA was at limiting dilution,
ie: present in some vials in batches of factor VIII concentrates, and not in others.
Each batch of factor VIII concentrate is manufactured from plasma derived from
10,000 or more donations and if one donation from a viraemic donor was present in
the pool with a hypothetical HAV titre of 106 copies/ml, there would be a titre of 102
copies/ml or less in the final plasma pool which would be below the sensitivity of
the RT-PCR used in this study. This uncertainty would be best resolved by
quantitative studies of the level of HAV RNA present in batches of factor VIII
concentrate that were definitely implicated in transmission.
The detection of three HAV RNA positive batches of Melate demonstrates that it is
possible to identify the virus in batches of factor concentrate. The fact that batch 91C
was PCR positive in both test sets while batches 9IB and 91D were only found to
be positive once is consistent with virus being present at limiting dilution in some
batches.
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The failure to detect HAV RNA in any of the production batches of factor VIII
concentrate and none of the pools from 12,000 blood donors suggests that factor VIII
concentrate produced using the SD method of virus inactivation is unlikely to
transmit HAV. This is confirmed by retrospective testing of stored samples showing
that there have been no seroconversions amongst Scottish haemophiliacs since the
introduction of SD treated products (pers comm Dr. H. Watson, Royal Infirmary,
Edinburgh). Therefore the reported cases of HAV transmission by factor VIII
concentrates may actually represent community acquired infections. The susceptibility
of haemophiliacs to HAV infection may have increased also, due to falling levels of
passive immunity previously provided by anti-HAV IgG present in intermediate-
purity factor concentrates (ie: concentrates prepared prior to 1991 in which dry heat
treatment was the viral inactivation method used which did not remove all protein
components) or because of falling antibody levels in the community in general.
Reports from around the world indicate that the age distribution of antibody to HAV
has changed over the last 10-20 years (pers comm Dr. Gillon, SNBTS, Edinburgh),
in that since 1970 childhood infection has become much less common in most "
Westernised " countries, the exact timing of this change being different in different
countries, and between different regions within the UK. This change in age
distribution has two implications for the transmission of HAV by blood products.
First, " herd " immunity is reduced, resulting in a reduction in the amount of
protective antibody in the donor pool and possibly an increase in transmission of
HAV by factor VIII concentrates. Secondly, the number of viraemic individuals in
the donating population will be increased as the age of infection shifts from
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childhood to young adulthood. Hepatitis A viraemia can be detected by RT-PCR
prior to clinical manifestations of disease and up to seven days after clinical onset
and the appearance of IgM-HA antibody (Yotsuyanagi et al., 1993). It is therefore
possible that blood donations may be taken in this asymptomatic period while the
individual is viraemic. The combination of the three factors of possible failure to
inactivate the virus during manufacture and the potential increase in incidence of
viraemia and loss of protective antibody in the donating population may be
contributing elements which have resulted in the transmission of HAV to
haemophiliacs through factor VIII concentrates. In the future it may be necessary to
boost antibody levels in the donor population, either by selecting naturally immune
donors for plasmapheresis or by boosting non-immune donors with vaccine to
overcome this problem.
7.3. VALIDATION OF THE HCV PCR AND COMPARISON WITH A
COMMERCIAL HCV PCR KIT
7.3.1. INTRODUCTION
The detection of HCV by RT-PCR is now widely used for the diagnosis and
confirmation of HCV infection in the clinical situation. A positive PCR result may
prove infection when a serological test gives an ambiguous result or when a patient
fails to mount an antibody response. Detection of HCV RNA may sometimes be the
only test available for diagnosis, for example, in patients with immune deficient
syndromes such as hypogammaglobunaemia. Alternatively a negative PCR result may
indicate that viraemia has resolved in a person with detectable HCV antibodies.
228
Many different HCV RNA extraction methods are used in different laboratories but
the most commonly used are guanidine thiocyanate denaturation followed by
phenol/chloroform extraction (Chomczynski and Sacchi, 1987) or proteinase K
digestion followed by phenol/chloroform extraction (described in chapter 2, section
2.4.). Some laboratories carry out a centrifugation step prior to extraction to
concentrate virus. Amplification of the 5'NCR is generally used for detection of
HCV, however many different primer sets have been described within this region and
it is possible that some genotypes may fail to be amplified by primers that include
polymorphic sites between the different genotypes (Wolff et al., 1992). The detection
of different HCV genotypes and subtypes and the possibility that their response to
interferon treatment may vary (Dusheiko et al., 1994) increases the need to develop
a reliable, reproducible and standardised RT-PCR system since PCR results have
consequences for patient management and monitoring.
A European group on viral hepatitis (" Eurohep ") aims to standardise HCV RNA
detection. A panel of well characterised fresh frozen plasma samples was sent to 30
hepatitis research laboratories in Europe, 7 in the USA and 1 in Japan. Each
laboratory detected HCV RNA by its own protocol and the results were sent to the
coordinating centre where each laboratory was assigned a code to ensure
confidentiality. Results were analysed and reported back to the participants. The
correlated results have been published (Zaaijer et al., 1993), the following section
reports the results obtained from testing the panel by the RT-PCR method described
in chapter 2, section 2.3.; 2.4.; 2.5.; 2.6.. In addition, the samples were tested by a
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new commercially available HCV PCR detection system (Amplicor) manufactured
by Roche. Comparison of the sensitivity and specificity of this kit with the " in house
" RT-PCR system was made. A standardised kit system would be the first step to
obtaining a uniform test for HCV RNA on a world wide basis.
7.3.2. SAMPLES
Eurohep samples were shipped frozen and coded to Edinburgh. The test panel
consisted of 22 samples and included 10 undiluted blood donor samples with and
without HCV infection and two 10-fold dilution series of 6 samples each. The panel
was tested using the guanidine thiocyanate and the proteinase K extraction methods,
followed by RT-PCR using primers in the 5'NCR (chapter 2, section 2.3.; 2.4.; 2.5.;
2.6.), as well as by the Roche Amplicor test. RT-PCR results from 48 Scottish blood
donor samples with known RIBA-3 status were compared with the Roche Amplicor
kit results.
7.3.3. THE ROCHE AMPLICOR HCV DETECTION KIT
All tests were carried out according to the manufacturers instructions. Briefly, target
RNA was prepared using a guanidine thiocyanate extraction method, HCV target
RNA was reverse transcribed and amplified in a single tube reaction using TtH DNA
polymerase. Biotinylated primers in the 5'NCR region were used with the
incorporation of dUTP in the reaction mix to prevent carryover of contaminants in
the PCR reaction. The products of the PCR were denatured and hybridised to a 5'
NCR oligonucleotide probe coated on the wells of a microtitre plate. The plates were
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then washed and incubated with an avidin-HRP (horse radish peroxidase) conjugate.
Substrate was added after another wash, colour development was allowed to proceed
in the dark, stop solution was added and the O.D. read at 450nm. A sample was
considered positive if the O.D. reading was >0.4 O.D. units.
7.3.4. RESULTS
Using all three methods (A: guanidine thiocyanate, B: proteinase K and C: the Roche
Amplicor kit) 3 HCV RNA positive samples were detected in the set of 10 donor
samples (table 7.2.). Sample no. 10 was determined by the Eurohep group to be a
weak positive, and failed to be identified by any of the three methods. In set 1 of the
10 fold dilution series, the first 2 dilutions out of 6 were positive using methods A
and C, while the third dilution was detected using method B. In set 2, the first
dilution only was detected using method A, the second dilution with method B and
dilutions 1 and 3 using method C. The third positive sample probably representing
a false positive reaction in the Amplicor test (table 7.2.). These results demonstrated
a ten fold increase in detection rate using the proteinase K method over the guanidine
thiocyanate method.
Further comparison between the " in house " RT-PCR and the Amplicor test kit was
made. 14 RIBA-3 confirmed/RT-PCR positive samples were also positive with the
Amplicor test. Testing of 9 RIBA-3 indeterminate/RT-PCR positive samples produced
1 Amplicor result that was discrepant. This sample showed reactivity with the c33c
antigen (band strength 4+) in the RIBA-3, was RT-PCR positive with the " in house
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" PCR and negative in the Amplicor test. The same sample was tested again with
both systems and the results confirmed. In addition when 2 follow up samples
obtained from the same donor were tested by RT-PCR, both were positive for HCV
RNA. Nine out of 10 RIBA-3 confirmed/RT-PCR negative samples produced
negative results with the Amplicor test, with 1 sample producing a positive signal.
Repeat testing of this sample generated a result that was marginally over the cut-off
level (result of 0.411 with a cut-off value of 0.4), suggesting a false positive result
in the first round of testing. Similarly, comparison of 15 RIBA-3 indeterminate/RT-
PCR negative samples produced 1 sample that gave a positive result initially but on
repeat testing it proved to be negative (table 7.3.). All discrepant results were
confirmed independently by Dr.B.Dow at Ruchill Hospital, Glasgow, using both PCR
systems as described.
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Table 7.2. EUROHEP PANEL
Blood Donor Result of Method Amplicor O.D.
Sample No. ABC
1 N N N 0.143
2 N N N 0.125
3 N N N 0.123
4 P P P 2.372
5 N N N 0.152
6 P P P 2.181
7 N N N 0.121
8 N N N 0.126
9 P P P 2.214
10 N N N 0.132
Log.dil./Series
-2/1 P P P 2.384
-3/1 P P P 2.001
-4/1 N P N 0.170
-5/1 N N N 0.128
-6/1 N N N 0.129
-7/1 N N N 0.133
-2/2 P P P 2.220
-3/2 N P N 0.116
-4/2 N N P 1.443
-5/2 N N N 0.118
-6/2 N N N 0.153
-7/2 N N N 0.169
P : Positive N : Negative
Cut-off value for Amplicor O.D. readings : 0.4 units
A : Guanidine Thiocyanate method
B : Proteinase K method
C : Roche Amplicor method
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Table 7.3.
Comparison of RT-PCR with Amplicor
Sample RIBA-3 RT-PCR Amplicor Amplicor
I.D. Result Result Result O.D.
RIBA-3 CONFIRMED/RT-PCR POSITIVE
13067 4-4-4-4 P P 2.354
13069 4-4-4-4 P P 2.342
13139 4-4-4-0 P P 2.256
13177 4-4-4-0 P P 2.231
13179 4-4-4-0 P P 2.252
13436 1-3-4-0 P P 2.659
13515 0-3-4-0 P P 2.598
13669 4-4-4-4 P P 2.598
13722 4-4-4-3 P P 2.618
13773 4-4-4-4 P P 2.566
15038 4-4-4-4 P P 2.199
15048 0-4-4-4 P P 2.130
15259 4-4-4-0 P P 2.361
14888 1-3-4-0 P P 0.862
RIBA-3 INDETERMINATE/RT-PCR POSITIVE
14827 0-4-0-0 P N 0.080*
14993 0-2-0-0 P P 2.365
15593 0-4-0-0 P P 2.187
10802 4-0-0-0 P P 2.673
10886 0-0-4-0 P P 2.618
8514 0-0-4-0 P P 2.691
5812 0-0-4-0 P P 2.666
5519 0-0-4-0 P P 2.607
4849 0-0-4-0 P P 2.375
*
Repeat test O.D. : 0.070




Comparison of RT-PCR with Amplicor (continued)
Sample RIBA-3 RT-PCR Amplicor Amplicor
I.D. Result Result Result O.D.
RIBA-3 CONFIRMED/RT-PCR NEGATIVE
13229 0-1-3-0 N N 0.083
13279 0-1-2-0 N N 0.122
13858 4-4-3-0 N P 1.290"
13995 4-4-4-0 N N 0.132
14484 3-4-4-2 N N 0.125
15215 2-3-3-2 N N 0.066
15455 0-2-2-0 N N 0.076
15992 0-1-1-0 N N 0.063
16056 4-4-4-4 N N 0.054
13241 0-0-2-1 N N 0.061
RIBA-3 INDETERMINATE/RT-PCR NEGATIVE
12065 0-3-0-0 N N 0.101
13055 0-0-0-1 N P 1.432"*
13065 0-1-0-0 N N 0.136
13084 0-0-3-0 N N 0.136
13116 0-0-0-2 N N 0.124
13118 2-0-0-0 N N 0.125
13122 2-0-0-0 N N 0.152
13129 0-0-0-1 N N 0.125
13149 0-0-0-2 N N 0.120
13173 0-0-1-0 N N 0.148
13101 0-0-0-2 N N 0.070
14926 0-0-1-0 N N 0.160
15199 4-0-0-0 N N 0.130
15218 0-0-0-3 N N 0.154
15287 0-2-0-0 N N 0.127
Repeat test O.D. : 0.411
"*
Repeat test O.D. : 0.058
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7.3.5. DISCUSSION
Detailed analysis was made by the Eurohep group of the results from 31 laboratories
on the supplied panel samples. Their results revealed that only 5 (16%) of the
participants generated perfect results in testing the blood donor panel and amongst
these 5 laboratories the sensitivity of detection in the dilution series varied by a
factor of 100. False negative results were mainly due to a lack of sensitivity, failure
to detect a weak positive sample in the blood donor panel was found along with
decreased detection in the dilution series. However 4% of the tests of strong positive
samples were reported as being negative. The rate of false positivity was even greater
at 11% of tests of negative samples, with contamination being the most likely
explanation for such results. The main conclusions derived from the study was that
contamination was a significant problem in some laboratories and that incorporation
of negative control samples would help to show if this occurred. The lack of
sensitivity in detection by some laboratories could be assessed by the inclusion of a
weak-positive control on a routine basis.
In the work from this laboratory, no false positive results were generated in testing
the Eurohep panel and the proteinase K digestion method provided a tenfold increase
in sensitivity over the guanidine thiocyanate method (table 7.2.: A and B) giving a
sensitivity comparable with that of laboratories with good results in the dilution
series. However the weak positive sample in the blood donor panel was not detected
by any of the 3 methods used here, a problem shared by 10 (33%) other laboratories.
It is important to establish a level of sensitivity for the RT-PCR system used and to
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monitor the sensitivity. These findings have been incorporated into our routine PCR
testing; the proteinase K extraction method is now used and sensitivity is measured
by testing five 10-fold dilutions of a HCV RNA positive plasma sample along with
any test samples (chapter 2, section 2.7.). Any variation in the end point detection
would indicate a decrease in the sensitivity of that set of test samples and the need
to retest the complete sample set.
Forty-eight Scottish blood donor samples with different strength and combination of
RIBA-3 band were selected to examine whether there was any particular RIBA-3
pattern that failed to be detected by either system and to compare the results
obtained. Forty-five samples produced identical results when tested with the " in-
house " RT-PCR and the Amplicor kit (table 7.3.). Of the 3 discrepant results, 1
(sample I.D.: 14827) appeared to be a false negative result while the other 2 are
likely to be false positives (sample I.D.s: 13858 and 13055)(table 7.3.). A trend that
emerges from these results is that a genuine positive result with the Amplicor test
produces an O.D value of >2.0 and so it may be possible to identify potential false
positive results by their low but positive O.D.. This trend is supported by the false
positive sample detected in the second dilution series of the Eurohep panel where the
third dilution sample gave an O.D. value of 1.443 (false positive) and the previous
dilution had generated a value of 0.116 (negative result).
The Amplicor kit provides a step towards automation of the PCR. Results for ninety
six samples could easily be obtained in one day by one person whereas using
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conventional techniques it takes approximately 2.5 days or longer (Jackson, 1990) to
obtain results on 48 samples. However care must be taken in interpreting the results
as false positive and negative reactions do occur.
7.3.6. APPENDIX TO SECTION 7.3.
A second Eurohep panel consisting of 26 coded samples (10 blood donor samples
and 2 dilution series) were tested in this laboratory in 1993 using the proteinase K
extraction method. The results were recently made available (June 1994) to the
participants. A full analysis comparing the results from this laboratory and other
participants will be made by the Eurohep group as before, but is not yet available.
Table 7.2a shows the results obtained in this laboratory compared with two reference
laboratories (ref.lab.) selected by the Eurohep group. Three positive blood donor
samples were detected by all three laboratories, ref.lab. 1 reported a weakly positive
sample not detected by ref.lab.2 or this laboratory. In the first dilution series, the
results from this laboratory were the same as ref.lab.2 a positive result was detected
to the third dilution, ref.lab. 1 reported a positive result in the fourth dilution and a
+/- result in the fifth. In the second dilution series this laboratory and ref.lab. 1
reported positive results to the fourth dilution with a +/- result in the fifth dilution
reported by ref.lab. 1. In the second series ref.lab.2 reported a positive result to the
third dilution. No false positive reactions were reported by this laboratory.
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Table 7.2a. EUROHEP PANEL
Blood Donor IH Ref. Ref.
Sample No. RT-PCR Lab 1 Lab 2
1 N N N
2 P P P
3 N N N
4 P P P
5 N P* N
6 N N N
7 P P P
8 N N N
12 N N N
13 N N N
Dil.Series
Dil.factor
100 P P P
1000 P P P
4000 P P P
16000 N P N
64000 N +/- N
256000 N N N
1024000 N N N
4096000 N N N
10 P P P
100 P P P
1000 P P P
4000 P P N
16000 N +/- N
64000 N N N
256000 N N N
1024000 N N N
IH RT-PCR : in-house RT-PCR (results from this laboratory)
*
reported as a weak positive
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7.4. THE ROLE OF PCR AS A VALIDATION ASSAY FOR VIRAL
INACTIVATION PROCEDURES
7.4.1. INTRODUCTION
The screening of individual blood donations prior to infusion or incorporation of
plasma into a plasma pool used in the manufacture of factor concentrates has proved
to be effective at reducing the transmission of infectious agents. To provide an
additional level of safety, blood product manufacturers are required to incorporate
virucidal inactivation procedures into the manufacturing process (chapter 1, section
1.3.). It is also necessary for manufacturers to provide evidence of the virucidal
potential of the virus inactivation methods (chapter 1, section 1.3.1.). Infectivity
assays using model viruses are widely used since there is no reliable culture system
for the agents HBV, HCV, HDV and parvovirus B19. Such model systems are only
a representation of the behaviour of an infective agent. However there is a case for
the use of the actual pathogenic agent as the results obtained would more accurately
mimic those of the virucidal process. Development of alternative methods for the
assessment of virus inactivation would therefore be required. In the following section,
RT-PCR was used to detect the presence of viral nucleic acid in blood products and
these results were compared with two different infectivity assay systems based on
tissue culture to investigate the potential role of PCR in monitoring virus inactivation
in production methods using solvent/detergent and heat treatment.
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7.4.2. SAMPLES
(1) HIV : HIV-1 (lab strain RF) was spiked at a ratio of 1:20 into intermediate-purity
factor VIII and factor IX concentrate and at 1:12 into fibrinogen concentrate
produced by standard manufacturing methods used at the PFC (refs in Hart et al.
1993). Spiking with HIV-1 at this ratio does not have any effect on the concentrates
during freeze-drying and virus inactivation by heating (pers. comm. Dr.H.Hart, PFC,
Edinburgh). Laboratory-scale freeze-driers were used that maintained the same yield,
stability and moisture levels during freeze-drying that occur during normal
production. Similarly the severe heating of the concentrates was carried out using
scaled models of the heat-cycle regimes. Samples were heated to 80°C and two
separate vials were removed at various time intervals (24, 48 and 72 hours). One vial
was designated for testing by the infectivity assay, the other for testing using RT-
PCR. The samples were reconstituted in distilled water and stored at -80°C until
testing. The tissue culture assays were carried out by Dr.H. Hart (PFC, Edinburgh)
and were based on the formation of syncytia in C8166 cells and described in Hart
et al., 1993. RT-PCR was carried out as described in chapter 2, section 2.5., 2.6..
HIV specific primers (Simmonds et al., 1990b) are described in chapter 2, section
2.6., table 2.5. (5' nucleotide positions relative to HIV clone HXB2).
(2) CANINE PARVOVIRUS : Canine parvovirus (CPV) is commonly used as a
model virus for parvovirus B19 (chapter 6) since it is not possible to maintain the
latter in culture. CPV was cultured to titres of 104 2 TCID50 and spiked at a ratio of
1:10 into high purity factor VIII concentrate. Samples were heated, as before, to 80°C
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and two separate vials were removed for infectivity assay or PCR testing at various
time intervals (8, 24, 48 and 72 hours). The tissue culture assays were carried out by
Dr.H. Hart (PFC, Edinburgh) and the presence of virus was detected by
haemagglutination of porcine red cells (Hart et al. Vox Sang in press). PCR was
carried out using primers derived from a consensus of feline and canine parvovirus
sequences (described in chapter 2, section 2.6., table 2.3.; 5' nucleotide numbered as
in Shade et al., 1986).
7.4.3. RESULTS
(1) HIV : Using dry-heat treatment at 80°C the infectivity of HIV-1 was rapidly
inactivated (table 7.4.). After 24 hours of heating, infectious HIV-1 was isolated from
the factor VIII and factor IX preparation which had been spiked with the higher HIV-
1 inoculum, but not from the fibrinogen concentrate (spiked at a lower level).
Infectious HIV-1 was not detected in any of the concentrates after 48 or 72 hours of
heating.
HIV-1 RNA detected by RT-PCR in the same material was found to persist even
after 72 hours of heating at 80°C, and over time the difference between the infectivity
and RT-PCR measurements became greater. The virus reduction index for HIV-1
measured by the infectivity assay was calculated as 5.0, 4.0 and 4.5, averaging 4.5
log10 (table 7.4.). The RT-PCR reduction indexes were 2.0, 2.0 and 1.0, averaging
1.71og10 for the three different concentrates. The reduction index measured by RT-
PCR was therefore less than that measured by infectivity assay. In addition, 105
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copies/ml of HIV-1 could be detected by RT-PCR after 72 hours of heating when the
infectivity assay failed to detect the presence of infectious HIV-1 particles.
(2) CANINE PARVOVIRUS
Similar results were obtained when PCR were compared to an infectivity assay for
the detection of CPV. Virus infectivity was decreased by a factor of 2.11og10 after 24
hours heating at 80°C, and fell below the sensitivity of the assay by 48 hours (table
7.5.). In contrast, there was no reduction in the titre of CPV detected by PCR, 6.8
X 108 copies/ml were detected for all time points, except the final time point which
was found to be 7.6 X 108 copies/ml (this difference is likely to be caused by
variation in pipetting and is probably not significant).
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Table 7.5.
COMPARISON OF CPV INFECTIVITY ASSAY






before freeze-drying 4.2 6.8 X 108
after freeze-drying 4.2 6.8 X 108
80°C
8 hours 3.3 6.8 X 108
24 hours 2.2 6.8 X 108
48 hours <2.1 6.8 X 108






In the UK, manufacturers of blood products are required to show that a single step
in the manufacturing procedure is capable of inactivating 5 logs of HIV-1 (Thomas
et al., 1988). Many different studies have been published on HIV-1 inactivation,
assessed by using different virus strains, culture cells and culture times (Prince et al.,
1986a,b; Spickett et al., 1989; Tersmette et al., 1986) and with no international
standard, comparison of different infectivity assays is difficult. The HIV-1 infectivity
assay system used in this work required a 28 day culture time and the presence of
virus was assessed by the detection of syncytia and the presence of p24 antigen in
the culture supernatant. One potential advantage of RT-PCR over the infectivity
assays is that a result would be available within 2 days and quantitation of the
number of virus particles could be made. However, the reduction index after 72 hours
heat treatment was only 1.71og10 measured by RT-PCR compared with 4.51og10 by
infectivity assay. Factor concentrate treated by heating to 80°C has been evaluated
in patient trials (Watson and Ludlam, 1992) and has been found to be effective based
on the prevention of transmission of HIV and HCV to haemophiliacs (Haemophilia
Directors for Scotland and Northern Ireland, 1993). The results of this study suggest
that heat stable RNA sequences, either intact or in fragments, can remain in
noninfective HIV samples.
A similar trend was observed on comparison of the results from the CPV infectivity
assay and the PCR results. PCR positive results were obtained from samples which
had no demonstrable infectivity in tissue culture. The use of solvent detergent as a
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virus inactivation procedure is primarily targeted at the elimination of lipid-enveloped
viruses, however terminal dry heat treatment of solvent detergent treated factor
concentrate is effective at inactivating the non-lipid enveloped virus HAV (Hart et
al., Vox Sang in press). Care must be taken in interpreting the CPV results since
transmission of human parvovirus B19 by factor concentrates has been shown to
occur with dry heat treated preparations (Bartolomei-Corsi et al., 1988; Lyon et
al.,1989). Parvovirus B19 has also been transmitted to haemophiliacs despite the
terminal heating to 100°C for 30 min of solvent/detergent treated concentrates
(Santagostino et al., 1994). The results presented here based on the CPV model
indicate that a longer period of heating (at least 24 hours) might be necessary to
inactivate virus. Although analogies can be drawn between CPV and parvovirus B19,
an in vitro system for B19 is necessary before a full assessment of inactivation
procedures can be made.
In conclusion, the poor correlation between the RT-PCR results and the infectivity
assay for both HIV-1 and CPV indicates that RT-PCR is probably not useful for the
evaluation of virus inactivation methods. The results obtained in this study along with
clinical evidence of parvovirus B19 transmission to haemophiliacs suggests that
alternative inactivation strategies are necessary to eliminate the risk of parvovirus
B19 transmission. Preliminary studies have been carried out using ultraviolet light
treatment (UV A and UV C) in the presence of psoralens (see chapter 1, section 1.3.
table 1.5.) on factor VIII concentrates spiked with parvovirus B19. Titration of
parvovirus B19 DNA before and after treatment showed 3 log reduction in titre after
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treatment (data not shown, work carried out in collaboration with Dr.H. Margolis-
Nunno, NYBDC, New York). This UV light/psoralen treatment may provide a
supplementary measure to standard manufacturing processes that will help improve




The aim of this thesis is to make a contribution through the use of PCR to the
improvement of the safety of blood and factor concentrates for clinical use. At
present safety depends on the selection of donors through interview and screening for
virus specific antibody or antigen in an attempt to prevent a viraemic unit from being
infused and reduce the virus load in a plasma pool prior to production of factor
concentrates. The cost of withdrawing a contaminated pool once it has gone into
production would be in the region of £100,000 to £1,000,000 (SNBTS unpublished
data). The benefits of identifying contaminated donations prior to use, from the
aspect of safety and monitory saving, are great. In addition, validated virus
inactivation procedures are required in the production procedure before factor
concentrates are licensed, providing a further level of safety. The properties of a virus
that would indicate potential transmission by blood or blood products are (a) those
that persist in the blood and at high titre; (b) those that have a long incubation period
before the development of symptoms and (c) those that are mild or asymptomatic
infections. The viruses considered in this thesis, namely HCV, parvovirus B19 and
HAV, each exhibit some of these characteristics, causing different problems clinically
and in the field of blood transfusion.
For HCV infection, there may be a long window period (6-12 months or longer), in
which an individual is viraemic but asymptomatic. Viraemia is generally low
(average titre 105 copies /ml), but usually results in chronic infection. The ultimate
severity of the disease can be life threatening, early diagnosis of infection is
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important not only from the transfusion microbiologists point of view but for the
individual also. Anti-HCV screening can detect most infected individuals. However
a considerable number of ELA positive samples produce an indeterminate result
(38.2%, this study) in RIBA-2 screening, a proportion of which (5.5%, this study) are
viraemic. Exclusion of all indeterminate donations from further use would be costly
and wasteful and so further confirmatory tests are required. Identification of viraemia
by RT-PCR was the approach taken in this work and proved effective at confirming
HCV viraemia in antibody positive and indeterminate donations. It was also
demonstrated that different HCV genotypes influence the serological response
elicited. Infection with HCV type 1 showed broad reactivity with antigens in RIBA-2,
while infection with other genotypes (2-6) elicited antibody responses restricted to
two antigens only (c22-3 and c33c). This observation provides an explanation for the
continued transmission of HCV by blood screened with assays that relied in reactivity
to one antigen alone (c 100-3). These results also indicate that infection with different
HCV genotypes will be detected with the currently available 2nd and 3rd generation
assays since reactivity with the c22-3 antigen was detected in all RIBA-2 positive,
PCR positive donors tested and in 92% of RIBA-2 indeterminate, PCR positive
donors. HCV type-specific PCR based and serological assays are currently being
developed (van Doom et al., 1994, Simmonds et al., 1993a). An ideal assay would
be one that is equally sensitive for the six different genotypes. The importance of
determining HCV genotype probably lies in the clinical situation since different
genotypes may vary in their infectivity, pathogenicity and response to interferon
treatment (Dusheiko et al., 1994). Preliminary data suggests that it may be important
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to identify subtypes of the different genotypes as individuals infected with HCV type
la show a better response to interferon treatment than those infected with lb (Takada
et al., 1992b; Yoshioka et al., 1992; Kanai et al., 1992). Conserved polymorphisms
in HCV subtypes la, lb, 2a, and 2b sequences have been identified, and the RFLP
system described in this thesis could be extended in order to differentiate these
subtypes.
The major benefits derived from use of the PCR in the blood transfusion setting is
the ability to detect virus in the " window period " or seronegative stages of infection
and for the detection of viruses in products made from large pools of plasma. The
techniques described in this thesis could be used to supplement serological screening
for other transfusion-transmitted viruses. For example, hepatitis B virus transmission
still occurs despite routine screening for hepatitis B surface antigen and might be
eliminated by screening donations for HBV DNA in pools. Another significant
problem is infection with human cytomegalovirus (HCMV) via blood transfusion to
immunocompromised individuals, such as transplant recipients. HCMV detection by
PCR can be performed more quickly and with greater sensitivity than conventional
serological techniques (Bevan et al., 1991). PCR can also be used for the detection
of bacterial pathogens. Transfusion of erythrocytes contaminated with the bacteria
Yersinia enterocolitica can cause sepsis with high mortality rates (Blumberg et al.,
1991). Asymptomatic blood donors are recognised as the source of transfusion
endotoxemia caused by Y. enterocolitica. Conventional methods for identifying the
bacteria require lengthy incubations of cultures (Feng et al., 1992; Kwaga et al.,
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1992) and could be replaced by PCR. There have also been reports of blood donors
who later developed Creutzfeldt-Jakob disease (CJD)(Esmonde et al., 1993). As yet,
transmission of CJD has not been linked to blood transfusion, and little is known
about the incubation period or nature of the infectious agent. Clearly identification
of the agent would be desirable, if it is found to be a virus the application of PCR
would be possible.
The application of the PCR in detecting virus nucleic acid remains largely a research
tool as it is considered too costly, time consuming and difficult to standardise for use
on a routine basis. In the work described in this thesis it has been attempted to carry
out PCR testing in a timescale and budget that would enable viraemic donations to
be withdrawn prior to use. For HCV the approach was to use RT-PCR to augment
and confirm the results of antibody screening. Two other viruses, parvovirus B19 and
HAV could potentially contaminate plasma pools or be transmitted through infusion
of infected donations. In adults infection is generally acute and asymptomatic in the
case of B19, viraemia precedes any symptoms and high virus titres can be attained
in infected individuals. At present, routine donor screening for B19 or HAV is not
carried out. Using a pooling system it was possible to screen a large number of
donations for the presence of contaminating virus and in addition provide information
on the epidemiology of infection.
While the pooling technique used in this thesis offers one approach to screening a
large number of donations, other techniques are available. The Roche Amplicor HCV
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PCR kit (described in chapter 7, section 7.3.3.) is a PCR based assay that has a
colorimetric readout. This similarity to ELISAs may be more attractive to Blood
Transfusion Service Departments in which staff are accustomed to microtitre plate
formats. Kits are also available for the detection ofHIV and CMV. Another approach
for rapid detection of HCV has been based on the direct capture of HCV RNA from
plasma (van Doom et al., 1994). HCV-RNA is hybridised to a complementary
biotinylated oligonucleotide, followed by capture of the resulting hybrid onto
streptavidin-coated beads followed by cDNA synthesis and PCR allowing for the
detection of (near) full length HCV RNA. Both of these assays have eliminated the
phenol/chloroform extraction and ethanol precipitation of nucleic acid and so have
greatly speeded up the processing of samples. A non-PCR based assay developed by
Chiron Corporation requires no sample preparation. A crude proteinase K lysate of
RNA is hybridised in solution to two sets of oligonucleotide probes one of which is
captured onto a solid phase. The other oligonucleotide hybridises to a branched DNA
molecule (bDNA) which serves to amplify the signal by binding multiple copies of
an enzyme linked oligonucleotide. A positive result is indicated by a
chemiluminescent signal (Urdea, 1993). Similar assays are available for HBV, HIV
and CMV. This assay is quantitative but is limited in its sensitivity. If the sensitivity
of the assay can be enhanced it would find widespread application in the field of
blood transfusion.
A criticism of the PCR has been the generation of false positive results due to
contamination with product from previous reactions. This can be overcome by having
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separate laboratories and designated equipment for each stage, from extraction, cDNA
reaction, primary PCR, secondary PCR to running the product on an agarose gel. An
additional measure taken by some laboratories is the use of uracil in place of
thymidine in the PCR reaction mix. The uracil becomes incorporated into amplified
sequences in subsequent reactions any amplified material from previous reactions is
destroyed by the enzyme uracil N-glycosylase before the next rounds of cycling. The
length of time taken in setting up reactions may be reduced with the advent of new
thermostable DNA polymerase enzymes now available that can be used in place of
Taq. Thermus thermophilics (Tth) offers the advantage of having reverse-transcriptase
properties in addition to polymerising activity and can therefore be used to carry out
both reactions in the one tube (Young et al., 1993) providing not only a saving in
time but a reduction in the possibility of contamination. The use of uracil and Tth
enzyme are both used in the Roche Amplicor Kit.
That blood products can be the source of virus transmission was demonstrated using
RT, PCR and direct sequence analysis, HAV, B19 and HCV sequences could be
detected in factor concentrates and/or intravenous immunoglobulin preparations.
Sequence analysis detected similarities between HCV sequences obtained from
recipients and contaminated batches of IVIG, and phylogenetic analysis demonstated
a link with the source of infection. PCR and other virus nucleic acid detection
techniques will undoubtably have a role in improving the safety of blood and blood
products in the future. Routine screening of blood donations, plasma pools and blood
products for viruses is recognised by transfusion centres worldwide as the next step
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in improving the safety of blood and its products.
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